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Abstract 
It is estimated that 366 million people were living with diabetes in 2011, 
and this is predicted to rise to 522 million by 2030. One of the most 
common complications of diabetes is diabetic neuropathy, where 
patients experience various symptoms of neuropathic pain including 
mechanical allodynia. Using a high fat diet (HFD) in combination with 
streptozotocin (STZ) produces a model of diabetes which mimics 
aspects of type 2 diabetes. The aim of this thesis was to characterise 
pain responses in the HFD/STZ model and to explore some of the 
peripheral and spinal mechanisms associated with the changes in 
somatosensory processing. The effectiveness of a variety of drugs in 
alleviating/preventing neuropathic pain was also investigated in this 
model. 
 
The effects of the HFD/STZ model on mechanical sensitivity, and 
changes in metabolic parameters were investigated, and it was found to 
cause a robust development of mechanical hypersensitivity and a large 
increase in plasma glucose and a contrasting decrease in plasma 
insulin. The impacts of the HFD/STZ model on peripheral nerve function 
and pathology, and spinal mechanisms of central sensitisation, were 
explored to help identify the mechanisms underpinning the behavioural 
pain phenotype in these rats. No neuronal degeneration was detected 
in DRGs or the spinal cord at the timepoints investigated, and a 
decrease in microglial activation and GFAP immunoreactivity was 
observed at later timepoints (day 50). Changes in neuronal responses 
in the dorsal horn of the spinal cord were then investigated, and there 
was a trend towards a decrease in mechanically evoked responses of 
spinal neurones in the HFD/STZ group, but no changes in the threshold 
for electrical activation of C-fibres, nor any significant changes to 
electrically evoked responses, were observed. There was no change in 
spontaneous firing, possibly due to the search criteria used. 
 
The effects of different types of interventions on aberrant pain 
responses were also investigated. As neuropathic pain often proves 
intractable, one of the key objectives is to develop new drugs, or to find 
alternative uses of current drugs, that are able to provide symptomatic 
relief of pain. The gold standard treatment for pain in diabetic 
neuropathy, pregabalin (10mgkg-1, p.o.), was effective at alleviating 
established mechanical hypersensitivity at day 37 in the HFD/STZ 
model. A novel MAGL inhibitor, MJN110 (5mgkg-1, i.p.), was found to be 
as effective as pregabalin in this model, highlighting a possible role for 
endocannabinoid modulators in providing pain relief in diabetes. The 
antidiabetic pioglitazone (10mgkg-1, p.o.), however, was unable to 
alleviate mechanical hypersensitivity when administered at day 21 for 
28 days. Two other antidiabetic drugs, linagliptin (3mgkg-1, p.o.) and 
metformin (200mgkg-1, p.o.), did show promise in preventing the 
development of mechanical hypersensitivity in this model when 
administered from day 4, independent of glycemic control. It is worth 
investigating these findings further since both of these drugs are 
already licensed and have undergone all necessary safety testing, and 
so could rapidly be put to use if effective. 
 
In conclusion, this thesis has highlighted the role that the HFD/STZ 
model can play in investigating underlying mechanisms of diabetic 
peripheral neuropathic pain, and its use in exploring potential new 
therapeutic options for alleviating this pain. 
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Chapter 1. 
General Introduction 
 
 
1.1. Diabetes 
Diabetes mellitus is a metabolic disorder characterised by elevated 
blood glucose. Globally, it is estimated that 366 million people were 
living with diabetes in 2011, and this is predicted to rise to 522 million 
by 2030 (IDF, 2012). Diabetes can be divided into two main categories: 
type 1 and type 2 diabetes, with type 2 accounting for approximately 
 RI GLDEHWLF FDVHV (Rydén et al., 2007). Type 1 diabetes is an 
DXWRLPPXQH GLVHDVH LQ ZKLFK WKH SDQFUHDWLF ȕ-cells in the islets of 
Langerhans are gradually destroyed by T cells, leading to the pancreas 
being unable to secrete enough insulin (Atkinson et al., 2001; Bluestone 
et al., 2010). In type 2 diabetes, the first stage is peripheral insulin 
resistance, where the sensitivity of tissues to insulin decreases (Rydén 
et al., 2007). The ȕ-cells initially secrete more insulin to compensate for 
the insulin resistance, but eventually become less effective (Campbell, 
. The hallmark of diabetes is hyperglycaemia  where fasting 
EORRGJOXFRVHLV7mM, or glycosylated haemoglobin (HbA1c) is  
(American Diabetes Association, 2013). Insulin levels generally have to 
fall below 0.5ngml-1 for hyperglycaemia to develop (Dobretsov et al., 
2007). In healthy individuals, inVXOLQLVVHFUHWHGIURPȕ-cells in response 
to elevated levels of glucose. The roles of insulin include: stimulating 
amino acid synthesis; suppressing gluconeogenesis; decreasing 
lipogenesis in fat tissue; and promoting the uptake of glucose in skeletal 
muscle and the liver, where it is stored as glycogen (Dobretsov et al., 
2007). *OXFDJRQZKLFK LV UHOHDVHGE\SDQFUHDWLFĮ-cells, performs an 
opposing role; causing an increase in the release of glucose. 
 
Diabetes leads to a wide variety of complications: microvascular 
diseases such as retinopathy, nephropathy and neuropathy (including 
diabetic autonomic neuropathy and focal neuropathy), as well as 
macrovascular diseases such as cardiovascular disease (Forbes et al., 
2013). The focus of this thesis, however, is diabetic peripheral 
neuropathy (DPN), also known as sensorimotor neuropathy or distal 
symmetric neuropathy. 
 
2 
1.1.1. Current treatments for diabetes 
Exogenous insulin is necessary in the control of type 1 diabetes, but 
there are a number of drugs available for the treatment of type 2 
diabetes (for review see Stumvoll et al., 2005), and these include: 
 Thiazolidinediones (TZDs), such as pioglitazone, which help to 
improve insulin resistance and increase glucose uptake into 
peripheral tissues. 
 Metformin, a biguanide, which reduces hepatic glucose 
production. 
 Glucagon-like peptide 1 (GLP-1) agonists (Gutniak et al., 
and dipeptidyl peptidase-IV (DPP-4) inhibitors such as linagliptin, 
which cause insulin secretion, as well as inhibiting hepatic 
glucagon secretion and slowing gastric emptying. 
 Sulfonylureas, such as glibenclamide, which stimulate insulin 
secretion from the pancreas. 
Those relevant to this thesis are discussed in more detail below. 
 
1.1.1.1. Pioglitazone 
TZDs such as pioglitazone act through a peroxisome proliferator-
activated receptor (PPAR): PPARȖ. PPARs are members of the nuclear 
hormone receptor superfamily (Dreyer et al.  ,VVHPDQQ et al., 
, and are activated by fatty acids, eicosanoids and synthetic 
compounds (Youssef et al., 2004). Once activated, they form 
heterodimers with retinoid X receptors (Kota et al., 2005). They are able 
to regulate the transcription of a wide variety of target genes through 
binding to a specific peroxisome proliferator response element in the 
promoter region of these genes (Berger et al., 2002), and they then 
stimulate transcription through recruitment of coactivators (Tan et al., 
2005). 
 
There are three different PPAR isoforms  ĮȕįDQGȖ(Berger et al., 
2005). PPARȖ is primarily expressed in the adipose tissue, but is also 
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found at lower levels in kidney, liver, and Schwann cells (Desvergne et 
al., as well as microglia and astrocytes in the brain (Bernardo et 
al., 2008; Moreno et al., 2004). It can also be found in pain pathways 
where it has been measured in adipocytes in the epineurium of the 
sciatic nerve, in L5 dorsal root ganglia (DRG), and in neurones in the 
dorsal horn of the spinal cord (Churi et al., 2008; Maeda et al., 2008). 
 
TZDs have been shown to alter the mRNA levels of a myriad of genes, 
but primarily those involved in glucose and lipid metabolism (Sears et 
al., 2007). They normalise expression of the glucose transporter, 
GLUT4, in adipose tissue and increase expression of GLUT1 in adipose 
tissue and skeletal muscle (Kramer et al., 2001). They are able to 
enhance adipocyte insulin signalling, and lipid uptake and metabolism, 
as well as attenuating lipolysis and free fatty acid release. TZDs are 
also able to stimulate the redistribution of lipids from insulin-resistant 
visceral fat depots into subcutaneous fat (Miyazaki et al., 2002) through 
promoting apoptosis in mature adipocytes in visceral fat, and 
stimulating adipogenesis in subcutaneous fat, resulting in an increase in 
smaller, more insulin-responsive adipocytes (Okuno et al. . As 
more lipolysis takes places in visceral fat $UQHU, the change to 
more insulin responsive adipocytes in subcutaneous fat leads to a 
decrease in levels of free fatty acids, therefore enhancing insulin 
sensitivity (Willson et al., 2000). 
 
TZDs are also able to reduce levels of pro-inflammatory cytokines, such 
as tumour necrosis factor-Į 71)Į) (Dandona et al., 2004), which is 
increased in obese rodents (Hotamisligil et al.  ;X et al., 2003) 
and also in patients with type 2 diabetes (Katsuki et al.=LQPDQ et 
al.  71)Į has been linked to insulin resistance due to 
interference with the insulin signalling cascade (Hotamisligil et al.
Hotamisligil et al.. 
 
All of these mechanisms mean TZDs are able to act as potent insulin 
sensitisers in peripheral tissue, as well as lowering blood glucose, 
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HbA1c, insulin and triglyceride levels and increasing HDL cholesterol 
levels (Aronoff et al., 2000; Diamant et al., 2003; Rosenblatt et al., 
2001). TZDs may even preserve ȕ-cell function - increasing islet mass, 
preserving insulin content and improving insulin secretion (Campbell et 
al., 2007; Kawasaki et al., 2005; Kawashima et al., 2011). This may be 
through a decrease in lipotoxicity LQWKHȕFHOOVUHVXOWLQJLQDQLQKLELWLRQ
of excessive apoptosis (Berger et al., 2005). 
 
1.1.1.2. Metformin 
Metformin improves glycemic control and decreases blood sugar levels 
through multiple mechanisms: a reduction in hepatic glucose output; the 
inhibition of gluconeogenesis; and by improving the sensitivity of muscle 
to insulin, leading to increased glucose uptake (Stumvoll et al.. 
 
Metformin causes increased phosphorylation and activation of AMP-
activated protein kinase (AMPK), which is termed the energy sensor of 
the cell (Tillu et al., 2012). AMPK responds to the cellular AMP:ATP 
ratio, and is an important regulator of lipid and glucose metabolism. 
When it is activated, it downregulates the expression of several genes 
through phosphorylation of multiple targets, including those involved in 
gluconeogenesis and lipogenesis in the liver. This leads to a reduction 
of lipid stores in muscle and liver (Kahn et al., 2005) and inhibition of 
hepatic glucose production (Zhou et al., 2001a). AMPK also switches 
on pathways that lead to the uptake and metabolism of glucose in 
muscle by increasing the translocation of the glucose transporter 
GLUT4 to the plasma membrane (Hardie, 2007). 
 
1.1.1.3. Linagliptin 
Linagliptin competitively and reversibly inhibits DPP-4 (Eckhardt et al., 
2007), an enzyme that cleaves GLP-1 and glucose-dependent 
insulinotropic polypeptide (GIP), two incretin hormones which are 
rapidly secreted from gut endocrine cells after eating (Drucker et al., 
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2006). These hormones activate GPCRs and cause glucose-dependent 
insulin secretion. GLP-1 also inhibits hepatic glucagon secretion, and 
slows gastric emptying (Drucker, 2006). In humans it has been shown 
that an oral dose of glucose causes an increased release of insulin 
compared to an intravenous dose, termed the incretin effect, but this 
effect is often much lower in type 2 diabetics (Nauck et al. . At 
higher concentrations, GLP-1 is still able to exert its insulinotropic 
activity (Nauck et al., and therefore augmentation of this incretin 
through inhibition of DPP-4 can help to control hyperglycaemia. 
 
/LQDJOLSWLQFDXVHVDSSUR[LPDWHO\LQKLELWLRQRI'33-4 (Rauch et al., 
2012) and has been shown to increase the levels of circulating GLP-1 
by around 2-fold (Rauch et al., 2012; Sarashina et al., 2010), and cause 
D UHGXFWLRQ RI DSSUR[LPDWHO\  LQ SHDN JOXFDJRQ (Rauch et al., 
2012). Linagliptin improves HbA1c, has a good safety profile, and is not 
associated with hypoglycaemia or weight gain (McGill, 2012). It is 
licensed to treat type 2 diabetes as a monotherapy, but can also be 
combined with other treatments such as metformin, utilising two 
complementary modes of action (Gallwitz, 2013). 
 
1.1.2. Animal models of diabetes 
Animal models of type 1 diabetes include those induced by chemical 
ablation of pancreatic ȕ-cells, and rodents who spontaneously develop 
autoimmune diabetes (Table 1.1). Models of type 2 diabetes include 
both obese and non-obese rodents, with varying severity of symptoms. 
Table 1.2 briefly describes the main models of type 2 diabetes, some of 
which are described in more detail in Chapter 2. Full descriptions and 
advantages/disadvantages are discussed elsewhere (for review see 
Chatzigeorgiou et al..LQJ5HHG et al.5HHV et al., 
2005; Srinivasan et al., 2007), but for brevity only those models 
mentioned in this thesis are described below. 
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The most frequently used model is the streptozotocin (STZ) model, as it 
is cheap and quick to set up, whereas the spontaneous autoimmune 
models are more expensive, disease onset is less predictable and they 
are also more time consuming. Non-obese diabetic (NOD) mice and 
biobreeding (BB) rats, however, can more accurately represent the 
disease in humans, as they share some of the genes that are linked 
with susceptibility to type 1 diabetes (for review see Driver et al., 2011; 
Yang et al., 2006). There are, however, concerns that observations 
from these highly inbred genetic strains are not representative of the 
heterogeneity of the human population (Srinivasan et al., 2005). The 
rodent models summarised in Table 1.1 and 1.2 produce many of the 
symptoms associated with diabetes, as well as signs of peripheral 
nerve dysfunction such as nerve conduction velocity (NCV) slowing, 
and development of mechanical sensitivity, and have been used to 
investigate pathogenic pathways in early diabetic neuropathy (Forbes et 
al., 2013). However the majority of these models tend to lack the 
advanced clinical characteristics of microvascular complications such 
as segmental demyelination, neurodegeneration, and subsequent axon 
or fibre loss (Sharma et al., possibly due to their relatively short 
lifespan. They are therefore not as useful for studying the long term 
complications, such as loss of sensory function, unless a long-term 
study is run. However nerve pathology, such as atrophy of sural axons 
and loss of large-calibre dermal and small-calibre epidermal axons, can 
be seen after 4 months of diabetes in ZDF rats (Brussee et al., 2008). 
This aspect is discussed further in Chapter 3. 
 
It has been postulated that STZ may have a direct neurotoxic effect that 
is partly responsible for the development of some of the signs of 
diabetic neuropathy (Bishnoi et al., 2011; Pabbidi et al., 2008b). It has 
been shown that the timecourse and the degree of thermal and 
mechanical hypersensitivity were similar in STZ rats that went on to 
develop hyperglycaemia and those rats that didnt (Bishnoi et al., 2011), 
and a similar effect was also seen with thermal hyperalgesia in STZ-
treated mice (Pabbidi et al., 2008b). They hypothesised that this may be 
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due to a direct neuronal effect of STZ, which leads to enhanced 
expression and function of the TRPV1 receptor in DRGs, as well as 
microglial activation, and increased levels of pro-inflammatory 
cytokines.  
 
However, other studies have ruled out a direct effect of STZ (Davidson 
et al.  5RPDQRYVN\ et al., 2010). Evidence for this comes from 
studies that show that when STZ rats are treated with insulin they 
exhibit a decrease in hyperglycaemia and attenuated pain sensation 
(Courteix et al.5RPDQRYVN\ et al., 2006), as well as a reversal 
of the upregulation of T-current density in small-sized DRG cells 
(Messinger et al. . This suggests that these aberrant pain 
sensations must be due to a combination of hyperglycaemia and 
hypoinsulinaemia, and not just a direct effect of STZ (Romanovsky et 
al., 2004). Mechanical hyperalgesia has also been shown to correlate 
with plasma insulin levels in normoglycaemic STZ rats, further 
substantiating a role of decreased insulin in the development of 
hypersensitivity (Romanovsky et al., 2006). Finally, pressure pain 
thresholds were restored to original levels in normoglycaemic STZ rats 
after four weeks, in parallel with the spontaneous recovery of insulin 
production in these animals (Romanovsky et al., 2010). Therefore, in 
this thesis, it was presumed that any development of mechanical 
hypersensitivity was not a direct neurotoxic effect of STZ. 
 
In this array of animal models of diabetes, the development of diabetic 
peripheral neuropathic pain (DPNP) can be investigated through a 
variety of methods. Most commonly, the development of mechanical 
hypersensitivity is examined using von Frey hairs, and the paw 
pressure test can be used to assess hyperalgesia. To look at thermal 
thresholds, both the Hargreaves and the hot plate test can be used. 
Finally, the formalin test can also be used in the diabetic model itself. 
Although this is not clinically relevant, it enables the investigation of the 
effect of hyperglycaemia on prolonged activation of nociceptive 
pathways in the peripheral and central nervous system (Calcutt, 2002). 
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Table 1.1 Summary of rodent models of type 1 diabetes 
Method of 
induction 
Model Features 
Chemical 
High dose STZ 
(45-PJNJ-1 in 
rats) 
STZ is used to destroy a high 
percentage of the pancreatic ȕ-cells 
resulting in little endogenous insulin 
production, which leads to 
hyperglycaemia and weight loss. 
Multiple low doses 
of STZ (20-
30mgkg-1 in rats) 
This induces insulitis, which causes a 
decrease in islet number and therefore 
a decrease in insulin secretion 
capacity. 
Spontaneous 
autoimmune 
NOD mice 
NOD mice develop insulitis at around 
34 weeks of age, which causes ȕ-cell 
destruction. Overt diabetes becomes 
apparent at around 12-30 weeks, and 
mice rapidly lose weight and require 
insulin treatment. 
BB rats 
BB rats develop diabetes between 8-
16 weeks of age. The level of diabetes 
is quite severe, and the rats rely on 
insulin therapy to survive. 
  
 Table 1.2 Summary of rodent models of type 2 diabetes 
Method of 
induction 
Model Features 
Obese models 
Lep ob/ob mice 
Mutation in the leptin gene. Obesity and mild hyperglycaemia develop by 4 weeks, and 
increase over time. Hyperinsulinaemia is also present. 
Lepr db/db mice 
Autosomal recessive mutation in the leptin receptor. Mice become obese, hyperglycaemic, 
hyperinsulinaemic and insulin resistant within 4 weeks and develop hypoinsulinaemia later, 
with a peak in hyperglycaemia between 3-4 months of age. 
Zucker diabetic 
fatty (ZDF) rats 
Mutated leptin receptor. Rats are initially hyperinsulinaemic with severe insulin resistance. 
When levels of insulin decrease, they become hyperglycaemic at 8-10 weeks of age. 
Induced obesity 
High fat diet 
(HFD) fed 
C57BL/6J mice 
$KLJKIDWGLHWW\SLFDOO\ZKHUHDURXQGRIHQHUJ\LVGHULYHGIURPIDWFDQOHDGWRREHVLW\
and the development of hyperinsulinaemia, insulin resistance and glucose intolerance. 
Chemically 
induced 
Nicotinamide 
(NAD) + STZ 
Rats administered NAD 15 minutes before STZ develop moderate, stable hyperglycaemia 
without any changes in plasma insulin levels as NAD has a protective effect on the cytotoxic 
action of STZ, resulting in only minor damage to pancreatic ȕ-cell mass. 
Neonatal STZ 
STZ administration to neonatal rats can lead to hyperglycaemia at 6 weeks, due to a 
decrease in normal ȕ-cell mass and ȕ-cell dysfunction. 
HFD/STZ 
The HFD causes insulin resistance, followed by a low dose of STZ, which causes 
hyperglycaemia to develop as a proportion of the ȕ-cells are destroyed. 
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1.2. Diabetic neuropathy 
The prevalence of diabetic neuropathy varies IURPZLWKLQRQH\HDU
RIGLDJQRVLVWRXSWR\HDUVafter diagnosis (PirDUW, with 
an average prevalence of DSSUR[LPDWHO\ (Said, 2007; Sugimoto et 
al., 2000), and the likelihood increasing with poor control of plasma 
glucose levels (Tesfaye et al. . It has been estimated that 
approximately 16-21 RI GLDEHWLF SDWLHQWV H[SHULHQFH FKURQLF painful 
DPN (Abbott et al., 2011; Daousi et al., 2004), and 40- RI WKRVH
with diabetic neuropathies experience pain (Veves et al., 2008). 
 
The positive symptoms of DPN can include tingling, burning, 
spontaneous pain, allodynia and hyperalgesia, whereas the negative 
symptoms include numbness and loss of sensation (Dobretsov et al., 
2007). The longest nerves are affected first, starting at the distal end, 
and so symptoms tend to follow a stocking and glove distribution; 
starting in the toes, and spreading up the foot and eventually the leg, 
and can also be seen in the fingers and the hands (Zochodne, 2007). 
Early on there is a loss of intra-epidermal nerve fibres (IENFs). The loss 
of protective sensation in the foot can lead to ulceration, which can 
ultimately result in amputation (Vinik et al., 2000). 
 
1.2.1. Mechanisms associated with diabetic 
neuropathy 
The first changes observed in diabetic neuropathy are a decrease in 
the NCV in motor and sensory neurones, shunting of excess glucose 
into the polyol pathway, microangiopathy and impairments of Na+/K+-
ATPase activity (Sima, 2003). Other important factors include 
inappropriate activation of protein kinase C (PKC) and poly(ADP-ribose) 
polymerase (PARP), and lack of neurotrophic support due to C-peptide 
and insulin deficiency 2EURVRYDE. 
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1.2.1.1. Microangiopathy 
Microangiopathy leads to abnormalities in blood flow as observed in the 
sciatic nerve and DRG in the STZ model (Sasaki et al.. This is 
due to impaired vasodilation with nitric oxide (NO), and increased 
activity of vasoconstrictors (Zochodne, 2007). There is also an increase 
in vascular permeability due to a rise in permeability factors such as 
vascular endothelial growth factor (Brownlee, 2001). As the disease 
develops there can be loss of microvascular cells, and thickening of the 
capillary basement membrane of the vasa nervorum, due to 
overproduction of the extracellular matrix, which is induced by growth 
factors. All of these changes lead to ischaemic damage to neurones 
and axons, resulting in axonal degeneration in peripheral nerves, due to 
severe demyelination. 
 
1.2.1.2. Oxidative stress 
In diabetes, metabolic abnormalities lead to increased production of 
mitochondrial superoxide by the electron transport chain (Brownlee, 
2001; Giacco et al., 2010). This in turn results in activation of the 
intertwined mechanisms described below, resulting in a common fate: 
further oxidative stress. Excessive reactive oxygen series (ROS), such 
as superoxide and hydrogen peroxide, and reactive nitrogen series, 
such as peroxynitrite, are produced, which can lead to damage to lipids, 
proteins and DNA (Edwards et al., 2008). Peroxidation of lipids leads to 
formation of products which are toxic to the cell, and if DNA is damaged 
this can lead to apoptosis. Accumulation of all these products can also 
cause a loss of neuronal function, and neuronal degeneration (Vincent 
et al., 2004a). Oxidative stress can also cause mitochondrial 
dysfunction, and when the mitochondrial permeability transition pore 
opens, there is a release of cytochrome c and initiation of the apoptotic 
cascade (Russell et al., 2002). Treatment with antioxidants has been 
shown to prevent the NCV slowing that occurs as a result of peripheral 
nerve dysfunction in STZ rats (Cameron et al.  9LQFHQW et al., 
2004b), but antioxidants such as Į-lipoic acid have demonstrated 
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limited effects on neuropathic symptoms in randomised double-blind 
placebo trials (Vincent et al., 2004b). 
 
1.2.1.3. Polyol pathway 
Hyperglycaemia results in more glucose being shunted through the 
polyol pathway. Figure 1.1 summarises this pathway; glucose is 
converted to sorbitol by aldose reductase with the oxidation of NADPH 
to NADP+, and then to fructose by sorbitol hydrogenase with NAD+ 
being reduced to NADH (Duby et al., 2004).  
 
 
 
Figure 1.1  The key features of the polyol pathway, adapted from 
(Brownlee, 2001). 
 
The polyol pathway uses up NADPH, which is important in the 
production of reduced glutathione (GSH), another antioxidant, and this 
depletion of GSH further promotes oxidative stress (Brownlee, 2005). 
The decrease in NADPH also leads to depletion of osmolytes such as 
taurine and nerve myo-inositol. Taurine is an antioxidant and 
vasodilator and its decrease leads to promotion of oxidative stress 
(Sima, 2003)$WDXULQHGLHWKDVEHHQVhown to improve the deficits 
in nerve conduction and blood flow that are seen in STZ mice (Pop-
Busui et al., 2001). The loss of myo-inositol causes a decrease in PKC, 
which leads to impaired Na+/K+-ATPase activity, resulting in increased 
levels of sodium which are associated with slowing of NCV (Cherian et 
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al. . The increased accumulation of fructose also leads to the 
formation of advanced glycation end-products. 
 
Diabetic transgenic mice overexpressing human aldose reductase had 
an increased accumulation of sorbitol and fructose, decreased PKC 
activity, more severe slowing of NCV and more severe neuronal 
atrophy. These symptoms were ameliorated by the aldose reductase 
inhibitor, WAY121- (Yagihashi et al., 2001). On the other hand, 
diabetic mice with a knockout for the aldose reductase gene showed no 
reduction in NCV, and no change in GSH level (Chung et al., 2003). 
Aldose reductase inhibitors, however, have failed to show promise in 
diabetic patients. 
 
1.2.1.4. Advanced glycation end-products (AGEs) 
 AGEs are formed when glucose, fructose or galactose covalently bond 
with proteins via the Maillard reaction (Ahmed, 2005). These first form a 
shift base, and then an Amadori product, followed by the irreversible 
formation of AGEs (Ulrich et al., 2001). AGEs can cause intermolecular 
cross-linking of proteins such as myelin, which can lead to 
demyelination (Brownlee, 2001). They can also bind to receptors, such 
as the Receptor for AGE (RAGE), which is found in DRGs, peripheral 
nerves, Schwann cells and epidermal fibres (Bierhaus et al., 2004; Toth 
et al., 2008). RAGE activates QXFOHDUIDFWRUNDSSD%1)ț%), leading to 
an increased expression of cytokines. RAGE also activates NADPH 
oxidases, leading to the generation of ROS (Wautier et al., 2001; Yan 
et al.  and so further increasing oxidative stress in the cell 
(Vincent et al., 2004a). 
 
1.2.1.5. PKC activation 
Hyperglycaemia also leads to increased production of diacylglycerol 
(DAG), which activates various PKC isoforms including PKC-ȕDQG -į, 
leading to changes in gene expression (summarised in Brownlee, 
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2005): eNOS is downregulated, and endothelin-1 and TGF-ȕ DUH
upregulated, which can lead to negative changes in blood flow. NFț%LV
also upregulated, which causes increased expression of pro-
inflammatory genes. PKC-ȕ inhibitors have been shown to improve 
some of the vascular deficits, such as decreased NCV and reduced 
blood flow, that are observed in STZ animals (Ahlgren et al.,VKLL 
et al.  1DNDPXUD et al. . PKC also plays a role in pain 
pathways and hyperalgesic priming. 
 
1.2.1.6. Hexosamine pathway 
Hyperglycaemia leads to excess fructose-6-phopshate being diverted 
from glycolysis to enter the hexosamine pathway, where it is converted 
to uridine diphosphate-N-acetyl glucosamine. This attaches to the 
serine and threonine residues of transcription factors, and can lead to 
altered gene expression, including upregulation of pro-inflammatory 
genes (Brownlee, 2001). 
 
1.2.1.7. Poly(ADP) ribose polymerase 
The PARP pathway is stimulated by free radicals and cleaves NAD+ 
(Edwards et al., 2008). This reduction in NAD+ can lead to a slowing of 
NCV, small fibre neuropathy, and development of painful symptoms 
such as thermal and mechanical hyperalgesia and tactile 
hypersensitivity (Edwards et al., 2008). It also affects glycolysis and 
mitochondrial respiration, which causes a decrease in energy 
production and can lead to cell death (Negi et al., 2010). 
 
1.2.1.8. Insulin and C-peptide 
As well as the importance of hyperglycaemia in diabetic neuropathy, the 
deficiency of insulin and C-peptide is also important, especially in type 1 
diabetes. This is supported by the Diabetes Control and Complications 
Trial (DCCT), which shows that tight glycaemic control is effective at 
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reducing the deYHORSPHQW RI GLDEHWLF QHXURSDWK\ E\  EXW not in 
preventing it entirely, suggesting that other factors must also be 
important (Sugimoto et al., 2000). C-peptide links the A and B chains of 
proinsulin together, and is cleaved by proteases. C-peptide has been 
shown to: improve Na+/K+-ATPase activity and ameliorate the decrease 
in NCV, as well as helping to prevent paranodal swelling and axonal 
degeneration (Zhang et al., 2001b); improve indices of sensory nerve 
function (by decreasing thermal thresholds) (Johansson et al., 2000); 
and prevent thermal hyperalgesia in BB/Wor rats (Kamiya et al., 2004). 
Both insulin and insulin-like growth factors (IGFs) are important 
neurotrophic factors involved in supporting peripheral neurones, and 
continuous subcutaneous infusion of IGF-2 was able to attenuate 
hyperalgesia in ZDF rats (Zhuang et al.. In STZ mice, insulin can 
decrease mortality and sensory loss, as well as improving neuropathic 
pain (Francis et al., and in STZ rats insulin can improve NCV, as 
well as increasing the number of myelinated fibres in the sural nerve 
(Singhal et al. . The importance of changes in insulin to the 
development of DPNP is discussed further in Chapter 2.  
 
 
 16 
1.3. Pain 
According to the International Association for the Study of Pain (IASP), 
pain can be defined as an unpleasant sensory and emotional 
experience associated with actual or potential tissue damage, or 
described in terms of such damage. Nociception, however, is the 
neural process involving detection of tissue injury, and refers to the 
physical response to pain, but is not tied to the emotional experience.  
 
1.3.1. Primary afferent nociceptors 
Nociception occurs through nociceptors, whose existence was first 
proposed by Sherrington  over a century ago, and these are 
defined by IASP as a high-threshold sensory receptor of the peripheral 
somatosensory nervous system that is capable of transducing and 
encoding noxious stimuli. Nociceptors can detect noxious heat or cold, 
and intense mechanical stimulation and noxious chemicals, but do not 
respond to innocuous stimuli (Burgess et al.  such as touch or 
warming/cooling. Fibres that innervate the body arise from cell bodies in 
the DRG (Julius et al., 2001). Nociceptors can be divided into three 
different sub-types depending on their conduction velocity: small 
diameter unmyelinated C-fibres, slightl\ODUJHU$į-fibres which are thinly 
myelinated, and myelinated, large diameter (>10Pm) Aȕ-neurones (for 
review see Willis et al., 2004). 
 
$ȕ-fibres are rapidly conducting and act as low threshold 
mechanoreceptors - responsible for proprioception and the detection of 
innocuous stimuli, but some Aȕ-fibres do function as nociceptors 
(Djouhri et al., 2004). This is important as it is Aȕ-fibres that are 
responsible for the development of allodynia (pain elicited by an 
innocuous stimuli), and after even a small drop in their threshold these 
nociceptive Aȕ-fibres become responsive to innocuous stimuli (Djouhri 
et al., 2004). It is Aį- and C-fibres that are mainly responsible for the 
GHWHFWLRQRIQR[LRXVVWLPXOL$į-fibres are thought to be responsible for 
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the rapid acute pain sensations of pricking and aching, whereas slowly 
conducting C-fibres produce a delayed, more diffuse, dull burning pain 
sensation (Willis et al., 2004). 
 
Two populations of $į-fibres exist: Type I and Type II (Treede et al., 
. Type I respond to high heat (~53°C), mechanical and chemical 
stimuli. They have a delayed onset to heat stimuli, but they then 
become sensitised and their discharge rate increases during a 
prolonged heat stimulus (Treede et al. . They sensitise to burn 
and chemical injury, and are responsible for development of primary 
hyperalgesia (Meyer et al., 2005). Type II, on the other hand, are mostly 
mechanically insensitive, and have a lower thermal threshold (~43°C) 
and a rapid and fast adapting response to heat and are thought to 
signal the first pain sensation from heat (Campbell et al.7UHHGH 
et al.7UHHGH et al.. 
 
C-fibre nociceptors can be polymodal, as some respond to noxious 
mechanical stimuli, intense heat and cold, as well as noxious chemical 
stimuli such as acid or capsaicin (Meyer et al., 2005). However some C-
fibre nociceptors are mechanically sensitive but do not respond to heat, 
whereas others can be mechanically insensitive but respond to noxious 
heat (Schmidt et al. . Furthermore, some C-nociceptors may 
initially be insensitive to both mechanical and thermal stimuli, known as 
silent or sleeping nociceptors, but are activated by irritant substances 
such as mustard oil in experimental conditions (Schmidt et al., or 
inflammatory mediators released during inflammation, and can then 
become sensitised to further mechanical and thermal stimuli. 
 
C-fibres can be divided into two classes based on their neurochemical 
content: peptidergic and non-peptidergic. Peptidergic neurones release 
substance P (SP) and calcitonin gene related peptide (CGRP) and 
express TrkA (a high affinity receptor for nerve growth factor (NGF)), 
and are reliant on NGF for normal function (Averill et al.0ROOLYHU 
et al.  $SSUR[LPDWHO\  RI DRG neurones require NGF for 
 18 
survival during embryonic development, but in the first three weeks of 
development approximately half of these neurones stop expressing 
TrkA, and these are then classified as non-peptidergic neurones 
(Bennett et al.  0ROOLYHU et al. . These neurones express 
the growth factor receptor, GFRĮ, as well as the receptor tyrosine 
kinase, RET, and are reliant on glial-derived neurotrophic factor 
(GDNF) for survival (Bennett et al.. They also express the P2X3 
receptor (an ionotropic ATP receptor), and can be labelled with the 
plant lectin IB4 (Molliver et al..  
 
Neurones can be desensitised by repeated stimulation. Repeated 
activation of the receptors present on the neurones can lead to a 
downregulation of these receptors, or an exhaustion of mediators. 
Nociceptors can be desensitised by application of capsaicin, a 
Transient Receptor Potential Vanilloid 1 (TRPV1) ligand. TRPV1 is 
expressed exclusively by small-diameter neurones within sensory 
ganglia (Caterina et al., 2001; Caterina et al.. Capsaicin causes 
firing of nociceptors and an initial period of enhanced sensitivity, which 
is followed by a refractory period in which responses to noxious stimuli, 
including capsaicin, are reduced -DQFVR. 
 
The predominant excitatory neurotransmitter in primary afferent fibres is 
glutamate, but a wide variety of substances are involved in the central 
transmission and modulation of nociceptive information. These can 
include other excitatory amino acids (EAAs), neuropeptides such as SP 
and CGRP, adenosine triphosphate (ATP) and NO, as well as 
prostaglandins (PGs) and neurotrophins such as NGF. 
 
Glutamate provides rapid transmission of excitatory pronociceptive 
inputs in the spinal cord, and can act on a variety of specific receptors. 
These include the metabotropic glutamate receptors: mGluR1-8, which 
are GPCRs and the ionotropic glutamate receptors: D-amino-3-hydroxy-
5-methyl-isoxazole (AMPA), N-methyl-D-aspartate (NMDA) and kainite, 
  
which are coupled to cation channels (Coggeshall et al.0D\HU et 
al., 2004). 
 
1.3.2. The organisation of the dorsal horn of the 
spinal cord 
Primary afferent nociceptors synapse with neurones in the dorsal horn 
of the spinal cord, and projection neurones convey the information to 
higher centres in the brain, where the information is processed. 
 
,Q WKHGLYLVLRQRI WKHGRUVDOKRUQRI WKHVSLQDOFRUGRIDFDW LQWR
six laminae was first described 5H[HG. Figure 1.2 shows how 
the laminae are organised; with I-VI comprising the dorsal horn, VII-IX 
making up the ventral horn, with lamina X surrounding the central canal. 
Laminae I and II make up the superficial dorsal horn (with lamina II 
further subdivided into an outer (IIo) and inner part (IIi)), and these 
together with V, VI and X are the main targets for primary nociceptive 
afferents. Lamina I receives nociceptive LQSXW IURP $į- and C-fibres, 
whereas laminae III and IV contain neurones responsive to the 
innocuous stimulation delivered by $ȕ-fibres, and lamina V receives 
both non-noxious and noxious input from monosynaptic $į- aQG $ȕ-
inputs and polysynaptic C-fibre inputs (Basbaum et al.. 
 
Three different populations of neurones exist within the dorsal horn of 
the spinal cord, and these are defined as: non-nociceptive, nociceptive 
specific (NS) and wide dynamic range (WDR) neurones (Willis et al., 
2004). Non-nociceptive neurones are located in IIi, III and IV, and are 
activated by innocuous stimuli. NS neurones are typically silent and are 
specifically activated by noxious stimuli mediated by peripheral 
nociceptors, and are found in both superficial (lamina I and IIo) and 
deep (lamina V, VI and X) layers. WDR neurones are able to encode 
the intensity of noxious stimuli, and have a graded respond to stimuli 
that range from low-threshold to those in the noxious range. They 
respond to thermal, mechanical and chemical stimuli mediated by Aȕ-, 
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$į- and C-fibres. These are also found in lamina IV, V, VI and X, as 
well as laminae I and IIo. WDR neurones also display a wind-up 
response (Price et al. , where the response of the neurone to 
repeated electrical stimulation at a set intensity, with a frequency of 
>0.5Hz, will increase dramatically, with each stimulus evoking a larger 
response than the last, and firing continuing even after cessation of 
stimulation 0HQGHOO  6FKRXHQERUJ et al. . NMDA 
antagonists are able to markedly reduce this wind-up and post stimulus 
discharge, suggesting that high frequency stimulation of NMDA 
receptors contributes to wind up through alleviation of the Mg2+ block 
(Dickenson et al.. 
 
Dorsal horn neurones can also be classified by their output destination. 
Propriospinal neurones allow communication between the ipsilateral 
and contralateral sides, as well as between different segments (Willis et 
al., 2004), and they are also able to initiate descending inhibition. 
Projection neurones are responsible for transmitting nociceptive 
information supraspinally, and are mostly found in laminae I, V and VI, 
whereas interneurones are responsible for inter- and intra-laminar 
transfer, integration and modulation of nociceptive information (Millan, 
. 
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Figure 1.2. Organisation of the Rexed laminae in the grey matter of the 
spinal cord, adapted from 5H[HG. 
 
 
1.3.3. Ascending pain pathways 
There are two types of ascending pathways: monosynaptic and 
polysynaptic. Monosynaptic pathways project directly from the dorsal 
horn to the higher brain centres and include the spinothalamic tract 
(STT), the spinomesencephalic tract, the spinoparabrachial tracts 
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(SPBT), and the spinohypothalamic tract. Polysynaptic pathways, on 
the other hand, include a relay station of second order neurones on 
their journey to higher brain centres, and these include the 
spinocervicothalamic pathway, and the postsynaptic dorsal column 
(PSDC) pathway. 
 
The STT transmits information to the thalamus, and it has projections 
originating from superficial lamina I and deeper laminae IV and V of the 
dorsal horn, and also laminae VII and VIII, with half of these originating 
LQ ODPLQD ,DQG WKHRWKHUVSOLWHYHQO\EHWZHHQ WKHRWKHU ODPLQDH
(Dostrovsky et al., 2006). The STT neurones in each of the different 
regions of the spinal cord receive afferent input from different primary 
afferent fibres. Lamina I STT cells receive input from Aį- and C-fibres, 
and so respond to noxious stimulation including noxious heat and cold, 
as well as pinch and itch. STT cells in laminae IV-V receive input from 
A-fibres, and also respond to a variety of stimuli encoded by WDR cells. 
Finally, STT cells in laminae VII-VIII receive input from skin, and muscle 
and joint inputs (Dostrovsky et al., 2005). 
 
The SPBT projects to the medulla and brainstem, which is important for 
the integration of nociceptive information with homeostatic, arousal and 
autonomic processes, and this information is then conveyed to the 
forebrain (Tracey et al., 2007).  
 
The thalamus can be seen as the key relay site for nociceptive 
information as it receives nociceptive information from the STT, and is 
able to encode information about intensity and topographic localisation 
and then transfer it to cortical and subcortical structures (Millan, 2002). 
The thalamus has also been hypothesised to be important in chronic 
pain, and a decrease in thalamic blood flow contralateral to the site of 
pain has been observed in patients with cancer (Di Piero et al., 
and a patient with a left medullary infarct (Garcia-Larrea et al., 2006). In 
patients with diabetic neuropathy, a decrease in N-acetylaaspartate 
(NAA), a marker of neuronal integrity, has been observed in the 
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thalamus, with a correlation between the reduction in NAA and the 
severity of the neuropathy (Selvarajah et al., 2008). Another study 
found lower levels of NAA in the thalamus of diabetic patients, and that 
these were further decreased in those that experienced pain (Sorensen 
et al., 2008). 
 
1.3.4. Descending control of pain 
The descending pain modulatory system, as seen in Figure 1.3, is an 
anatomical network that plays an important role in determining the 
experience of pain, as it can have facilitatory as well as inhibitory 
effects, and these can be altered depending on emotional or 
pathological state, and are affected by arousal and expectation (Fields 
et al., 2005). It is thought that sustained facilitation of pain transmission 
may be an underlying mechanism of chronic pain (Porreca et al., 2002). 
 
The PAG-RVM (periaqueductal grey-rostral ventromedial medulla) 
system is important in the descending control of pain (Fields et al., 
. The PAG receives input from the dorsal horn and is connected 
to the hypothalamus and frontal cortex, as well as limbic forebrain 
structures such as the amygdala, and receives input from the 
spinomesencephalic tract (Millan, 2002). The PAG projects to the RVM, 
which is responsible for transmitting information to the dorsal horn of 
the spinal cord. The role of the PAG in descending control was first 
established in experiments where stimulation of, or microinjections into, 
the PAG resulted in behavioural analgesia to noxious stimuli (Mayer et 
al.0D\HU et al., and similar effects have also been shown 
in humans 0D\HU. 
 
The RVM includes the nucleus raphe magnus and projects to both the 
superficial layer and the deep dorsal horn via the dorsolateral funiculus. 
It mediates bidirectional control as it can exert both facilitatory and 
inhibitory influences (Porreca et al., 2002). Electrical stimulation of the 
RVM can be antinociceptive and cause decreased responses of dorsal 
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horn neurones (Fields et al., but at a lower intensity it can also 
prove facilitatory (Zhuo et al., and these effects can also be seen 
by microinjection with neurotransmitters (Zhuo et al.. If a lesion 
is created in the RVM or if it is inactivated with lidocaine, stimulation of 
the PAG no longer has an analgesic action, highlighting the importance 
of the RVM as a relay for the PAG to connect with the dorsal horn. 
 
Within the RVM, there are three types of cells: ON, OFF and NEUTRAL 
(Fields et al.. OFF-cells are tonically active and pause their firing 
immediately before a withdrawal response as they are inhibited by 
noxious stimuli (Fields et al.3RUUHFD et al., 2002). It is thought 
that it is the OFF-cells that cause descending inhibition of nociception, 
as decreases in OFF-cell firing have been shown to correlate with 
increased nociceptive transmission (Fields et al., and activation 
of OFF-cells has been correlated with inhibition of nociceptive input 
(Fields et al.. ON-cells accelerate their firing before a withdrawal 
reflex occurs, and it has been postulated that ON-cells enable the RVM 
to have a facilitatory role in pain. Increased activity of ON-cells has 
been observed in models of hyperalgesia, and administering a drug in 
the RVM while monitoring neuronal activity, and also the threshold for a 
reflex to nociceptive stimulation, confirms that ON-cells are responsible 
for facilitation (for review see Heinricher et al.. 
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Figure 1.3. Descending control of pain. The modulatory pathway links 
higher brain centres to the PAG, which projects to the RVM, which 
exerts inhibitory (-) or facilitatory (+) effects on nociceptive processing. 
Adapted from (McMahon et al., 2005). 
 
 
1.3.5. Neuropathic pain 
Neuropathic pain is defined by IASP as pain caused by a lesion or 
disease of the somatosensory nervous system, and is chronic and 
potentially irreversible. Acute pain, and the ability to detect noxious 
stimuli serves an important evolutionary role by acting as a warning 
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system to ensure an organisms survival and well being, through reflex 
withdrawal responses to a noxious stimuli and protective behaviour of a 
damaged tissue. Neuropathic pain, however, fulfils no physiological 
purpose and can be considered pathological 0LOODQ. 
 
It has been estimated that one in six of the general population are 
affected by neuropathic pain at some point, and symptoms include 
spontaneous pain, allodynia, hyperalgesia (heightened sensation of 
pain) and abnormal sensations such as dysesthesias and paresthesias 
(Campbell et al., 2006). As well as being present in diabetic 
neuropathy, it can also be caused by nerve injury, autoimmune 
disease, infections such as shingles, and neurotoxicity (e.g. by 
chemotherapy agents) (Zimmermann, 2001).  
 
1.3.6. Origins of pain in diabetes 
Diabetic neuropathy is a progressive disease with pain experienced 
due to a wide variety of causes. Painful symptoms usually occur at the 
onset of diabetic neuropathy, although there tends to be no correlation 
between the intensity of pain symptoms and the extent of the sensory 
deficit, and can be influenced by the patients psychological and 
emotional state (Guastella et al.. 
 
Oxidative stress and the other processes described in section 1.2.1, 
lead to neuronal death. The loss of small Aį- and C-fibres leads to 
changes in pain sensation and temperature perception, whereas the 
loss of larger Aȕ-fibres can cause a loss of vibration sensation, and 
tactile discrimination (Guastella et al.. Along with sensory loss, 
destruction of C-fibres also causes painful symptoms such as burning, 
as well as paresthesias and dysesthesias (Guastella et al.. As 
the disease progresses further and there is greater neuronal loss, 
chronic pain can still be experienced, even without peripheral 
stimulation, due to the development of central sensitisation, but 
eventually the sensory deficits overtake and there is sensory loss. 
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1.3.6.1. Involvement of primary afferent fibres 
When nerves in diabetic patients become injured, this leads to the 
accumulation of sodium channels along portions of the injured axons. In 
the STZ model an increase in the expression of the TTX-S sodium 
channel, Nav1.7, has been observed, along with a reduction in the 
expression of the TTX-R sodium channel, Nav1.8, which is preferentially 
expressed in small DRG neurones (Hong et al., 2004). An increase in 
Nav1.3, and Nav1.6 has also been observed, which would be expected 
to lead to a lowered firing threshold (Craner et al., 2002). Despite a 
decrease in Nav1.8, there is an increase in its phosphorylation, which 
results in a modification of the channel properties (Hong et al., 2004), 
and post-translational modification of Nav1.8 by methylglyoxal is 
associated with enhanced sensory neurone excitability (Bierhaus et al., 
2012). These changes in sodium channels result in an increase in TTX-
S and TTX-R sodium currents in small DRG neurones, which correlates 
with the development of hyperalgesia and mechanical hypersensitivity, 
and persists in the long term (Hirade et al.+RQJ et al., 2004). In 
large A-fibre DRG neurones an increase in TTX-S Nav1.2, Nav1.3 and 
Nav1.7, as well as TTX-R Nav KDV EHHQ REVHUYHG UHVXOWLQJ LQ DQ
increase in sodium currents, and a shift of the voltage-dependent 
activation kinetics in the hyperpolarising direction (Craner et al., 2002; 
Hong et al., 2006). Normalisation of Nav1.7 levels in STZ rats was able 
to reduce pain related behaviours (Chattopadhyay et al., 2012). 
Increased nodal persistent sodium currents have been associated with 
neuropathic pain in humans with diabetic neuropathy (Misawa et al., 
. 
 
The changes in these channels facilitate the generation of ectopic 
electrical impulses and hyperexcitability (Devor, 2005). In the STZ rat 
model, nociceptive fibres have been shown to fire in an exaggerated 
spontaneous manner (see Chapter 4 for more detail) (Ahlgren et al., 
 &KHQ et al., 2001), and increased excitability of regenerating 
nerve fibres may also lead to aberrant discharge (Brown et al.. 
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Ectopic discharges are also seen in models of nerve damage such as 
the chronic constriction injury (CCI) model, and spinal nerve injury at 
both the level of peripheral neurones (Tal et al.:DOO et al. 
as well as DRGs (Kajander et al./LX et al., 2000; Study et al., 
;LH et al.. Spontaneous firing has been shown to cause a 
reduction in thermal, mechanical and chemical thresholds (Howe et al., 
, and nerve injury can also lead to spontaneous discharges in 
neighbouring uninjured axons, as well as the injured neurones 
themselves (Ali et al. . Ectopic discharges can lead to 
spontaneous pain and paresthesias (Devor, 2006), as well as 
contributing to the development and maintenance of central 
sensitisation (discussed later). Transection of, or anaesthetising the 
dorsal roots in the spinal nerve ligation (SNL) model, and therefore 
blocking ectopic discharges, reduced behavioural signs of neuropathic 
pain (Yoon et al.. 
 
As described previously, there is increased activation of PKC in diabetic 
neuropathy, and PKC also plays a role in nociceptive processing in 
primary afferents and hyperalgesic priming (for review see Velazquez et 
al., 2007). PKC activation can cause depolarisation of unmyelinated C-
fibres by increasing sodium conductance (Dray et al.5DQJ et al., 
, and enhance currents caused by noxious thermal stimuli 
(Cesare et al. . PKC inhibitors have been shown to block this 
depolarisation (Burgess et al.0F*XLUN et al.. 
 
In rats, PKC activation is able to increase capsaicin induced TRPV1 
currents by increasing depolarisation of TRPV1 (Zhou et al., 2001b), 
which allows the receptor to conduct at lower, non-noxious 
temperatures, and also at physiologically relevant pHs (Crandall et al., 
2002), while PKC inhibitors decrease these currents (Zhou et al., 
2001b). Inflammatory mediators, such as EUDG\NLQLQJDODQLQDQG71)Į 
enhance the activity of TRPV1 through PKC-dependent pathways, 
which may play a role in hyperalgesic priming (see references in 
Velazquez et al., 2007). PKC inhibitors can decrease thermal 
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hyperalgesia and C-fibre hyperexcitability in STZ rats (Ahlgren et al., 
. As well as in the periphery, PKC can also modulate 
neurotransmission at the level of the spinal cord through increasing 
excitatory neurotransmission and decreasing inhibitory tone. 
 
1.3.6.2. Involvement of spinal sensitisation 
Sensitisation can occur at both the peripheral and central level, and is 
important in the development of pain in diabetic neuropathy. Peripheral 
sensitisation involves a reduced threshold for activation and an 
amplification in the responsiveness of primary afferent nociceptors, and 
occurs when these neurones are exposed to inflammatory mediators, 
which are released by damaged tissues (Dickenson et al., 2002). 
Central sensitisation, which was first proposed thirty years ago (Woolf, 
, develops following a primary afferent barrage, which leads to 
sustained activation of WDR neurones in the spinal cord. These 
neurones become sensitised, and at this point input from primary 
afferent neurones is no longer required to elicit responses from these 
neurones. To demonstrate this, pre-treatment with a local anaesthetic 
can prevent the cutaneous hyperalgesia that develops following 
intradermal capsaicin administration, but if the anaesthetic is only given 
after injection of capsaicin, there is no effect on hyperalgesia (LaMotte 
et al. 1), suggesting that peripheral inputs are required for the 
onset of hyperalgesia, but are not required to maintain it. 
 
Central sensitisation is characterised by an increased responsiveness 
of nociceptive neurones in the central nervous system (CNS) to both 
normal and subthreshold afferent input. The recruitment of low-
threshold Aȕ-fibres means that their input is able to drive nociceptive 
pathways, resulting in a reduction in the threshold for activation. Central 
sensitisation also results in an increase in spontaneous activity, as well 
as an enlargement of peripheral receptive fields (Coderre et al.. 
These effects are due to increases in membrane excitability, synaptic 
facilitation, and decreases in inhibitory transmission (for references see 
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Latremoliere et al.. The result of central sensitisation is that pain 
is no longer coupled to the intensity or duration of a peripheral stimulus, 
and painful sensations can occur in the absence of noxious stimuli. 
There are a number of mechanisms underlying the development of 
central sensitisation, and a variety of receptor systems are involved. 
 
GABAergic interneurones are important in both pre- and post-synaptic 
inhibition of responses of dorsal horn neurones. Blocking these 
interneurones with Ȗ-Aminobutyric acid (GABA)A/B antagonists causes 
mechanical hypersensitivity and thermal hyperalgesia in naive rats, 
whereas GABAA/B agonists were able to abolish the mechanical 
hypersensitivity and thermal hyperalgesia seen in SNL rats (Malan et 
al., 2002). Therefore the loss of inhibitory GABAergic interneurones 
causes disinhibition of neurones in the dorsal horn, leading to increased 
neurotransmission, which can contribute to central sensitisation. 
 
When nerves are injured, this causes a phenotypic switch where 
damaged A-fibres begin to synthesise excitatory neurotransmitters that 
are normally associated with C-fibres, such as CGRP and SP (Miki et 
al.  1RJXFKL et al. . The release of substance P causes 
activation of post-synaptic NK1 receptors, which leads to downstream 
activation of intracellular signalling pathways such as mitogen-activated 
protein kinase (MAPK) and extracellular-signal related kinase (ERK). 
These pathways lead to activation of NMDA receptors, along with PKC, 
which potentiates these NMDA-currents through alleviation of the 
voltage dependent Mg2+ block (Chen et al.. Activation of NMDA 
receptors results in synaptic potentiation (Woolf et al.  where 
nociceptive stimuli produce larger postsynaptic potentials, resulting in 
hyperexcitability of dorsal horn neurones. NMDA receptor antagonists 
are able to reduce the facilitation of these responses (Woolf et al., 
, and NMDA receptor phosphorylation in the spinal cord coincides 
with the development of mechanical hypersensitivity in the SNL model 
(Gao et al., 2005). 
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Upregulation of AMPA and NMDA receptors in the spinal cord has also 
been implicated in the development of central sensitisation, and the 
increase in AMPA receptor expression coincided with the development 
of mechanical and thermal hyperalgesia in the partial nerve ligation 
(PNL) model (Harris et al.. mRNA of AMPA and NMDA subunits 
is upregulated in the STZ model (Tomiyama et al., 2005), and 
hyperalgesia and mechanical hypersensitivity can be prevented in this 
model by administration of AMPA- and NMDA-receptor antagonists 
(Begon et al., 2000; Calcutt et al.  0DOFDQJLR et al. , 
demonstrating the important role these receptors play in central 
sensitisation. 
 
Neurochemical changes in the spinal cord, such as the release of 
excitatory amino acids, cytokines and reactive oxygen species cause 
glial activation, which also plays an important role in the development of 
neuropathic pain and is discussed further in Chapter 3. 
 
1.3.6.3. Involvement of higher centres 
As well as the involvement of primary afferent fibres and spinal cord 
neurones, it has also been hypothesised that higher order pain 
signalling neurones are involved in the generation and/or amplification 
of pain signals. Fischer et al.  made recordings from neurones in 
the thalamic ventral posterolateral nucleus, which relays sensory input 
from the periphery. Increases in spontaneous activity, evoked activity to 
both innocuous and noxious stimuli, as well as enlarged receptive fields 
were reported in the STZ rat model, and this spontaneous activity was 
generated even in the absence of signals from primary sensory 
neurones (Fischer et al. . STT neurones also display increased 
spontaneous activity, enlarged receptive fields and increased 
responses to mechanical stimuli (brush and pinch), which may be due 
to the aberrant activity that is observed in the afferent nerves in the STZ 
model (Chen et al., 2002a). 
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There is also an increase in serotonergic neurones in the RVM and 
noradrenergic neurones in the A5 noradrenergic cell group in STZ rats, 
as well as increased levels of serotonin and noradrenaline at the spinal 
cord and increased c-Fos expression in the ventrolateral PAG (VLPAG) 
(Morgado et al., 2011b). As the PAG is responsible for relaying 
messages from the higher brain centres, such as the amygdala and 
anterior cingulate cortex, via the RVM (Heinricher et al. , this 
suggests that in diabetes there may be impairments to descending pain 
modulation. The high levels of noradrenaline increase the release of 
GABA, which is increased in the STZ model (Malmberg et al., 2006; 
Morgado et al., 2008). This increase in GABA, unexpectedly, has an 
excitatory effect in diabetes, due to a decrease in the expression of the 
potassium chloride co-transporter 2 (KCC2) (Jolivalt et al., 2008; 
Morgado et al., 2008). This leads to an increase in intracellular chloride 
concentrations, and when GABA binds to GABAA receptors, there is an 
efflux of chloride creating a depolarising event (Coull et al., 2003). This, 
in combination with increased serotonergic activity, results in enhanced 
activity of spinal neurones, and therefore increased facilitation.  
 
A further study went on to demonstrate that Fos expression (a marker 
of neuronal activation) increases over time in diabetes, suggesting that 
spontaneous neuronal activity increases as the disease progresses 
(Morgado et al., 2011a). The PAG, which has facilitatory as well as 
inhibitory effects on pain modulation (Heinricher et al.9DQHJDV 
et al., 2004), shows a universal increase in Fos expression at 4 weeks, 
but at 10 weeks this was limited to only the VLPAG. c-Fos expression is 
also increased in both superficial and deeper laminae of the dorsal horn 
in STZ rats (Morgado et al., 2007). 
 
A recent study has shown that in STZ rats there is a decrease in 
descending pain inhibition as evidenced by a decrease in the 
spontaneous activity of OFF-cells, as well as the absolute number, and 
this is coupled with an increase in spontaneous activity of ONcells 
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indicating an increase in descending pain facilitation from the RVM 
(Silva et al., 2013). 
 
Increased C-fibre evoked wind-up is observed in the STZ mouse model 
(Kimura et al., 2005), indicating the enhanced excitability of spinal cord 
neurones. While the conditioning stimulus generates both inhibitory and 
excitatory influences in normal animals, the decrease in ȝ-opioid 
receptors in the dorsal horn of the spinal cord in diabetes (Chen et al., 
2002b) means that there is less recruitment of the inhibitory system, 
leading to enhanced wind-up (Kimura et al., 2005). 
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1.4. Aims of the thesis 
The aim of this thesis was to characterise pain responses in the 
HFD/STZ model and to explore some of the peripheral and spinal 
mechanisms associated with the changes in somatosensory 
processing. The effectiveness of a variety of drugs in 
alleviating/preventing neuropathic pain was also investigated in this 
model. 
 
The objectives were to:  
1, study the development of mechanical hypersensitivity in the 
HFD/STZ model. 
2, investigate underlying mechanisms by examining indices of 
neurodegeneration in the DRG and spinal cord, and the potential 
contribution of microglia and astrocytes in the spinal cord. 
3, characterise the electrically and mechanically-evoked responses of 
wide dynamic range neurones in the dorsal horn of the spinal cord. 
4, explore the possibility of using currently prescribed antidiabetics 
versus existing and novel analgesics to alleviate pain responses in this 
model. 
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Chapter 2. 
Assessment of the HFD/STZ diabetic model 
 
2.1. Introduction  
2.1.1. The STZ model of diabetes 
As discussed in Chapter 1, there is an array of animal models of 
diabetes. One of the most frequently used models is the STZ model, as 
it is quick, easy and cheap to set up. 
 
Streptozotocin (2-deoxy-2-(3-(methyl-3-nitrosoureido)-D-glucopyranose) 
is a toxin which selectiYHO\GHVWUR\VSDQFUHDWLFȕ-cells, and is derived 
from Streptomyces achromogenes. It enters through the glucose 
transporter, GLUT2, and causes alkylation of DNA (Szkudelski, 2001). 
Other effects include formation of superoxide radicals, which cause the 
release of toxic amounts of nitric oxide, which also damages DNA 
(Szkudelski, 2001). Alkylation of DNA leads to overstimulation of PARP, 
which causes a decrease in NAD+, and subsequently ATP, leading to 
the necrosis of ȕ-cells (Lenzen, 2008). It is this activation of PARP that 
is considered one of the main reasons for the diabetogenicity of STZ 
(Szkudelski, 2001). Depletion of NAD+ also results in the inhibition of 
insulin synthesis and secretion (Lenzen, 2008). 
 
A wide range of doses of STZ are used in the induction of diabetes in 
rats, and these vary from multiple low doses (20mgkg-1) (Skalska et al., 
2010; Taliyan et al., 2012; Zhang et al., 2008), to high doses of up to 
75-PJNJ-1 (Aubel et al., 2004; Lindner et al., 2006; Nadig et al., 
2012), with the majority ranging somewhere between 45-70mgkg-1. 
 
Administration of STZ leads to hyperglycaemia and hypoinsulinaemia, 
which is evident in the first few days after injection, and is maintained at 
a similar level as the model develops. Other symptoms that are typically 
associated with STZ administration are stunted growth, polydipsia, 
polyuria and polyphagia (Chatzigeorgiou et al.. 
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2.1.2. Neuropathy in the STZ model 
The development of changes in mechanical and thermal thresholds in 
response to nociceptive and non-nociceptive stimuli has been 
extensively studied in the STZ model. A decrease in mechanical 
withdrawal thresholds is first seen 1-2 weeks after injection with STZ, 
and reduces further as the model progresses (Ahlgren et al. 
Calcutt et al.&RXUWHL[ et al.'REUHWVRY et al., 2003; Fuchs 
et al., 2010; Xu et al., 2011). There are conflicting reports about 
whether thermal hyperalgesia (Courteix et al.)XFKV et al., 2010; 
Ulugol et al., 2004) or hypoalgesia (Bianchi et al., 2012; Fox et al., 
 0DOFDQJLR et al.  3LUL] et al.  is seen in the STZ 
model. Recent reports have suggested that STZ causes thermal 
hyperalgesia in the early stages, which is followed by thermal 
hypoalgesia after approximately six weeks (Bishnoi et al., 2011; Pabbidi 
et al., 2008a; Pabbidi et al., 2008b), similar to what is seen clinically 
2EURVRYDD. 
 
A variety of drugs are effective at reversing the manifestation of pain 
behaviours in the STZ model. Four weeks after STZ administration, 
high single doses of morphine (20mgkg-1) and baclofen (16mgkg-1) 
were able to reverse mechanical hyperalgesia in the paw pressure test, 
and chronic treatment (for 6 days) with MK-801 (0.1mgkg-1) completely 
reversed mechanical hyperalgesia (Malcangio et al. . Another 
study looked at the acute effect of five drugs on mechanical withdrawal 
thresholds at 3 and 7 weeks after STZ injection (Yamamoto et al., 
. Pregabalin (30mgkg-1) was the most effective and reversed the 
decrease in withdrawal thresholds at both timepoints. Mexiletine 
(100mgkg-1) and morphine (10mgkg-1), however, were only able to 
partially reverse the decrease in withdrawal thresholds at 3 weeks, and 
were ineffective by 7 weeks. Other studies have also shown 
hyporesponsiveness to morphine, with its antinociceptive abilities 
abolished 12 weeks after STZ administration (Nielsen et al., 2007). 
Amitriptyline (3mgkg-1) was only able to partially alleviate mechanical 
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hypersensitivity at 7 weeks, and diclofenac (10mgkg-1) was ineffective 
at all timepoints. 
 
2.1.3. Criticisms of the STZ model 
The STZ model has been criticised as it can leave animals in poor 
condition. Fox et al.  expressed doubts as to its validity as a 
model of diabetic neuropathy, as the animals suffered from diarrhoea, 
polyuria, enlarged and distended bladders, and reduced growth. These 
rats were assessed to be chronically ill, as they appeared very lethargic 
and displayed no e[SORUDWRU\EHKDYLRXUDQGZHUHUHmoved before 
the end of the four week study. They hypothesised that the behavioural 
results obtained might not be valid as they could be caused by general 
ill-health rather than neuropathy itself. The body condition score of rats 
has also been correlated with withdrawal thresholds (Hoybergs et al., 
2008), emphasising the importance of monitoring rats for weight loss 
and general body condition, to ensure that any behavioural data 
obtained cannot be attributed solely to their poor condition.  
 
2.1.4. Alternatives to the STZ model 
While the STZ model has been widely used, it is a model of type 1 
diabetes, but only a small proportion of cases of diabetes are 
accounted for by type 1 diabetesZLWK-of sufferers having type 
2 diabetes (Cheng, 2005). There are several alternatives to the single 
high-dose of STZ that can produce a model which more closely 
resembles type 2 diabetes: 
 
Nicotinamide, an antioxidant, can be administered 15 minutes before 
STZ, which leads to moderate hyperglycaemia, glucose intolerance and 
reduced insulin stores (Masiello et al.. NAD is able to scavenge 
free radicals, as well as causing inhibition of PARP, and increasing 
levels of NAD+, and this helps to reduce the amount of damage that is 
  
caused to ȕ-cells (Szkudelski, 2012). This model can therefore be 
considered more typical of type 2 diabetes, and doses of each 
compound can be adjusted to alter the severity of diabetes that is 
produced. This model is also quite stable and so can be used for 
longer-term studies looking at different diabetic complications 
(Szkudelski, 2012). 
 
Another alternative is to give an intraperitoneal (i.p.) injection of STZ to 
neonatal rats, which leads to only partial destruction of the ȕ-cell 
population. This leads to moderate hyperglycaemia which increases 
with age, abnormal glucose intolerance and an initial increase in insulin 
levels as the rat attempts to maintain glucose homeostasis (Takada et 
al., 2007). However, by 12 weeks of age, the rats show a decrease in 
pancreatic insulin content, indicating that the ȕ-cells have become 
exhausted, resulting in overt hyperglycaemia. These features are 
similar to the natural course of type 2 diabetes in humans. While those 
two models are both valid alternatives to the STZ model, they do not 
take into account the risk factors which often contribute to the 
development of type 2 diabetes such as a poor diet, and a sedentary 
lifestyle, which both contribute to obesity, and can lead to diabetes 
(Cheng, 2005).  
 
2.1.5. The HFD/STZ model 
,Q/XR et al. reported an alternative to the high dose STZ model. 
A low dose of STZ in combination with either a high fat or high sugar 
diet was shown to induce diabetes in mice, with a disease progression 
more similar to that of type 2 diabetes in humans. The diet caused the 
mice to become insulin resistant, resulting in a compensatory increase 
in the production of insulin. This is similar to that of the prediabetes 
state which involves impaired fasting glucose and impaired glucose 
tolerance, which is associated with insulin resistance (Bock et al., 
2006). It was only following injection of STZ, when a proportion of the ȕ-
cells were destroyed, leading to a decrease in the production of insulin, 
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that the mice developed hyperglycaemia. Importantly, the same dose of 
STZ did not cause any changes in the mice that were fed a normal diet 
(Luo et al.. 
 
In 2005, this model was replicated in rats (Srinivasan et al. (2005), 
which were fed a high fat diet  FDORULHV DV IDW for two weeks, 
which led to increased body weight, blood plasma glucose, insulin, 
triglycerides and total cholesterol, and a decrease in the glucose 
disappearance rate during an insulin-glucose tolerance test, indicating 
that the rats were becoming insulin resistant. STZ injection (35mgkg-1) 
in the HFD rats resulted in frank hyperglycaemia, but only decreased 
insulin to what would be considered a normal level. They proposed that 
this model was more clinically relevant, and also had the benefit of 
being much cheaper than genetic models of type 2 diabetes. Further 
studies investigated the influence of the dose of STZ, in combination 
with a high fat diet, on this model of diabetes (Zhang et al., 2008). STZ 
at 45mgkg-1, given as a single dose, was shown to result in diabetes 
PRUHWKDQRI WKH WLPHFRPSDUHGWR-35mgkg-1 STZ. They also 
found that only the higher dose was able to produce a blood glucose 
concentration of over 10mM (24.5mM). This finding, and data from my 
own pilot experiments, prompted me to select 45mgkg-1 STZ for the 
studies described in this thesis.  
 
2.1.6. HFD/STZ: a model of diabetic neuropathy? 
While the HFD/STZ model has been shown to produce all the metabolic 
changes we would expect  polyuria, polydipsia, stunted growth rate, 
and related changes in glucose and insulin, the development of 
mechanical hypersensitivity has not yet been widely investigated. Of the 
handful of groups who have assessed altered nociception in the 
HFD/STZ model, results have not always been in agreement, and the 
length of time the high fat diet is fed before injection, the percentage of 
fat in the diet, and the dose of STZ have varied between groups. 
Davidson et al. (2011b; 2012) fed a high fat diet for 8 weeks followed by 
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30mgkg-1 of STZ and in the Hargreaves test they observed a 
hypoalgesic response, with an increase in withdrawal latency from the 
thermal stimulus, which was confirmed by Yang et al. (2011) who gave 
4 weeks of a high fat and high sucrose diet, followed by 35mgkg-1 of 
STZ. Conversely, Kumar et al.  fed rats a HFD for 2 weeks and 
administered 35mgkg-1 of STZ, but saw a hyperalgesic response in the 
tail-immersion and hot-plate test. Similar discrepancies in the findings of 
thermal nociception have also been reported in the STZ model, where 
there are reports of both thermal hypoalgesia and hyperalgesia.  
 
2.1.7. Aim of the study 
The aim of this study was to investigate the effects of a HFD in 
combination with STZ on metabolic parameters and mechanical and 
thermal sensitivity, to determine whether the metabolic changes 
produced in this model resulted in the development of hypersensitivity.  
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2.2. Methods 
2.2.1. Animals 
All experiments were carried out under Personal Home Office Licence 
DQG3URMHFW+RPH2IILFH/LFHQFHin accordance with 
WKH8.+RPH2IILFH$QLPDOV6FLHQWLILF3URFHGXUHV$FW and IASP 
guidelines. 18 male Sprague-Dawley rats (200-250g), obtained from 
Charles River (Kent, U.K.), were individually housed on a normal light 
cycle (lights on: 07:00 - ZLWKIUHHDFFHVVWRWKHhigh fat diet 
IDWE\FDORULFFRQWHQW'GLHW Research Diets, New Jersey, USA) 
and tap water at all times. Food and water intake, and body weight 
were monitored at least twice weekly. 
 
2.2.2. The HFD/STZ model of diabetes 
After three weeks consumption of the high fat diet, the rats were divided 
into two stratified groups on the basis of body weight and mechanical 
withdrawal thresholds, and they received an i.p. injection of STZ 
(45mgkg-1, at 3mlkg
-1; n=12) or citric acid buffer (n=6). STZ (batch/lot 
QXPEHU . ZDV SXUFKDVHG IURP 6LJPD $OGULFK 3RROH 8.
and dissolved in 0.05M citric acid, pH 4.5. 
 
A blood sample was drawn from the tail vein, and a minimum plasma 
glucose concentration of 15mM was required to confirm diabetes. Any 
HFD/STZ rat with a plasma glucose concentration lower than this was 
excluded from any further analysis. 
 
2.2.3. Development of the HFD/STZ model 
In a pilot study, a dose of STZ (55mgkg-1) caused two spontaneous 
deaths, and several rats that were in poor health throughout the study, 
leading to a lower dose of 45mgkg-1 being chosen for this study. This 
dose produced all of the same metabolic symptoms that were seen 
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previously, but left the rats in better health. An even lower dose has 
been shown to result in a much smaller percentage of rats going on to 
develop diabetes (Zhang et al., 2008), whereas in this study all 12 of 
the rats injected with STZ had plasma glucose levels of >15mM. 
 
As was established in the introduction, it is of upmost importance that 
rats are regularly monitored to ensure that any behavioural data 
obtained cannot be explained away as a side effect of their poor 
condition, and animals seen to be in very ill-health must not be allowed 
to continue in a study. Therefore in this, and future studies, a set of 
strict guidelines was followed to decide if/when to remove a rat from a 
study. It was decided that rats showing a combination of the following 
symptoms must be humanely killed: 
 
x Lethargy. 
x Lack of response to stimuli such as handling. 
x Partially closed eyes. 
x Significant lack of grooming. 
x Huddling in corners, fluffed up appearance, sitting hunched 
over, cold. 
x Weight loss of greater than 25RIWKHLULQLWLDOERG\ZHLJKW 
 
Rats were therefore closely monitored at all times, and body weight was 
measured and general condition was observed at least once a day. 
Rats that H[KLELWHG ZHLJKW ORVV RI  RUJUHDWHU LUUHVSHFWLYH RIDQ\
other symptoms) in the first week after dosing with STZ, were drawn to 
the attention of the NACWO, and their continuance in the study was 
carefully considered. Any rats H[KLELWLQJ ZHLJKW ORVV RI EHWZHHQ 
DQGRI WKHLU LQLWLDOERG\ZHLJKWZLWKQRRWKHUVymptoms or loss of 
condition were allowed to remain on the study, but were checked twice 
daily. 
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2.2.4. Behavioural testing 
von Frey testing was carried out to assess the sensitivity of the 
hindpaws to mechanical stimulation using calibrated von Frey hairs of 
bending forces 1, 1.4, 2, 4, 6, 8, 10 and 15g (Semmes-Weinstein 
monofilaments, Linton Instrumentation, Norfolk, UK). The day before 
behavioural testing commenced, the rats were acclimatised to the 
apparatus by placing them in the testing equipment (transparent 
Perspex boxes with a wire mesh floor; Medical Engineering Unit, 
University of Nottingham, UK) and leaving them to settle for half an 
hour, and then applying a 10g von Frey hair five times to each hindpaw. 
On the day of testing, the rats were allowed to habituate for 30 minutes 
before testing began. A modified form of the up-down method (Dixon, 
 was utilised to determine the mechanical withdrawal threshold. 
von Frey filaments were applied to the plantar surface of each hindpaw 
in turn for five seconds, with an interval of >3 seconds between 
repetitions. Stimulations were performed three times, or until a 
withdrawal response was elicited. The 6g von Frey hair was applied 
first: if there was a response, the next lowest von Frey hair was applied; 
and if there was no response, the next highest von Frey hair was 
applied.  This was repeated until there was either no response at the 
highest weight (15g) or the lowest force that elicited a withdrawal 
response was found (Guasti et al. . All behavioural testing was 
carried out between 08.00-12.00. As diabetic neuropathy produces a 
bilateral injury, the average withdrawal response of both hindpaws was 
calculated. 
 
The Hargreaves test was performed to evaluate thermal sensitivity 
(Hargreaves et al. . Rats were placed in a clear Plexiglass 
chamber on an elevated platform and allowed to habituate for 30 
minutes. A radiant heat source was positioned underneath the hindpaw, 
and the time from initiation of radiant heat until paw withdrawal was 
measured automatically. There was a cut off of 20 seconds to avoid 
tissue damage. Each paw was tested five times, with at least 5 minutes 
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between each trial to avoid sensitisation, and the mean withdrawal 
latency was calculated. 
 
All behavioural testing was performed blind to the treatment groups. 
 
2.2.5. Blood sampling 
After a four hour fast, 100µl of blood was taken from the lateral tail vein 
by vein stab and collected into lithium heparinised tubes (Sarstedt 
Microvette CB300) and plasma was separated by centrifugation 
(2,400 g for 5 min at 4°C) to produce a single aliquot of plasma 
(approximately 50ȝO ZKLFK ZDV IUozen (-80°C) and subsequently 
assayed for glucose (Thermoelectron infinity glucose reagent; 
Microgenics, UK) and insulin (Mercodia rat insulin ELISA; Diagenics, 
Milton Keynes, UK). 
 
2.2.6. Oral glucose tolerance test (OGTT) 
An oral glucose tolerance test was performed at day 120. Rats were 
deprived of food overnight and the following day the lateral tail vein was 
cannulated, and a baseline blood sample (120µl) was taken 
immediately before the glucose load (2g/kg p.o.), along with an aliquot 
of whole blood (25µl) for HbA1c determination (direct enzymatic HbA1c 
assay; Diazyme, Germany) into an EDTA vial (Sarstedt Microvette 
CB300K2E). Further blood samples were taken 15, 30, 45, 60, 120 and 
180 minutes post glucose administration and plasma was separated by 
centrifugation as described above. 
 
2.2.7. Total pancreatic insulin content 
The pancreas (n=1 for HFD/Veh, n=3 for HFD/STZ) was removed, 
weighed and homogenized in acid HWKDQRO PROO LQ>YROYRO@
ethanol) for subsequent determination of total pancreatic insulin content 
(Mercodia rat insulin ELISA). 
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2.2.8. Statistics 
Statistical advice was sought from a statistician at RenaSci. 
 
Analysis of body weight, food intake and water intake was by an 
analysis of covariance (ANCOVA) with Tukeys post-hoc test, with the 
average of day -7 to 0 as the covariate. Analysis of plasma glucose, 
plasma insulin, the OGTT, HbA1c and mechanical withdrawal 
thresholds was by a Mann Whitney test. Additional analysis of the 
OGTT was by a Friedman test with Dunns multiple comparison post-
hoc test. Analysis of the Hargreaves test was by an unpaired t-test. 
 
In all analyses, a p value of less than 0.05 was considered statistically 
significant. 
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2.3. Results 
2.3.1. Effects of HFD/STZ on body weight, and food 
and water intake 
Prior to injection with STZ, both groups of HFD rats exhibited a steady 
weight gain of ~53g per week (Figure 2.1A). The day after injection with 
STZ there was a dip in the body weight of the HFD/STZ group, and 
after this they exhibited a significantly stunted growth rate in 
comparison to the HFD/Veh group (p<0.001), with a difference of 
~260g between the two groups at the end of the study (521±30g vs. 
782±52g at day 120). The HFD/STZ group exhibited a fourfold increase 
in daily water consumption (22.0±0.8g vs. 88.3±6.2g at 120 days post 
STZ), compared to the HFD/Veh controls (p<0.001) and this was 
evident from the first days after injection with STZ (Figure 2.1B). The 
HFD/STZ group also exhibited a small increase in food consumption, 
compared to the HFD/Veh group (Figure 2.1C), although this was only 
significant at certain points throughout the study (p<0.05). 
 
2.3.2. Effects of HFD/STZ on metabolic parameters 
The present study also demonstrated that the HFD/STZ model caused 
changes in metabolic parameters that are indicative of diabetes. At day 
-5, prior to injection of STZ, the mean plasma glucose concentration 
was 8.5±0.4mM in the HFD/Veh group and 8.4±0.5mM in the HFD/STZ 
group. Following injection with STZ this remained stable in the 
+)'9HK JURXS DW mM, whereas it increased threefold to 
24.mM (p<0.001) in the HFD/STZ group (Figure 2.2A). In the 
HFD/STZ group, plasma insulin concentration decreased 
(1.05±0.17ngml-1) whereas there was a slight increase in the HFD/Veh 
JURXS ngml-1) compared to levels prior to STZ injection 
(2.41±0.63ngml-1 in the HFD/Veh group and 2.01±0.33ngml-1 in the 
HFD/STZ group at day -5; Figure 2.2B; p<0.001), These values were 
maintained throughout the rest of the study. 
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Figure 2.1 Effects of HFD/STZ (n=12) on (A) body weight, (B) water 
intake and (C) food intake, in comparison with HFD/Veh (n=6). All data 
represent mean ± SEM, analysis was by an ANCOVA (with the average 
of day -7 to 0 as a covariate): * p<0.05, ** p<0.01.  
In comparison to HFD/Veh controls, body weight and water intake, 
p<0.001 from day 1 
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Figure 2.2 Effects of HFD/STZ (n=12) on (A) fasting plasma glucose 
and (B) fasting plasma insulin, in comparison with HFD/Veh (n=6). 
Blood was collected after a four hour fast. All data represent mean ± 
SEM (day 134 n=2 for HFD/Veh, n=6 for HFD/STZ, no statistical 
analysis was performed at this time point). The error bar at day 134 for 
glucose is too small to be visible. Analysis was by a Mann-Whitney:  
** p<0.01, *** p<0.001. 
B 
A 
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A measure of average plasma glucose concentration is HbA1c. HbA1c 
is formed when haemoglobin reacts with glucose molecules, and is 
found in red blood cells. These cells have a life cycle of about two 
months, thus the amount of glycosylated haemoglobin they contain is 
directly related to the average plasma glucose concentration during this 
time (Koenig et al.. As shown in Figure 2.3, HbA1c levels were 
significantly increased (p<0.01) in the HFD/STZ group compared to the 
HFD/Veh controls.  
 
 
 
 
 
Figure 2.3 Effects of HFD/STZ (n=12) on HbA1c levels, in comparison 
with HFD/Veh (n=6). All data represent mean ± SEM, analysis was by a 
Mann Whitney: ** p<0.01 
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An OGTT was performed to determine how quickly glucose was cleared 
from the blood following the delivery of a glucose load. In the HFD/Veh 
group there was an increased production of insulin, which was 
significant from 30 minutes until 60 minutes (p<0.01), and had returned 
to basal levels after 120 minutes (Figure 2.4B). This increase in insulin 
prevented a large fluctuation in the plasma glucose concentration, 
resulting in only a small, but significant (p<0.05) increase from 15 to 60 
minutes (Figure 2.4A). Significantly less insulin was produced in the 
HFD/STZ group (p<0.001, compared to HFD/Veh); with only a 
significant increase from basal levels seen at 15 minutes (p<0.05), and 
as a result there was a much larger increase in plasma glucose 
concentration (p<0.001, compared to HFD/Veh, Figure 2.4A). However, 
as with the HFD/Veh group, plasma glucose concentration had returned 
close to basal levels at 120 minutes post glucose administration.  
 
Finally, pancreatic insulin content in the HFD/STZ group was also 
quantified at the end of the study. Levels of pancreatic insulin in the 
HFD/STZ group were very low (5700ȝJLQVXOLQJSDQFUHDV). Due 
to time limitations and the resources required for this test, pancreatic 
insulin concentration was only assessed in one sample from the 
+)'9HKJURXS ȝJ LQVXOLQJSDQFUHDV), and therefore statistical 
analysis could not be performed.  
 
All of these results confirm that the HFD/STZ model of diabetes 
produces robust metabolic changes that can be correlated with the 
disease in humans. 
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Figure 2.4 Effects of HFD/STZ (n=12) on (A) plasma glucose and (B) 
plasma insulin during an OGTT, in comparison with HFD/Veh (n=6). 
Rats were fasted overnight, and the next morning (day 120) a glucose 
load was given (2g.kg-1, p.o.) and blood samples were collected at 0, 
15, 30, 45, 60, 120 and 180 minutes. All data represent mean ± SEM, 
analysis was by a Mann Whitney: 
** p<0.01, *** p<0.001 (HFD/STZ vs. HFD/Veh) 
Additional analysis was by a Friedman test with Dunns multiple 
comparison post-hoc test: 
& p<0.05, && p<0.01, &&& p<0.001 (HFD/Veh vs. HFD/Veh at T0) 
# p<0.05, ## p<0.01, ### p<0.001 (HFD/STZ vs. HFD/STZ at T0) 
 
 
B 
A 
B 
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2.3.3. Effects of HFD/STZ on mechanical withdrawal 
thresholds 
The mean mechanical withdrawal threshold of the hindpaws of 
HFD/Veh controls throughout the study (14.1±0.6g) was consistent with 
responses in naive rats. Following injection of STZ, there was a 
progressive decrease in the mechanical withdrawal threshold of the 
hindpaws in the HFD/STZ rats, compared to the HFD/Veh controls. A 
significant difference in the hindpaw withdrawal thresholds of the two 
groups was first evident at day 46 (Figure 2.5). By day 120, the mean 
mechanical withdrawal threshold of the HFD/STZ group was 7.0±0.7g 
compared to 14.2±0.5g in the HFD/Veh group. This decrease in 
mechanical withdrawal threshold is indicative of the presence of 
mechanical hypersensitivity. It is noteworthy that the development of 
mechanical hypersensitivity is very slow in comparison to the metabolic 
changes. 
 
Figure 2.5 Effects of HFD/STZ (n=12) on mechanical withdrawal 
threshold of the hindpaws, in comparison with HFD/Veh (n=6). All data 
represent mean ± SEM, analysis was by a Mann-Whitney: 
* p<0.05, ** p<0.01, *** p<0.001 
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Finally, the Hargreaves test was carried out on two consecutive days at 
the end of the study to determine whether the thermal withdrawal 
latency was altered in the HFD/STZ rats compared to the HFD/Veh 
controls. There were no significant differences in the thermal withdrawal 
latency between the two groups at these two timepoints (Figure 2.6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6 Effects of HFD/STZ (n=12) on thermal withdrawal latency in 
the Hargreaves test, in comparison with HFD/Veh (n=6). All data 
represent mean ± SEM, analysis was by an unpaired t-test. 
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2.4. Discussion 
2.4.1. Metabolic effects in the HFD/STZ model 
In the present study, the combination of a HFD and a single dose of 
STZ were examined for their ability to produce a type 2-like model of 
diabetes. The HFD/STZ model resulted in all of the metabolic changes 
that were expected (Srinivasan et al., 2005). There was a decreased 
growth rate, and a huge increase in water consumption, which resulted 
in a large increase in urine production. These changes were evident in 
the first few days after STZ injection, and were significant from the first 
week onwards. The rats also developed hyperglycaemia, and 
hypoinsulinaemia, with a large rise in plasma glucose levels, and a 
corresponding decrease in plasma insulin. Injection of STZ significantly 
reduced food intake during the first week, but after this the intake 
fluctuated in both groups but remained relatively stable, with the 
HFD/STZ group taking in more calories than the HFD/Veh controls in 
general, which was significant at several timepoints. In the OGTT, 
administration of glucose in the HFD/Veh rats caused a significant 
increase in the production of insulin, followed by a rapid decrease in 
plasma glucose levels. However, in the diabetic HFD/STZ rats, the 
insulin-secretory response was greatly decreased and the level of 
plasma insulin was only significantly changed from basal levels at 15 
minutes. This increase did not bring it close to the basal level of the 
HFD/Veh rats, resulting in a much larger increase in plasma glucose 
levels. 
 
2.4.2. Mechanical withdrawal thresholds in the 
HFD/STZ model 
The mechanical withdrawal threshold of the hindpaws in the HFD/Veh 
group was stable throughout the duration of the study, but in the 
HFD/STZ group the mechanical withdrawal threshold was decreased 
significantly by day 46 and this decrease persisted for a further ten 
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weeks until the study was terminated. The timecourse of the changes in 
mechanical withdrawal threshold of the hindpaws in the HFD/STZ rats 
was slower than the rapid metabolic changes produced in this model. 
This indicates that the development of mechanical hypersensitivity is 
not just a direct consequence of hyperglycaemia, but must also be due 
to other underlying mechanisms, some of which will be investigated in 
Chapters 3 and 4. 
 
The timecourse of the change in mechanical withdrawal thresholds in 
the HFD/STZ model reported in this first study is slower than the rapid 
development of mechanical hypersensitivity reported in the STZ-alone 
model, where changes are first seen after 1-2 weeks (Ahlgren et al., 
&DOFXWW et al.&RXUWHL[ et al.'REUHWVRY et al., 2003; 
Fuchs et al., 2010; Xu et al., 2011). However in the studies in Chapters 
3-5 there was a slightly faster progression, with a significant decrease 
in mechanical withdrawal thresholds first reported between 2-3 weeks 
after STZ injection. 
 
There has only been one other report looking at the development of 
mechanical hypersensitivity in the HFD/STZ model so far, in which 2 
weeks of high fat diet followed by 35mgkg-1of STZ was reported to not 
alter mechanical withdrawal thresholds of the hindpaw, mechanical 
hyperalgesia in the pinprick test or thermal/cold thresholds, compared 
to a higher dose of STZ alone (Ferhatovic et al., 2013). However this 
study resulted in a much more moderate model of diabetes, with lower 
plasma glucose levels and a steady increase in body weight. 
 
Previous studies suggest that it is not just prolonged hyperglycaemia 
that is responsible for the development of mechanical hypersensitivity, 
but also insulin deficiency. Insulin implantation has been shown to 
prevent the development of mechanical hypersensitivity, and 
established hypersensitivity was reversed by prolonged insulin 
treatment, but not by a single insulin injection (Calcutt et al. . 
Similarly, Hoybergs et al. (2007) showed that low-dose insulin 
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administration, which did not significantly change hyperglycaemia, 
reversed tactile hypersensitivity and mechanical hyperalgesia. 
Furthermore, in a long term (24 week) study, insulin implantations at 
day 7 after STZ restored blood glucose, and also prevented the 
development of mechanical hypersensitivity (Otto et al., 2011). Thus it 
seems likely that the development of mechanical hypersensitivity is 
related, in part, to a prolonged insulin deficiency (Calcutt et al.. 
 
The relationship between plasma insulin and glucose and the 
development of mechanical hypersensitivity was further investigated by 
Romanovsky et al. (2004). In this study, mechanical hypersensitivity 
was compared between STZ treated rats that became hyperglycaemic 
(20-25mM) and those that maintained normal blood sugar levels, but 
displayed a decrease in pancreatic ȕ-cell area and plasma insulin 
levels, similar to early stage type 1 diabetes (Romanovsky et al., 2010). 
Interestingly, both groups of rats showed a decrease in mechanical 
withdrawal thresholds as soon as 1 week after STZ injection, which was 
fully developed at 3 weeks (Romanovsky et al., 2004). They concluded 
that it could not be solely hyperglycaemia that was responsible for the 
development of hyperalgesia. In a further study, Romanovsky et al. 
(2006) found that in STZ treated rats that did not go on to develop 
hyperglycaemia, plasma insulin levels were correlated with paw 
pressure withdrawal thresholds. Furthermore, low-dose injections of 
insulin, which increased plasma insulin without affecting plasma 
glucose levels, reversed changes in mechanical sensitivity 
(Romanovsky et al., 2006). More recently, Otto et al. (2011) 
hypothesised that insulin deficiency and impaired insulin signalling 
results in a loss of neurotrophic support which contributes to changes in 
sensory afferent fibre function. 
 
Finally, at the end of this study, the thermal nociceptive thresholds were 
examined in all of the HFD/STZ and HFD/Veh control rats over two 
days. No difference was seen on the first day, and the withdrawal 
latency was slightly longer in the HFD/STZ rats on the second day, but 
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no significance was seen. As no significant changes in thermal 
withdrawal thresholds were seen in this first study, and due to the 
inconsistencies in the literature so far, the remaining work in this thesis 
focuses on the changes in mechanical withdrawal thresholds in this 
model of diabetes. 
  
Chapter 3. 
Investigating the impact of the HFD/STZ 
model on peripheral nerve function, and 
spinal mechanisms of central sensitisation  
 
3.1. Introduction 
The work in this chapter will investigate the impact of the HFD/STZ 
model on peripheral nerve function and spinal mechanisms of central 
sensitisation, to help identify the mechanisms underpinning the 
behavioural pain phenotype in these rats. 
 
Fluoro-Jade-B and CGRP are used as measures of peripheral nerve 
function and pathology, as well as for investigating changes in the 
spinal cord. 
 
3.1.1. Fluoro-Jade B 
Fluoro-Jade B is a fluorescent ligand which is used to detect and 
quantify degenerating neurones. It stains cell bodies, dendrites, axons 
and axon terminals, and although the exact mechanism is unknown, it 
has been speculated that it may bind to a polyamine (Schmued et al., 
2000).  
 
Fluoro-Jade has been used to detect whether neuronal death is 
induced in the brain in diabetic models when exposed to 
hypoglycaemia. No neuronal death was detected in the hippocampus or 
the cortex at 1 or 4 weeks in STZ treated rats, or in the hypothalamus at 
8 weeks following STZ treatment (Lechuga-Sancho et al., 2006). 
However neuronal death has been induced in the cortex by 
hypoglycaemia at 1 week in STZ treated rats (Bree et al.. Fluoro-
Jade has also been used to detect degenerating neurones in the spinal 
cord (Kudo et al., 2006; Marmiroli et al.  1JX\HQ et al., 2004; 
Orendacova et al., 2005; Saganová et al., 2006) and DRGs (Lazaridis 
et al., 2011; Marmiroli et al.  in a variety of models that induce 
neuronal death, although there are some reports that it also stains 
astrocytes in the spinal cord (Anderson et al., 2003). 
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As no neuronal death has been detected in the brain of STZ rats, I was 
interested in investigating whether any neuronal death occurs in the 
DRGs or spinal cord of HFD/STZ rats, and whether this might play a 
role in the progression of diabetic neuropathy. 
 
3.1.2. CGRP 
CGRP plays an important role in the transmission and modulation of 
peripheral and central nociceptive processing 1HXJHEDXHU . 
CGRP is synthesised and stored in primary afferent axons, especially 
small DRG cells and unmyelinated axons (van Rossum et al. 
Willis et al., 2004). CGRP receptors are mostly found in laminae I and II 
in the spinal cord, the major terminal site of nociceptive primary 
afferents, but they can also be found in deeper laminae (Ye et al., 
. 
 
Levels of CGRP in the spinal cord can be increased by noxious stimuli 
(Morton et al.  6FKDLEOH et al.  and by inflammation 
(Schaible et al.  :LOOLV et al., 2004), as well as electrical 
stimulation of unmyelinated afferents (Morton et al.6FKDLEOH et 
al. and administration of carrageenan (Garry et al.. The 
CCI model of neuropathic pain is, however, associated with a decrease 
in CGRP immunoreactivity (Bennett et al.<X et al.. Spinal 
application of CGRP has pro-nociceptive effects (Li et al., 2001; Oku et 
al.6XQ et al., 2004a; Sun et al., 2003; Sun et al., 2004b), and a 
CGRP antagonist (CGRP8-37), or anti-CGRP antiserum, prevents or 
reduces central sensitisation of dorsal horn neurones (Neugebauer et 
al.6XQ et al., 2004a; Sun et al., 2004b; Yu et al., 2002), as well 
as attenuating hypersensitivity in animal models of inflammatory and 
neuropathic pain (Jang et al., 2004; Kawamura et al..XUaishi et 
al.  6XQ et al., 2003; Yu et al. . CGRP knock-out mice 
showed no pain responses in the hot plate test, and no development of 
secondary hyperalgesia in a model of knee joint inflammation (Zhang et 
al., 2001a) 
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The impacts of STZ induced diabetic neuropathy on levels of CGRP in 
different tissues in the rat have varied, as outlined below in Table 3.1. 
An increase in CGRP-positive fibres and basal CGRP release has been 
reported in the skin, whereas a decrease in CGRP content/mRNA 
levels/CGRP-positive neurones has been reported in nerves and 
DRGs. Finally, in the spinal cord, there was no change in basal CGRP 
release at 5 weeks in STZ treated rats, but an increase in capsaicin-
stimulated release of CGRP was observed (Bishnoi et al., 2011). 
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 Table 3.1 Summary of the effects of STZ-induced diabetes on CGRP 
expression/release in different tissues. 
 
  
Tissue Change Reference 
Skin 
Doubling of basal and capsaicin-evoked 
release of CGRP in 8 week STZ rats 
(Ellington et 
al., 2002) 
Increase in CGRP-positive fibres in 12 
week STZ rats 
(Karanth et 
al.,  
Vagus 
nerve 
Decrease in CGRP content in 8 week 
STZ rats 
(Calcutt et al., 
 
No change in the levels of CGRP-positive 
neurones in the nodose ganglion in 8, 16 
or 24 week STZ rats 
(Regalia et al., 
2002) 
Sciatic 
nerve 
Decrease in CGRP content in 4 week 
STZ rats 
(Brewster et 
al.
Diemel et al., 
 
DRGs 
Decrease in mRNA levels in 4 week STZ 
rats 
(Brewster et 
al.
Diemel et al., 
 
Decrease in CGRP positive neurones in 4 
week and 12 month STZ rats 
(Adeghate et 
al., 2006; 
Zochodne et 
al., 2001) 
Spinal 
cord 
No change in basal CGRP release in 5 
week STZ rats, but an increase in 
capsaicin-stimulated release of CGRP 
(Bishnoi et al., 
2011) 
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3.1.3. Microglia 
Glial cells are 10 to 50 times as numerous as neurones in the CNS and 
belong to one of three groups: microglia, astrocytes or oligodendrocytes 
(Gao et al., 2010). Glia play an important role in central sensitisation in 
neuropathic pain, and so it is important to elucidate their role in the 
spinal cord in the HFD/STZ model. 
 
Microglia represent 5-RIJOLDLQWKH&16(Tsuda et al., 2005). It is 
currently believed that microglia derive from the yolk sac macrophages 
that seed the rudimental brain during early foetal development (for 
review see Ginhoux et al., 2013). When resting, microglia have a small 
soma with thin, branching processes which survey the 
microenvironment for stimuli such as CNS trauma, ischemia and 
infection (Tsuda et al., 2005). 
 
There are a wide variety of pathways that lead to activation of microglia 
(Smith, 2010), and these include:  
- Matrix PHWDOORSHSWLGDVH003, which is thought to contribute 
to the initiation of neuropathic pain through IL-1ȕ cleavage 
(Kawasaki et al., 2008). 
- Fractalkine, a chemokine which is cleaved by MMPs, and its 
receptor CX3CR1, which is mainly expressed by microglia. 
CX3CR1 expression is increased during neuropathic pain, and it 
is thought that fractalkine can attract CX3CR1-expressing 
microglia to sites of ongoing pathology (Verge et al., 2004). 
- Monocyte chemoattractant protein-1 (MCP-1, OR CCL2), and its 
receptor CCR2, which is upregulated in microglia following nerve 
injury (Zhang et al., 2006a) 
- Toll-like receptors (TLRs), which cause activation of NFțB, and 
the subsequent release of IL-1ȕ, IL-6 and TNFĮ UHVXOWLQJ in a 
positive feedback loop in the pain-pathway (Kim et al., 2007a). 
TLR4 activation has been shown to correlate with the onset of 
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behavioural sensitivity in the spared nerve injury (SNI) model 
(Tanga et al., 2004). 
- Neuregulin-1 (NRG1), a growth factor, is released by primary 
afferents and binds to erbB2, 3 and 4, which are expressed by 
microglia. Blockade of erbB2 reduces accumulation of microglia 
and attenuates hypersensitivity in the SNL model (Calvo et al., 
2010). 
- ATP and its receptors (especially P2X4 and P2X7) (Hide et al., 
2000; Inoue et al., 2007; Tsuda et al., 2013). 
 
Microglia can also be activated by ROS, NO, substance P (Zhou et al., 
2010), brain-derived neurotrophic factor (BDNF), PGs, glutamate (Tikka 
et al., 2001) and heat shock proteins which are upregulated by 
peripheral nerve injury (Costigan et al..  
 
Once microglia are activated, they show dramatic changes in 
morphology including: hypertrophy and thickened and retracted 
processes (Eriksson et al.; increases in the levels of microglial 
markers such as ionized calcium binding adapter molecule 1 (Iba1) and 
CD11b (Tsuda et al., 2005); as well as proliferation (Gehrmann et al., 
 5RPHUR-Sandoval et al., 2008a). Activation of microglia and 
phosphorylation of p38 MAPK is involved in Ca2+ sensitive intracellular 
signalling cascades and leads to the production of pro-inflammatory 
cytokines (Hanisch, 2002; Kim et al. D .UHXW]EHUJ 
Ledeboer et al., 2005; Zhuo et al., 2011). They also release cytotoxic 
molecules such as ROS (Kim et al., 2010), NO (Tikka et al., 2001), and 
PGs (Candelario-Jalil et al., 2007), as well as BDNF (Coull et al., 2005), 
substance P, excitatory amino acids, and ATP. These substances can, 
in turn, activate nearby astrocytes, microglia and neurones (Zhou et al., 
2010). 
 
Microglial activation in the spinal cord has been seen in a variety of 
animal models of pain, including the formalin model (Fu et al., 2000; Fu 
et al.  6ZHLW]HU et al. , models of peripheral nerve injury 
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(Colburn et al.  &R\OH , and spinal nerve transection 
(Sweitzer et al. . Minocycline, a second-generation tetracycline 
with anti-inflammatory properties (for review see Garrido-Mesa et al., 
2013), selectively prevents the activation of microglia and blocks the 
release of pro-inflammatory cytokines IL-1ȕ and TNFĮ (Ledeboer et al., 
2005; Padi et al., 2008). Minocycline is able to attenuate the 
development of neuropathic pain in sciatic inflammatory neuropathy 
and acute spinal immune activation with intrathecal HIV-1 gp120 
(Ledeboer et al., 2005), CCI (Padi et al., 2008), and L5 spinal nerve 
transection (Raghavendra et al., 2003). Minocycline is not, however, 
effective against already established hypersensitivity (Ledeboer et al., 
2005; Padi et al., 2008; Raghavendra et al., 2003). 
 
As well as a role in models of nerve injury, microglia have also been 
shown to play a part in the development of painful symptoms in animal 
models of diabetes. Microglia are upregulated in the spinal cord of rats 
as soon as 4 days after injection with STZ (Talbot et al., 2010), as well 
as at later timepoints; 2-4 weeks (Tsuda et al., 2008); 3 weeks (Kim et 
al., 2012b); 4 weeks (Morgado et al., 2011a); and 5 weeks (Wodarski et 
al. . In STZ treated mice, a slower change in the number of 
microglia was reported, with no change evident at 1 month, but an 
increase at 3 months, peaking at 5 months, and decreasing slightly by 8 
months post model induction (Toth et al., 2010). An increase in the 
density of Iba1-positive endoneurial macrophages was also seen in the 
sciatic and tibial nerves of STZ rats (Nukada et al., 2011). However, in 
the db/db mouse model of type 2 diabetes, no change in spinal 
microglial activation was observed at postnatal week 6 or 16 (Liao et 
al., 2011). 
 
An increase in ERK (Tsuda et al., 2008), JNK and p38 phosphorylation 
(Sweitzer et al., 2004) in both neuronal and microglial cells in the spinal 
cord and DRG of STZ treated rats has been reported, indicating an 
increase in their activation, which correlates with the hyperalgesic state 
(Daulhac et al., 2006). Inhibitors of all three of these signalling 
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molecules were able to attenuate these painful symptoms (Daulhac et 
al., 2006; Sweitzer et al., 2004).  
 
Treatment with minocycline in STZ animals also causes a decrease in 
microglial activation, as well as attenuating the increased levels of IL-
ȕ %15 71)Į DQG 7539 DQG UHYHUsing cold and tactile 
hypersensitivity (Morgado et al., 2011a; Pabreja et al., 2011; Talbot et 
al., 2010). Infusion of lidocaine in the early phase, but not the late 
phase, was also able to attenuate tactile hypersensitivity in STZ mice 
through inhibition of microglial activation (Suzuki et al., 2011). 
 
3.1.4. Astrocytes 
Astrocytes are the most abundant cells in the CNS, and they are able to 
form networks with themselves and are closely associated with 
neurones and blood vessels (Saravia et al., 2002). This enables them 
to play a role in maintaining the balance of the neuronal environment 
through homeostatic regulation of water, ions and pH (Montgomery, 
, as well as protecting against toxic insults such as reactive 
oxygen species (Lamigeon et al., 2001). Astrocytes also play a role in 
synaptic transmission, where excess amino acids such as glutamate 
are removed from the synaptic cleft by excitatory amino acid 
transporters (EAATs; Nakagawa et al., 2010), preventing over-
excitation and neurotoxicity. They also play a role in mediating glucose 
metabolism, as uptake of excess glutamate leads to stimulation of 
glycolysis, where glucose is converted to lactate. This produces ATP, 
which is used for the synthesis of glutamine from glutamate (Magistretti 
et al.. 
 
Nociceptive stimuli, as well as pro-inflammatory cytokines, can lead to 
activation of astrocytes, as they express receptors for nociceptive 
neurotransmitters such as glutamate, substance P and CGRP 
(Marchand et al., 2005). They can also be activated by MMP2 
(Kawasaki et al., 2008). When astrocytes are activated, they exhibit a 
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hypertrophic morphology, with thickened process, and upregulation of 
glial fibrillary acidic protein (GFAP), an intermediate cytoskeletal 
filament protein specific for astrocytes. In turn, activation of astrocytes 
leads to further production and release of pro-inflammatory cytokines, 
chemokines, prostaglandins, NO, ATP, D-serine and glutamate, which 
can contribute to enhanced pain sensitivity. As with microglia, activation 
of astrocytes leads to activation of ERK and JNK signalling pathways, 
which release pro-inflammatory factors which can lead to further 
astrocyte activation (Milligan et al.. 
 
An increase in GFAP staining due to hypertrophy of activated 
astrocytes, known as astrogliosis, has been observed in the spinal cord 
in a variety of neuropathic and inflammatory pain models, paralleling 
the development of hypersensitivity (Garrison et al.2EDWD et al., 
2006; Raghavendra et al., 2004; Sweitzer et al.  :DQJ et al., 
. Whereas microglia numbers undergo a more rapid increase, and 
then a later decrease, astrogliosis has a more delayed initiation, but is 
then sustained long-term (up to 150 days in one study) (Raghavendra 
et al., 2004; Tanga et al., 2004; Zhang et al., 2006a). It is therefore 
hypothesised that upregulation of astrocytes contributes to the 
maintenance of chronic pain, whereas microglial activation is 
responsible for the development. However this pattern is not always 
observed in all animal models of pain (see Colburn et al. 
Romero-Sandoval et al., 2008a). Fluorocitrate, which functionally and 
morphologically suppresses glial cell activation, reduced 
hypersensitivity for 5 days in a postoperative pain model (Obata et al., 
2006), as well as attenuating thermal and mechanical hyperalgesia in 
the zymosan model (Meller et al., and attenuating the induction, 
and reversing the early phase of developed mechanical 
hypersensitivity, in neonatal capsaicin-treated adult rats (Nakagawa et 
al., 2007). 
 
In contrast to this upregulation of astrocytes in animal models of chronic 
pain, there are conflicting reports about the changes in levels of GFAP 
  
staining in various models of diabetes. Some groups have shown a 
significant decrease in GFAP staining in areas of the brain including the 
cerebral cortex, hippocampus, cerebellum and corpus callosum in STZ 
rats (Coleman et al., 2004; de Senna et al., 2011; Lechuga-Sancho et 
al., 2006; Renno et al., 2012; Zuo et al., 2011). In the retina, the 
intensity of GFAP staining in astrocytes was decreased as soon as 1 
month following STZ injection, and decreased further as the studies 
progressed (Barber et al., 2000; Rungger-Brandle et al., 2000). 
Conversely, other groups have shown an increase in GFAP staining in 
the hippocampus, cerebral cortex, and cerebellum at 6 week in STZ 
rats (Baydas et al., 2003), and in the hippocampus in NOD and STZ 
mice (Saravia et al., 2002). 
 
In the spinal cord, a decrease in the number of GFAP-immunoreactive 
astrocytes was seen in the dorsal and ventral horns, as well as the 
central region, with the number decreasing further between 6 and 12 
weeks after STZ injection (Afsari et al., 2008), and this has also been 
reported at 5 weeks in the same model (Wodarski et al. . 
However, there have also been reports of no change in GFAP 
expression at 4 weeks post-STZ (Tsuda et al., 2008), and in a recent 
report an increase in GFAP expression was seen at 3 weeks (Kim et 
al., 2012b). In the db/db mouse model of type 2 diabetes, an increase 
in the amount of GFAP staining was seen in the dorsal horn of the 
spinal cord from 8 weeks of age, and was maintained thereafter (Dauch 
et al., 2012; Liao et al., 2011). L-Į-aminoadipate (a specific astrocyte 
inhibitor) was able to attenuate mechanical hypersensitivity and phenyl-
alpha-tert-butyl nitrone (an antioxidant) significantly decreased the 
levels of GFAP, suggesting that oxidative stress may be an underlying 
cause of the increase in spinal GFAP expression (Liao et al., 2011). 
 
The role(s) of astrocytes and microglia in any of the models of diabetic 
neuropathy have yet to be fully elucidated, as seen in some of the 
conflicting results described above. It is therefore of upmost interest to 
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quantify levels of activated microglia and astrocytes in the spinal cord in 
the HFD/STZ model. 
3.1.5. Aim of the Study 
The aim of this study was to investigate the effect of the HFD/STZ 
model on immunohistochemical staining in the DRGs and spinal cord. 
Fluoro-Jade B staining was used to investigate whether any neuronal 
death could be detected in the DRGs or spinal cord, and the expression 
of CGRP positive neurones was also investigated, as well as the 
activation of microglia and astrocytes in the spinal cord. 
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3.2. Methods 
For detailed methods of induction of diabetes, blood sampling and von 
Frey testing see Chapter 2. 
 
3.2.1. Animals 
All experiments were carried out under Home Office Licence 40/3124, 
in accordance with the UK Home Office Animals (Scientific Procedures) 
$FW  DQG ,$63 JXLGHOLQHV. 47 male Sprague-Dawley rats (200-
250g), obtained from Charles River (Kent, UK), were individually 
housed on a normal light cycle (lights on: 07:00 -  Zith free 
access to either nRUPDO FKRZ RU D KLJK IDW GLHW  IDW E\ FDORULF
FRQWHQW'diet; Research Diets, New Jersey, USA) and water at 
all times. The rats were divided into two stratified groups on the basis of 
body weight, and the lean/Veh group were fed chow, and the HFD 
group were fed the high fat diet. After three weeks consumption of diet, 
the HFD group was stratified into two further subgroups on the basis of 
body weight and mechanical withdrawal thresholds, and the lean/Veh 
and HFD/Veh groups received an i.p. injection of citric acid buffer, and 
the HFD/STZ group received an i.p. injection of STZ (45mgkg-1). Blood 
samples were taken at days -5, 8, 23 and 44. von Frey testing was 
carried out twice weekly. 
 
3.2.2. DRG and spinal cord immunohistochemistry 
Tissue was removed and prepared for immunohistochemistry at the 
following stages of the model: day 10 (Lean/Veh: n=6; HFD/Veh: n=6; 
HFD/STZ: n=3); day 30 (Lean/Veh: n=5; HFD/Veh: n=5; HFD/STZ: 
n=4); and day 50 (Lean/Veh: n=6; HFD/Veh: n=6; HFD/STZ: n=4). 
 
Rats were overdosed with sodium pentobarbital and transcardially 
SHUIXVHG ZLWK  VDOLQH IROORZHG E\  SDUDIRUPDOGHK\GH 3)$
Sigma, U.K.) in 0.1M phosphate buffered saline (PBS). The lumbar 
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spinal cord, as well as L4, L5 and L6 DRGs were excised and post-
fixed LQ3)$IRUKRXUVDQG WKHQVWRUHGLQVXFURVHLQ0
3%6 VRGLXP D]LGH VROXWLRQ DW oC. Spinal cord tissues were 
frozen with dry ice and fixed to a microtome stage (Leica SM2010R) 
with mounting media and sliced into 40um sections through L4/L5. 
DRGs were suspended in mounting media, and frozen in a chilled 
acetone solution, and then sliced on a cryostat (Leica CM3050) into 
15ȝm sections, and mounted onto Superfrost Plus microscope slides 
(Thermo-Scientific, UK). 
 
 
 
Table 3.2 Primary and secondary antibodies used in 
immunohistochemistry experiments 
Primary 
antibody 
(source) 
Dilution/ 
conditions 
Secondary 
antibody 
(all Molecular 
Probes, 
Oregon) 
Dilution/ 
conditions 
Rabbit anti- 
Iba1 (Wako, 
Japan) 
1:1000, 72hrs, 
4°C 
Alexaflour 488 
donkey anti-
rabbit 
1:500, 2hrs, RT 
Mouse anti- 
GFAP (Thermo-
Fisher, UK) 
1:100, 18hrs, 
RT 
Alexaflour 568 
donkey anti-
mouse 
1:500, 2hrs, RT 
Rabbit anti- 
CGRP 
(Millipore, UK) 
1:1000, 18hrs, 
RT 
Alexaflour 488 
goat anti-rabbit 
1:500, 2hrs, RT 
Mouse anti- 
NeuN (Fisher 
Scientific, UK) 
1:100, 1hr, RT 
Alexaflour 568 
donkey anti-
mouse 
1:500, 2hrs, RT 
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3.2.2.1. NeuN and Fluoro-Jade B 
A pilot study was run double-labelling spinal cord and DRG sections 
with Fluoro-Jade B and GFAP as it has previously been reported that 
Fluoro-Jade B can stain astrocytes in the spinal cord, instead of 
degenerating neurones (Anderson et al., 2003; Damjanac et al., 2007). 
In this pilot study, there was no colocalisation between Fluoro-Jade B 
and GFAP (data not shown), and so double-labelling with NeuN was 
run in this study instead. 
 
Neuronal cells were stained using NeuN and dying or degenerating 
neurones were stained using Fluoro-Jade B (Millipore) (Schmued et al., 
2000). The same protocol used for Iba1/GFAP was followed for staining 
with NeuN, but whereas the spinal cord sections were mounted after 
the secondary antibody had been washed off, the whole process was 
carried out on DRG sections which were already annealed to 
microscope slides. The sections were allowed to air-dry on a slide 
warmer at 50°C for half an hour, and then the following solutions were 
applied: 
 VRGLXPK\GUR[LGHLQDOFRKROPLQXWHV 
 DOFRKROPLQXWHV 
 distilled water, 2 minutes 
 SRWDVVLXPSHUPanganate, 3 minutes 
 distilled water, 2 minutes 
  )OXRUR-Jade B solution (freshly made up from stock 
solution each day) 
 distilled water, 3 minutes (x3) 
The slides were then dried on a slide warmer at 50°C, immersed in 
xylene for 1 minute, and then coverslipped with DPX. 
 
3.2.2.2. CGRP 
The same protocol was followed as for Iba1/CGAP except only using 
the CGRP primary and secondary antibodies (Table 3.2). 
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3.2.2.3. Iba1 and GFAP 
Microglial cells were stained using Iba1 and astrocytes were stained 
using GFAP. Sections were blocked for 1 hour in 0.1M PBS containing 
JRDWVHUXP7ULWRQ;-100 at room temperature (RT). Sections 
were then incubated with an Iba1 primary antibody (Table 3.2) diluted 
with Trizma Triton X-100 buffered saline (TTBS). Five 10 minute 
washes in 0.1M PBS were carried out, and then sections were 
incubated with secondary antibody (Table 3.2), and another five 10 
minute washes were carried out. This process was then repeated on 
the same sections, this time using GFAP primary and secondary 
antibodies (Table 3.2). Sections were then mounted on gelatinised 
microscope slides, air-dried overnight at RT in the dark and cover-
slipped using Fluoromount (Sigma). 
 
3.2.3. Quantification of antibody staining 
7 individual spinal cord sections and 6 DRG sections were analysed per 
rat. For Iba1 and GFAP, and NeuN and Fluoro-Jade B, images were 
taken of the dorsal horn, ventral horn and central region, whereas only 
images of the dorsal horn were taken for CGRP. The mean of the left 
and right half of the dorsal and ventral horn was calculated for each 
section. 
 
Iba1 and GFAP, and CGRP stained sections were visualised using a 
20× 0.4NA objective lens on a Leica DMIRE2 fluorescence microscope, 
running Volocity 5.5 (PerkinElmer) equipped with a Hamamatsu Orca 
ER camera. NeuN and Fluoro-Jade B stained sections were visualised 
using a 20× 0.4NA objective lens on a Leica DMIRB fluorescence 
microscope, running Volocity 5.5 equipped with a Hamamatsu Orca ER 
camera. 
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Figure 3.1 Schematic diagrams of L4, L5 and L6 of the spinal cord with: 
orange boxes marking the approximate dorsal horn region utilised for 
Iba1, GFAP and Fluoro-Jade B quantification; blue boxes marking the 
eyebrow region of the superficial dorsal horn used for CGRP 
quantification; and turquoise boxes and purple boxes marking the 
ventral horn and central region respectively that were utilised for GFAP 
quantification. Adapted from (Sagar et al., 2011) 
 
3.2.3.1. NeuN and Fluoro-Jade B 
Images were acquired using an exposure time of 400ms for Fluoro-
Jade B, and 600ms for NeuN. A heat map was applied on each image 
so that positively stained cells could be more easily identified from 
background staining. The total number of cells positively-stained with 
Fluoro-Jade B was counted manually for each DRG and spinal cord 
section. 
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3.2.3.2. CGRP 
Images were acquired using an exposure time of 35ms. 
Immunofluorescence was quantified via region of interest analysis as 
eyebrow staining in the superficial dorsal horn, using threshold 
intensity values on Velocity 5.5 software. 
 
3.2.3.3. Iba1 and GFAP 
Images were acquired using an exposure time of 444ms for Iba1. Only 
activated, and not the total number of microglia, were counted manually 
in a quadrant of the dorsal horn in individual sections. Microglia were 
defined as activated if they displayed a clearly swollen cell body with 
reduced processes, which differ from normal or resting microglia where 
cell bodies are largely absent and large ramified processes are 
displayed (as illustrated in Figure 3.2). Assessment was performed by 
two independent blinded investigators, who quantified total number of 
activated microglia.  
 
The mean fluorescence grey intensity was also measured. Background 
fluorescence was measured by taking an image of an area within the 
sample, using the parameters described above, which contained no 
labelled structures, that was then subtracted from all images using 
IMAGE J (NIH open software with Macbiophotonics plugins). Following 
background subtraction, mean fluorescence grey intensity was 
determined for each image using IMAGE J. 
 
For quantification of GFAP, single-plane images of the superficial dorsal 
horn of the spinal cord were acquired uVLQJDQH[SRVXUHWLPHRIPV
and mean fluorescence grey intensity was measured as described 
above. All image analysis, cell counts and fluorescence measurements 
were performed off-line on captured images taken from stained 
sections. 
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 Figure 3.2 Scale bar is 100ȝm. An image at 40x magnification of Iba1 
staining in the dorsal horn of the spinal cord. Pink arrows indicate 
examples of resting/ramified microglia, and white arrows indicate 
examples of activated microglia. 
3.2.4. Statistics 
Analysis of body weight, food intake and water intake was by an 
ANCOVA with Tukeys post-hoc test, with the average of day -7 to 0 as 
the covariate. Analysis of plasma glucose, plasma insulin and 
mechanical withdrawal thresholds was by a Kruskal-Wallis test with 
Dunns post-hoc test. Analysis of all immunohistochemistry was by a 2
way analysis of variance (ANOVA) with Bonferroni post-hoc test. In all 
analyses, a p value of less than 0.05 was considered statistically 
significant. 
 
Rats were excluded from analysis of pain behaviour if in the two weeks 
before injection with STZ the average hindpaw mechanical withdrawal 
threshold was <10g. In this study, this represented 6 rats  3 lean/Veh, 
2 HFD/Veh and 1 HFD/STZ. 
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3.3. Results 
3.3.1. Effects of HFD/STZ on body weight, and food 
and water intake 
Consistent with the previous chapter, the HFD/STZ group exhibited a 
significantly stunted growth rate in comparison to both the lean/Veh and 
the HFD/Veh controls (p<0.001), with the HFD/Veh group gaining 
significantly more weight than the lean/Veh controls (p<0.05, Figure 
3.3A). Water intake was significantly increased in the HFD/STZ group 
(p<0.001), and there was no difference between the lean/Veh and the 
HFD/Veh controls (Figure 3.3B). The HFD/Veh group had a significantly 
higher caloric intake than the lean/Veh controls (p<0.05, Figure 3.3C), 
whereas the HFD/STZ group had a significant decrease in caloric 
intake in the first week after injection with STZ (p<0.001), and the 
caloric intake was then maintained at around the same level as the 
HFD/Veh controls, increasing significantly at various timepoints during 
the study. 
 
3.3.2. Effects of HFD/STZ on metabolic parameters 
and development of mechanical hypersensitivity 
Again, consistent with Chapter 2, there was a threefold increase in the 
plasma glucose levels in the HFD/STZ rats, and this remained stable 
for the duration of the study (Figure 3.4A). A small increase in plasma 
glucose concentration was also seen in the HFD/Veh group in 
comparison to the lean/Veh controls, although this was only significant 
at day -5 (p<0.05). The plasma insulin concentration was significantly 
decreased in the HFD/STZ group at day 8 (p<0.001), and this 
decreased further as the model developed (Figure 3.4B). There was an 
increase in the plasma insulin levels in the HFD/Veh group compared to 
the lean/Veh control group at day -5 (p<0.01), indicating that the HFD 
leads to the development of hyperinsulinaemia. 
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Figure 3.3 Effects of HFD/STZ on (A) body weight, (B) water intake 
and (C) food intake, in comparison with HFD/Veh and lean/Veh 
controls. Up to day 10: n=17 for lean/Veh and HFD/Veh, and n=11 for 
HFD/STZ. Up to day 30: n=11 for lean/Veh and HFD/Veh, and n=8 for 
HFD/STZ. Day 30 onwards: n=6 for lean/Veh and HFD/Veh, and n=4 
for HFD/STZ. All data represent mean ± SEM, analysis was by an 
ANCOVA (with day -7 to 0 as covariate) with Tukeys post-hoc test:  
(* vs. HFD/Veh, # vs. lean/Veh)  
* p<0.05, ** p<0.01, *** p<0.001; # p<0.05, ## p<0.01, ### p<0.001 
In comparison to HFD/Veh controls, body weight and water intake for 
HFD/STZ, p<0.001 from day 3. 
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Figure 3.4 Effects of HFD/STZ on (A) fasting plasma glucose and (B) 
fasting plasma insulin, in comparison with HFD/Veh and lean/Veh 
controls. n numbers are displayed on the graphs. All data represent 
mean ± SEM, analysis was by a Kruskal-Wallis test with Dunns post-
hoc test: * p<0.05, ** p<0.01, *** p<0.001 
A 
B 
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Consistent with Chapter 2, the combination of HFD/STZ was associated 
with a progressive decrease in mechanical withdrawal thresholds of the 
hindpaws (Figure 3.5). There was no difference in mechanical 
withdrawal thresholds between the lean/Veh and the HFD/Veh controls, 
with the mechanical withdrawal thresholds of both groups stable at 
~15g. At day 10, the first timepoint at which tissue was collected for 
immunohistochemistry, there was no significant difference in 
mechanical withdrawal thresholds. The decrease in mechanical 
withdrawal thresholds in the HFD/STZ group first became significant at 
day 15, and continued to decrease as the model progressed until day 
50. 
 
 
Figure 3.5 Effects of HFD/STZ on mechanical withdrawal thresholds of 
hindpaws, in comparison with HFD/Veh and lean/Veh controls. Up to 
day 10: n=14 for lean/Veh, n=15 for HFD/Veh, and n=10 for HFD/STZ. 
Up to dD\  Q  for lean/Veh, n=10 for HFD/Veh, and n=8 for 
HFD/STZ. Day 30 onwards: n=5 for lean/Veh and HFD/Veh, and n=4 
for HFD/STZ. All data represent mean ± SEM, analysis was by a 
Kruskal-Wallis test with Dunns post-hoc test:  
(* vs. HFD/Veh) * p<0.05, ** p<0.01, *** p<0.001 
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3.3.3. Effects of HFD/STZ on degenerating neurones  
The effect of HFD/STZ treatment on the total number of Fluoro-Jade B 
positive cells per rat in DRGs (Figure 3.6A) and the dorsal horn of the 
spinal cord (Figure 3.6B) was quantified. Overall, there were very few 
Fluoro-Jade B positive cells present in either tissue. No significant 
changes in the number of Fluoro-Jade B positive cells in either the 
DRGs, or the spinal cord, were observed at any of the timepoints in the 
HFD/STZ model.  
 
Tissues were also stained with NeuN to assess the colocalisation 
between NeuN and Fluoro-Jade B, ensuring that any Fluoro-Jade B 
positive cells were indeed neurones, and not astrocytes as has been 
previously reported (Damjanac et al., 2007). All of the Fluoro-Jade B 
positive cells were found to colocalise with NeuN. 
 
Figure 3.7A-C shows representative stitched merged images of DRGs, 
showing colocalisation between Fluoro-Jade B positive cells (green) 
and NeuN staining (red) and Figure 3.8A-C shows representative 
images of Fluoro-Jade B staining in dorsal horn spinal cord sections in 
a lean/Veh, HFD/Veh and HFD/STZ rat respectively. The intensity of 
staining of any Fluoro-Jade B positive cells observed in this model was 
very low when compared to models which produce severe 
neurodegeneration, as can be seen in Figure 3.8D. 
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 Figure 3.6 Effects of HFD/STZ on total number of Fluoro-Jade B 
positive cells per rat in (A) DRGs and (B) the dorsal horn of the spinal 
cord at different timepoints, in comparison with HFD/Veh and lean/Veh 
controls. n numbers, representing total number of rats, are displayed on 
the graphs (total number of Fluoro-Jade B positive cells in 7 spinal cord 
sections and 6 DRGs were quantified for each rat). All data represent 
mean ± SEM, analysis was by a 2-way ANOVA. 
B 
A 
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Figure 3.7 (A-C) Representative stitched merged images composed of 
20x magnification tiles, showing colocalisation of Fluoro-Jade B staining 
(green) and NeuN staining (red) in DRGs in a Lean/Veh, HFD/Veh and 
HFD/STZ rat respectively. Scale bar is 100ȝm. Arrows indicate Fluoro-
Jade B positive staining. Images have been altered in Image-J 
(minimum brightness set to 20, and maximum brightness set to 150 for 
Fluoro-Jade B, and 15 and 75 respectively for NeuN) 
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Figure 3.8 Scale bar is 50ȝm (A-C) Representative images at 20x magnification of Fluoro-Jade B staining in dorsal horn spinal cord 
sections in a Lean/Veh, HFD/Veh and HFD/STZ rat respectively. Arrows indicate positive staining. Images have been altered in 
Image-J (minimum brightness set to 20, and maximum brightness set to 150). (D) Image taken from Kudo et al. (2006) showing 
Fluoro-Jade B staining in the spinal cord after hemorrhagic shock and cardiac arrest, to compare intensity of staining.
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3.3.4. Effects of HFD/STZ on expression of CGRP 
The impact of the HFD/STZ model on peptidergic afferent fibre 
innervations into the dorsal horn was assessed by the quantification of 
CGRP immunofluorescence in the superficial laminae of the dorsal horn 
of the spinal cord. Overall, there were no differences in CGRP 
immunofluorescence in the superficial dorsal horn between any of the 
groups at an\RI WKH WLPHSRLQWV )LJXUHA), except for a significant 
decrease in the expression of CGRP in the HFD/Veh controls at day 10, 
in comparison to the lean/Veh group (p<0.01). Figure B-D shows 
representative images of CGRP staining in dorsal horn spinal cord 
sections in a lean/Veh, HFD/Veh and HFD/STZ rat, respectively. 
 
 
 
 
 
 
 
 
 
 
As seen on page 88: 
Figure 3.9 (A) Effects of HFD/STZ on expression of CGRP in the 
superficial laminae of the dorsal horn, in comparison with HFD/Veh and 
lean/Veh controls. n numbers, representing total number of rats, are 
displayed on the graph (mean of 7 spinal cord sections per rat). All data 
represent mean ± SEM, analysis was by a 2-way ANOVA with 
Bonferroni post-hoc test: ** p<0.01. (B-D) Representative images at 20x 
magnification of CGRP staining in the superficial laminae of the dorsal 
horn of the spinal cord in a Lean/Veh, HFD/Veh and HFD/STZ rat 
respectively. Scale bar is 50ȝm. Images have been altered in Image-J 
(minimum brightness set to 20, and maximum brightness set to 100). 
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3.3.5. Effects of HFD/STZ on activation of glia 
The number of activated microglia in the dorsal horn of the spinal cord 
was compared at different timepoints and between the different 
treatment groups. Although there were some small differences between 
the absolute numbers of activated microglia at the different timepoints 
in the lean/Veh and HFD/Veh groups, overall there was no significant 
change. In the HFD/STZ group there was a tendency for the number of 
activated microglia in the dorsal horn to be lower at all timepoints, but 
this was most evident at the later timepoints (Figure 3.10A). However 
statistical analysis with a 2-way ANOVA did not reveal any significant 
differences. It was evident, however, that there was a large amount of 
variability in the data, in particular at the early timepoints and in the 
lean/Veh and HFD/Veh groups. To overcome this issue the number of 
activated microglia in the HFD/Veh and HFD/STZ group were 
expressed as a percentage of the lean/Veh controls and a non 
parametric Mann-Whitney analysis was performed. This revealed a 
significant decrease (p<0.05) in the number of activated microglia in the 
HFD/STZ group, in comparison with the HFD/Veh group at both day 30 
and day 50 (Figure 3.10B). Analysis of the mean grey intensity of Iba1 
staining revealed no differences between any of the groups at any of 
the different timepoints (Figure 3.10C). Figure 3.11A-C shows 
representative images of Iba1 staining in dorsal horn spinal cord 
sections in a lean/Veh, HFD/Veh and HFD/STZ rat respectively, with 
examples of activated microglia indicated with arrows. 
 
The expression of GFAP in the dorsal horn of the spinal cord was also 
compared at different timepoints and between the different treatment 
groups. Again, there was no significant change in the expression of 
GFAP at the different timepoints in the lean/Veh and HFD/Veh 
treatment groups. In the HFD/STZ model there was a tendency for the 
expression of GFAP in the dorsal horn to be lower, and this was most 
evident at day 50 (Figure 3.12A). As with the microglia, statistical 
analysis with a 2-way ANOVA did not reveal any significant differences 
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as there was a large amount of variability in the data. When the 
expression of GFAP in the HFD/Veh and HFD/STZ group was 
expressed as a percentage of the lean/Veh control and a Mann-
Whitney analysis was performed, this revealed a significant decrease 
(p<0.05) in the expression of GFAP in the HFD/STZ group at day 50, in 
comparison with the HFD/Veh group. The expression of GFAP was also 
examined in the ventral horn and the central region, and this revealed a 
similar pattern, with a decrease in GFAP expression in the HFD/STZ 
group. In the ventral horn, a significant decrease (p<0.05) can be seen 
in the HFD/STZ group, in comparison to both control groups at day 50, 
with no change evident until this later timepoint (Figure 3.12B). In the 
central region, a significant decrease in the HFD/STZ group, in 
comparison with both control groups is also seen at day 50, but in this 
region a decrease is also observed as soon as day 10, and this 
decrease is significant compared to the lean/Veh controls at this 
timepoint (Figure 3.12C). Figure 3.13A-C shows representative images 
of GFAP staining in dorsal horn spinal cord sections in a lean/Veh, 
HFD/Veh and HFD/STZ rat respectively.  
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Figure 3.10 Effects of HFD/STZ on (A) number of activated microglia 
per quadrant in the dorsal horn (B) number of activated microglia 
(expressed as a percentage of lean/Veh controls) and (C) mean grey 
intensity of Iba1 staining in the dorsal horn at different timepoints, in 
comparison to HFD/Veh and lean/Veh controls. n numbers, 
representing total number of rats, are displayed on the graphs (mean of 
7 spinal cord sections per rat). All data represent mean ± SEM, analysis 
was by a 2-way ANOVA for A and C, and a Mann-Whitney test for B:  
* p<0.05 
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Figure 3.11 (A-C) Representative images at 20x magnification of Iba1 
staining in the dorsal horn of the spinal cord in a Lean/Veh, HFD/Veh 
and HFD/STZ rat respectively. Scale bar is 50ȝm. Arrows indicate 
examples of activated microglia. Images have been altered in Image-J 
(minimum brightness set to 20, and maximum brightness set to 120). 
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Figure 3.12 Effects of HFD/STZ on mean grey intensity of spinal GFAP 
immunofluorescence in the (A) dorsal horn, (B) ventral horn and (C) 
central region at different timepoints, in comparison with HFD/Veh and 
lean/Veh controls. n numbers, representing total number of rats, are 
displayed on the graphs (mean of 7 spinal cord sections per rat). All 
data represent mean ± SEM, analysis was by a 2-way ANOVA with 
Bonferroni post-hoc test: * p<0.05, ** p<0.01 
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Figure 3.13 (A-C) Representative images at 20x magnification of GFAP 
staining in the ventral horn of the spinal cord in a Lean/Veh, HFD/Veh 
and HFD/STZ rat respectively. Scale bar is 50ȝm. Images have been 
altered in Image-J (minimum brightness set to 20, and maximum 
brightness set to 100). 
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3.4. Discussion 
The inclusion of a lean/Veh group provided an important additional 
control to this study which was absent in Chapter 2. Specifically, this 
allowed me to demonstrate that the HFD produced an increase in 
glucose and insulin by the time the STZ injection was given, indicating 
that the rats may already be insulin resistant at this stage, as discussed 
in the previous chapter (Srinivasan et al., 2005). The development of 
mechanical hypersensitivity in this study was consistent with the data 
presented in Chapter 2, although the decrease in mechanical 
withdrawal thresholds was evident at an earlier timepoint. The points at 
which tissue was collected represent timepoints: when there is no 
mechanical hypersensitivity (day 10); when there is an evident, but not 
maximal, decrease in withdrawal thresholds (day 30); and when 
mechanical hypersensitivity is well established (day 50). The aim was 
that using these timepoints would reveal any effects of time on the 
parameters being investigated. 
 
The present study investigated the impact of the HFD/STZ model on 
peripheral nerve function. The number of Fluoro-Jade B positive cells in 
DRGs and spinal cord was assessed to determine the presence of 
neuronal degeneration. No changes in the total number of Fluoro-Jade 
B positive cells in the DRG or spinal cord are reported, with numbers of 
Fluoro-Jade B cells being very low in all groups. Immunohistochemistry 
was also used to investigate potential changes in the expression of 
CGRP, and activation of microglia and astrocytes in the spinal cord in 
the HFD/STZ model. Reports from previous studies of animal models of 
diabetes have been mixed, and some of the results herein are 
consistent with the current literature whereas others are at odds with 
what has been seen previously. The HFD/STZ model elicited no 
significant changes in CGRP expression in the spinal cord. A decrease 
in activated microglia in the dorsal horn was observed, and there was a 
significant decrease in GFAP expression in the dorsal and ventral horn, 
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as well as the central region, which became more obvious at the latest 
time point - 50 days after STZ injection.  
3.4.1. Fluoro-Jade B staining 
The number of Fluoro-Jade B positive cells present in the DRGs and 
dorsal horn of the spinal cord was very low in all three groups, and 
HFD/STZ had no significant effect on the number of positive cells. As 
Fluoro-Jade B stains for dying or degenerating neurones, this would 
suggest that there is very little neurodegeneration taking place in the 
HFD/STZ model at the timepoints studied. The intensity of the Fluoro-
Jade B staining was also very low when compared to previous studies 
by other groups who used Fluoro-Jade in the spinal cord, where a very 
obvious staining of neurones was reported. However, these studies 
used models of ischemia, acute inflammation or neurodegeneration, 
where any neuronal death is very apparent (Kudo et al., 2006; Nguyen 
et al., 2004; Orendacova et al., 2005; Saganová et al., 2006). In future, 
it would be advantageous to also run a control group of rats which 
underwent an ischemic insult, so that the Fluoro-Jade B positive 
staining in the HFD/STZ model could easily be compared to the 
changes seen in a robust model of neuronal degeneration. 
 
All of the Fluoro-Jade B positive cells were colocalised with NeuN, 
confirming that they were neurones. In a previous study, no 
colocalisation between Fluoro-Jade positive cells and NeuN was 
observed in a model using a moderate hypoglycaemic insult (Tkacs et 
al., 2005). They hypothesised that when neurones undergo cell death, 
NeuN is broken down, and so this, along with the very low intensity 
staining of Fluoro-Jade B would suggest that any neurodegeneration 
taking place is not in the advanced stages. 
 
Consistent with my data, no neuronal death has been detected with 
Fluoro-Jade in the brain of STZ rats at 2 or 8 weeks (Bree et al.
Lechuga-Sancho et al., 2006; Won et al., 2012), and so it is possible 
that no neuronal death occurs in diabetic rats until later timepoints. 
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These results in the spinal cord are in agreement with what has been 
seen in the literature so far. As reviewed in Mizisin et al. (2007), no 
changes in the grey matter of the spinal cord have been reported in 
animal models of diabetic neuropathy, with reductions in perikaryal 
volume of motor and sensory neurones, but no signs of neuronal 
degeneration (Sidenius et al. . However there have been 
conflicting reports about whether there is structural injury and neuronal 
loss in sensory ganglia. Two studies have revealed a significant 
increase in apoptosis in the DRG at 1 month (Russell et al., and 
also 3 and 12 months following STZ treatment in rats (Schmeichel et 
al., 2003). Zochodne et al. (2001) examined neuronal numbers in 
dorsal root ganglion at 2 and 12 months after STZ injection, and 
reported a significant reduction in neurone diameter and area, and a 
trend towards a decrease in neuronal number at the later timepoint. 
These results were confirmed in a similar study, with no neuronal loss 
observed, but instead an increase in the ratio of small type-B neurones 
to large type-A neurones (Kishi et al., 2002), with a similar pattern 
observed at 1 month (Sidenius et al.. No neuronal loss has been 
reported in the DRG at 3 months in STZ treated rats (Severinsen et al., 
2007). In the diabetic BB rat, there is no change in neurone number at 
4 months (Kamiya et al., 2005b), but there is severe neuronal loss of 
SP and CGRP neurones in the DRG at 10 months of age (Kamiya et 
al., 2006). In the present study, the latest timepoint was 7 weeks, and 
so in agreement with the aforementioned studies, no neuronal 
degeneration/loss was observed at this early stage of diabetic 
neuropathy. It would therefore be interesting to carry out a longer term 
study, to see if these effects could be observed after a longer duration 
of diabetes in this model. These data add to the hypothesis that the 
STZ model should be considered a model of the early stages of 
diabetic neuropathy, as it does not exhibit the sort of structural changes 
in nerves that we would expect to see in human diabetic neuropathy 
(Wattiez et al., 2012). 
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3.4.2. CGRP expression 
Changes in the levels of CGRP in diabetic animal models have not yet 
been fully elucidated. So far there have been reports of an increase in: 
the basal release of CGRP in the skin (Ellington et al., 2002), the 
capsaicin-stimulated release of CGRP in the skin and spinal cord 
(Bishnoi et al., 2011; Ellington et al., 2002), and the number of CGRP-
positive fibres in skin (Karanth et al. , whereas no change has 
been seen in: the levels of CGRP immunoreactive neurones in the 
nodose ganglion of the vagus nerve (Regalia et al., 2002) or the spinal 
cord and DRG (Jiang et al., 2004; Terenghi et al.. Conversely, a 
decrease has been seen in: CGRP content in the vagus nerve (Calcutt 
et al., and the sciatic nerve (Brewster et al. Diemel et al., 
, the number of CGRP-positive neurones in the DRG (Adeghate 
et al., 2006), and finally the expression of CGRP mRNA in the DRG 
(Zochodne et al., 2001) and sciatic nerve (Diemel et al. . 
Therefore the results reported here of no significant changes in CGRP 
expression in the spinal cord add another piece of the puzzle, but the 
full picture of the role of CGRP in diabetic neuropathy is yet to be 
elucidated. 
 
3.4.3. Microglial activation 
The changes in the number of Iba1 positive cells morphologically 
identified as activated microglia in the spinal cord in this study are not in 
agreement with the existing literature. In general, an upregulation of 
activated microglia in the spinal cord has been reported in STZ treated 
rats over a similar timescale to that investigated in this study. Changes 
in the number of activated microglia are seen as soon as 4 days after 
STZ injection (Talbot et al., 2010), and then at various timepoints over 
the following five weeks. However the method by which activation of 
microglia is calculated varies between the different studies. Some use 
Iba1 as a marker of microglia (Talbot et al., 2010; Tsuda et al., 2008; 
Wodarski et al., whereas others used CD11b/OX-42 (Kim et al., 
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2012b; Morgado et al., 2011a; Tsuda et al., 2008). Whereas Iba1 stains 
all microglia, and their activation state can then be assessed by 
morphological changes, CD11b only stains classically activated 
microglia, and will not stain for alternatively activated or resting 
microglia. In these studies, activation of microglia is then assessed by 
calculating mean pixel energy (Talbot et al., 2010), or by densitometric 
analysis (Morgado et al., 2011a), whereas others count cell bodies 
stained with Iba1 (Tsuda et al., 2008; Wodarski et al., and some 
go further and assess whether the microglia being counted appear 
activated. In future studies looking at microglia in the diabetic model, it 
would be sensible to use both antibodies, and a consistent method of 
detecting activation so that results could be more easily compared 
between groups. In this study, Iba1 was used, and only activated 
microglia were counted, assessed as those displaying large cell bodies 
and thickened retracted processes (Eriksson et al. . As the 
expected increase in microglial activation was not observed using this 
method, the mean grey intensity of these sections was also calculated 
to see whether this method would confirm these findings. Using this 
method, no change in Iba1 expression was seen between any of the 
three groups at the three different timepoints. As the greater numbers of 
activated microglia in the lean/Veh and HFD/Veh controls would be 
expected to show an increased expression of Iba1 (Tsuda et al., 2005), 
it is possible that although there were fewer activated microglia in the 
HFD/STZ group, there was actually an overall increase in the number of 
microglia, even if they did not show the classic changes in morphology 
that are indicators of activation. 
 
Tsuda et al. (2008) also investigated whether microglial activation was 
altered in different segments of the spinal cord, and found that they 
were most strongly activated in the L4 segment, with weaker Iba1 
immunofluorescence in segments L5 and L6. In this study lumbar 
regions 4-6 of the spinal cord were all cut together, and so the different 
segments were unable to be identified with certainty, and so any 
positive results that may have been seen in L4 may have been masked 
  
by the inclusion of L5 and 6. Therefore in a future study, these lumbar 
regions should be cut separately to see whether there are more 
regional specific changes 
 
Another factor that would be interesting to investigate in future 
immunohistochemistry studies in the HFD/STZ model, would be to 
double-label cells with markers for phospho-ERK (Morgado et al., 
2011a; Sweitzer et al., 2004; Tsuda et al., 2008) and phospho-p38 
(Morgado et al., 2011a; Sweitzer et al., 2004), as these MAPK 
pathways are often activated in microglia. As no increase in the number 
of activated microglia was observed in this study, double-labelling with 
these markers would either confirm that there is less activation of 
microglia, or may be able to show that although no increase in number 
is seen, there is in fact an increase in the activation of these MAPK 
pathways in the microglia, despite no change in the phenotypic state. It 
would also be of interest to see whether treatment with minocycline, 
which inhibits activation of microglia, would be effective at preventing 
the development of mechanical hypersensitivity in the HFD/STZ model. 
All of these further ideas would help to explain, or build upon, the 
results observed in this study. 
 
3.4.4. Astroglial activation 
To date previous studies of GFAP expression in the spinal cord in the 
STZ model have been mixed. A decrease in GFAP immunoreactivity 
has been reported by some groups (Afsari et al., 2008; Wodarski et al., 
, no change by others (Tsuda et al., 2008), and finally an increase 
in GFAP immunoreactivity in one recent report (Kim et al., 2012b). My 
data report a significant decrease in GFAP-immunoreactive astrocytes 
in three different regions of the spinal cord in the HFD/STZ model, 
which is particularly evident at the latest timepoint. This finding is in 
agreement not only with studies in the spinal cord, but also in other 
regions of the CNS such as the brain and the retina, where decreases 
in GFAP expression have also been reported (Barber et al., 2000; 
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Coleman et al., 2004; de Senna et al., 2011; Lechuga-Sancho et al., 
2006; Renno et al., 2012; Rungger-Brandle et al., 2000; Zuo et al., 
2011). 
 
It is important to note that although a decrease in GFAP 
immunoreactivity in the brain of STZ treated rats has previously been 
reported, this did not correlate with a decrease in astrocyte number per 
se (Coleman et al., 2004). The basis for these decreases in GFAP 
immunoreactivity may be related to the large decrease in insulin 
exhibited in these models (Afsari et al., 2008). Co-application of insulin 
and thyroid hormone has been shown to alter the morphology of 
astrocytes, with cell processes becoming thicker and more distinct, as 
well as increasing the activity of glutamine synthase (Aizenman et al., 
, and enhancing the expression of GFAP in astrocytes (Toran-
Allerand et al. . These effects of insulin on astrocytes were 
reversible (Aizenman et al., suggesting that insulin may play an 
important role in regulating normal astrocytic function. The decrease in 
GFAP-immunoreactive astrocytes demonstrated in HFD/STZ rats may 
be indicative of an altered metabolic and functional role, meaning that 
the astrocytes are unable to maintain their neuronal support role in the 
CNS (Afsari et al., 2008). This idea is further consolidated by the 
demonstration that insulin treatment restores GFAP levels in the 
diabetic STZ-treated rat (Coleman et al., 2010). 
 
The changes in GFAP immunoreactivity suggest that the contribution of 
astrocytes to spinal cord homeostasis in this model may be altered. 
Glutamate-transporter 1 (GLT-1 or EAAT2), and glutamate/aspartate 
transporter (GLAST) are predominantly expressed in astrocytes, with 
GLT-1 found predominantly in the superficial dorsal horn (Regan et al., 
2007; Rothstein et al.;LQ et al.. In nerve injury models of 
pain, astrocyte activation has been associated with decreased GLT-1 
and GLAST (Sung et al., 2003; Xin et al., as well as a decrease 
in other glutamate transporters, such as excitatory amino-acid carrier 1 
(Sung et al., 2003; Wang et al., 2006), resulting in a decrease in 
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glutamate uptake (Binns et al., 2005). Whether the decrease in GFAP 
staining reported herein in the HFD/STZ model is associated with a 
decrease in these transporters remains to be determined. It has been 
hypothesised that decreased GLT-1 expression can lead to pain 
hypersensitivity, due to enhanced glutamatergic synaptic 
neurotransmission (Nakagawa et al., 2010), and inhibition of glutamate 
transporters has been shown to produce spontaneous nociceptive 
behaviours and thermal and mechanical hypersensitivity (Liaw et al., 
2005; Weng et al., 2006). 
 
No changes in GLT-1 or GLAST expression, but an increased uptake of 
glutamate was observed in the brain of 4 and 8 week STZ treated rats 
(Coleman et al., 2004; Coleman et al., 2010). An increase in the level of 
glutamate in the peripheral nerve in 4 week STZ treated rats has also 
been reported (Li et al., 2004), but the presence of mechanical 
hypersensitivity was not investigated in any of these studies. GCPII, 
which reduces glutamate release, attenuated hyperalgesia in the BB rat 
(Zhang et al., 2006b). It would therefore be interesting to see whether 
the expression of GLTs, and the levels of glutamate, are altered in the 
spinal cord of HFD/STZ rats.  
 
In conclusion, I have demonstrated a decrease in GFAP expression in 
the spinal cord, no change in CGRP expression, and no neuronal 
degeneration induced in the HFD/STZ model by 7 weeks. However, a 
decrease in activated microglia was observed in this study, and this 
warrants further investigation to see whether this result can be repeated 
in this model. As pain behaviour is evident in the HFD/STZ model, and 
some of the changes described in this chapter only go part way to 
explaining its development, the next stage was to investigate whether 
there is a change in neuronal responses, which was investigated in 
Chapter 4. 
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Chapter 4. 
Electrophysiological characterisation of 
spinal neuronal responses in the HFD/STZ 
model of diabetes, and the effects of 
pioglitazone intervention 
 
4.1. Introduction 
4.1.1. Involvement of primary afferent fibres in the 
STZ model 
Aȕ-, Aį- and C-fibres have all been postulated to be important in the 
development of painful symptoms in diabetic neuropathy. Sustained 
mechanical stimulation (Chen et al., 2001) and noxious chemical stimuli 
(Chen et al., 2003) have been shown to elicit a greater number of 
action potentials in C-fibres in the STZ model than in controls, with only 
a subset of C-fibres (1 in 3) being markedly hyper-responsive (Ahlgren 
et al. &KHQ et al., 2003; Chen et al., 2001). In agreement with 
this, a facilitation of responses to suprathreshold mechanical stimulation 
in C-fibres (Ahlgren et al.  $KOJUHQ et al.  6X]XNL et al., 
2002), as well as an increase in spontaneous firing, and a decrease in 
response thresholds in response to ramp-pressure stimulation have all 
been observed in STZ rats (Suzuki et al., 2002). This increase in 
afferent firing may lead to sensitisation of spinal nociceptive circuits 
(Kamiya et al., 2005a). 
 
Other groups have hypothesised that Aȕ- and Aį-fibres also play a role 
in the development of painful symptoms. When resiniferatoxin was used 
to desensitise unmyelinated C-fibres, the development of mechanical 
hypersensitivity was unaffected in the STZ model (Khan et al., 2002). 
Indeed, Aȕ- and Aį-fibres developed abnormal spontaneous 
discharges, a decrease in their activation threshold, and an increase in 
evoked responses to von Frey filaments. A decrease in mechanical 
thresholds in Aį-fibres has also been seen in STZ treated rats between 
3-7 weeks (Ahlgren et al.. 
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4.1.2. Involvement of WDR neurones in the dorsal 
horn of the spinal cord in the STZ model 
As discussed in Chapter 1, the spinal cord plays a pivotal role in the 
integration and modulation of noxious inputs, and is a critical site 
involved in sensitisation mechanisms associated with chronic pain. 
Previous studies in models of diabetes have shown that dendritic spine 
remodelling in the spinal cord is seen at 4 weeks after STZ injection 
when mechanical hypersensitivity and hyperalgesia are apparent, but 
not before the painful symptoms develop at 1 week, suggesting that this 
too may play a role in neuropathic pain (Tan et al., 2012). They also 
examined the activity of WDR neurones at L4-L5 in the spinal cord in 
the STZ model at 4 weeks, and an increase in spontaneous activity, 
enlarged receptive fields and increased peripherally evoked responses 
to brush, press, pinch and von Frey stimuli was observed (Tan et al., 
2012). An increase in the response of somatic WDR neurones to a 
brush stimulus in 4-11 week STZ treated rats was also seen when the 
thoracic region, T3, of the spinal cord was examined (Ghorbani et al., 
2011). 
 
In a previous study of spinal dorsal horn WDR neurone activity (T12-L2) 
in 6 week STZ treated rats, an increase in spontaneous activity was 
reported (Pertovaara et al., 2001), but there was no change in noxious 
heat-evoked responses, after discharges, or receptive field size, and 
there was a decrease in the responses evoked by mechanical 
stimulation (2, 4, 12 and 75g von Frey hairs). 
 
Previous studies in STZ rats have therefore consistently demonstrated 
an increase in the spontaneous activity of WDR neurones, but the 
impact of these models of diabetic neuropathy on evoked responses of 
spinal neurones is less consistent. This may reflect the different models 
and timescales involved, as well as the experimental methods such as 
the depth of anaesthesia. It will be interesting to explore this aspect in 
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the HFD/STZ model to see how evoked neuronal responses to 
mechanical and electrical stimulation are altered. 
 
4.1.3. Pioglitazone and other PPARȖDJRQLVWV 
Pioglitazone is one of a class of drugs called the thiazolidinediones that 
are used to treat type 2 diabetes. The TZDs act on the nuclear receptor 
PPARȖ and their mechanisms of action are discussed in Chapter 1. 
Recently it has been demonstrated that they may also play a positive 
role in diseases such as atherosclerosis, cancer and 
neurodegenerative disorders such as Alzheimers disease (Churi et al., 
2008). They have also shown promise in alleviating inflammatory and 
neuropathic pain through a variety of different mechanisms, as 
discussed below. I was therefore interested in investigating a potential 
role of pioglitazone in alleviating the mechanical hypersensitivity that is 
observed in the HFD/STZ model. 
 
4.1.4. PPARȖDJRQLVWV in inflammatory pain 
Table 4.1 summarises the effects of thH33$5ȖDJRQLVWV-Deoxy-ǻ-
12,14-prostaglandin J2 (15d-3*- D QDWXUDO DJRQLVW RI 33$5Ȗ
(Desvergne et al. ), rosiglitazone, and pioglitazone, in the 
carrageenan and post-incisional models of inflammatory pain. It can be 
seen that they are able to reduce inflammation, and that these effects 
were blocked by bisphenolAdiglycidyl ether %$'*(RU*:WZR
33$5Ȗ DQWDJRQLVWV LQGLFDWLQJ WKDW WKHLU HIIHFWV DUH PHGLDWHG WKURXJK
this receptor (Cuzzocrea et al., 2004; Morgenweck et al., 2010). 
 
It is hypothesised that these PPARȖDJRQLVWV might work by regulating 
macrophage polarity to induce an analgesic effect, which is elaborated 
on in the discussion, and transplanting rosiglitazone-treated peritoneal 
macrophages to the injured site in the post-incisional model had an 
analgesic effect (Hasegawa-Moriyama et al., 2012; Takahashi et al., 
2011).
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Table 4.1 Summary of the effects of acute doses of PPARȖ agonists in various models of inflammatory pain. 
Drug Model Behavioural Outcomes Biochemical outcomes Reference 
Rosiglitazone 
100mgkg-1, i.p. 
Carrageenan in rats - 
Inhibited paw oedema (only 
when given before carrageenan) 
(Taylor et al., 2002) 
Rosiglitazone 
10mgkg-1, i.p. 
Carrageenan in rats - 
Inhibited paw oedema, and 
attenuated the increase in 
PARP, iNOS and COX-2 in the 
lungs. 
Effects blocked by BADGE 
(Cuzzocrea et al., 2004) 
Pioglitazone 
25-50mgkg-1, i.p. 
Carrageenan in rats 
No effect on mechanical 
hypersensitivity 
Inhibited paw oedema 
(Oliveira et al., 2007) 
 
15d-PGJ2 
200ȝg, i.t. 
Rosiglitazone 
50ȝg, i.t. 
Carrageenan in rats 
Reduced thermal 
hyperalgesia 
- Inhibited paw oedema 
- Attenuated increase in Fos-
staining in the dorsal horn 
(Morgenweck et al., 
2010) 
Rosiglitazone 
10ȝg into the paw 
Post-incisional pain in 
mice (induces paw 
swelling and infiltration 
of immune cells) 
Attenuated thermal 
hyperalgesia and 
mechanical 
hypersensitivity 
- Inhibited paw oedema 
- Attenuated the infiltration of 
immune cells 
- Increased the ratio of M1 
(pro-inflammatory): M2 (anti-
inflammatory) macrophages 
(Hasegawa-Moriyama et 
al., 2012) 
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4.1.5. PPARȖ agonists in neuropathic pain 
Table 4.2 summarises the effects of PPARȖ agonists in different models 
of neuropathic pain. The effects of these drugs are thought to be 
mediated, at least in part, by actions at the level of the spinal cord; 
perhaps through decreasing the activation of microglia, leading to a 
decrease in pro-inflammatory cytokines, and modifying central 
sensitisation. This could explain their long lasting effects after 
administration has ceased. 
 
4.1.6. PPARȖDJRQLVWV in diabetic neuropathy 
$OLPLWHGQXPEHURIVWXGLHVKDYHDOVRHYDOXDWHGWKHHIIHFWVRI33$5Ȗ
agonists in models of diabetic neuropathy. Troglitazone treatment was 
shown to protect against the slowing of NCV and fibre atrophy in STZ 
rats, as well as acting as a IUHHUDGLFDOVFDYHQJHUDQGUHGXFLQJ71)Į
production (Qiang et al. . Rosiglitazone treatment was able to 
improve thermal hypoalgesia, as well as reducing oxidative stress in the 
sciatic nerve in STZ-treated mice, without having any effect on 
hyperglycaemia (Wiggin et al., 2008). Evidence that rosiglitazone 
activated genes responsible for glucose metabolism, as well as 
oxidoreductase activity has been generated using microarray analysis 
(Wiggin et al., 2008). Pioglitazone has also been shown to be effective 
at reducing oxidative stress (Majithiya et al., 2005), as well as having a 
neuroprotective effect on NCV, restoring PKC activity, decreasing levels 
of ERK activity, and reducing macrophage infiltration in the STZ model 
(Yamagishi et al., 2008). 
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Table 4.2 Summary of the effects of PPARȖ agonists in various models of neuropathic pain. 
i.p: intraperitoneal; p.o: oral; i.t: intrathecal; i.c.v: intracerebroventricular; SNI: spared nerve injury; PNL: partial sciatic nerve ligation; 
CA: cold allodynia; MH: mechanical hypersensitivity; BADGE and *: are PPARȖ antagonists 
Drug Model Behavioural Outcomes Biochemical outcomes Reference 
15d-PGJ2 
100-200ȝg, i.t. 
Rosiglitazone 
200ȝg, i.t. 
Acute dose 
SNI in rats 
- Decreased MH and CA 
- Effects blocked by BADGE 
- i.p./i.c.v administration were ineffective 
- 
(Churi et al., 
2008) 
Pioglitazone 
0.3-30mgkg-1, p.o. 
1 - 10 mgkg-1, i.p. 
Various 
SNI in rats 
- 7 days pre-SNI and 7 weeks post-SNI 
prevented mechanical and cold 
hypersensitivity 
- A single injection 15 minutes before SNI 
reduced hyperalgesia for the next 2 weeks. 
- 2 x daily injections for 7 days, 24 hours after 
SNI, decreased established hypersensitivity 
- Pioglitazone was still effective for a week 
after its termination 
- *:EORFNHGWKHDPHOLRUDWLYHHIIHFWVRI
pioglitazone 
- Attenuated the increase in 
GFAP-positive staining in the 
spinal cord 
- Attenuated the increase in 
p-ERK in the dorsal horn 
(Morgenweck et 
al., 2013) 
Pioglitazone 
1-25mgkg-1, p.o. 
4 days 
PNL in mice Prevented the development of MH 
Attenuated the increase in 
activated microglia 
(Iwai et al., 2008) 
  
 Pioglitazone 
25 mgkg-1, p.o. 
Various 
PNL 
in mice 
- Prevented the development of MH when 
administered for one week after PNL, and for 
a week after administration had ceased. 
- Reduced the magnitude of established MH 
when given on days 7 to 13, but a single 
acute dose had no effect 
Attenuated the increase in TNF-Į
and IL-6 when administered for 7 
days 
(Maeda et al., 
2008). 
Rosiglitazone 
10 mgkg-1, i.p. 
Day 1-3, 5-7 or 26-
28 
PNL in mice 
- Early administration attenuated the 
development of MH 
- No effect at the later timepoint 
- Early administration 
attenuated the increase in 
activated microglia and MMP-
L126DQG&2;-2 
(Takahashi et al., 
2011) 
Rosiglitazone 
5-10mgkg-1, p.o 
28 days 
Tibial and 
sural nerve 
transection in 
rats 
Attenuated mechanical and cold hyperalgesia, 
but not thermal hyperalgesia 
Attenuated the increase in GSH, 
and the decrease in 
myeloperoxidase activity (a 
specific marker of inflammation) 
(Jain et al. 
Pioglitazone 
10mgkg-1, p.o. 
14 days 
Spinal nerve 
transection in 
rats 
Prevented the development of MH and 
mechanical hyperalgesia 
- Attenuated the increase in 
TNF-Į,/-6 and IL-1ȕand 
inhibited the activation of 
NFțB. 
- Attenuated the increase in 
GFAP-positive staining in the 
spinal cord 
 
(Jia et al., 2013; 
Jia et al., 2010) 
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4.1.7. Aim of the study 
The primary aim of the work in this chapter was to characterise the 
impact of the HFD/STZ model of diabetes on the electrically and 
mechanically evoked responses of WDR neurones in the dorsal horn of 
the spinal cord at 7 and 11 weeks after model induction. 
 
The second aim of this study was to investigate the ability of the PPARȖ 
ligand pioglitazone to alter already established mechanical 
hypersensitivity in the HFD/STZ model, and to determine whether this 
was associated with changes in the response profiles of WDR neurones 
in the spinal cord in HFD/STZ rats.  
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4.2. Methods 
For detailed methods of induction of diabetes, blood sampling and von 
Frey testing see Chapter 2. 
 
4.2.1. Animals 
All experiments were carried out under Home Office Licence 40/3124, 
in accordance with the UK Home Office Animals (Scientific Procedures) 
$FW  DQG ,$63 Juidelines. 47 male Sprague-Dawley rats (200-
250g), obtained from Charles River (Kent, UK), were individually 
housed on a normal light cycle (lights on: 07:00 -  ZLWK IUHH
access to either QRUPDO FKRZ RU D KLJK IDW GLHW  IDW E\ FDORULF
content; D1Giet; Research Diets, New Jersey, USA) and water at 
all times. After three weeks consumption of chow/HFD, the HFD groups 
were stratified into three groups on the basis of body weight and 
mechanical withdrawal thresholds, and all rats then received either an 
i.p. injection of STZ (45mgkg-1), or citric acid buffer. Blood samples were 
taken at day 18, 46 and 74. von Frey testing was carried out weekly. 
 
4.2.2. In vivo electrophysiology 
4.2.2.1. Induction of anaesthesia 
To induce anaesthesia, the rat was placed in an induction chamber (a 
transparent plastic box), and isoflurane (Abbott, Kent, UK) was 
GHOLYHUHG DW  LQ D PL[WXUH RI  QLWURXV R[LGH DQG  R[\JHQ
(both BOC gases, UK) via a Vapotech series 3 vaporiser. Expelled 
gases were removed and absorbed by a Cardiff aldasorber (Datesand 
Ltd, Manchester, UK). Once an areflexic state was attained, the level of 
LVRIOXUDQHZDVUHGXFHGWR$UHIOH[LDZDVGHILQHGDVWKHDEVHQFHRI
a righting reflex when the induction chamber was gently tilted to the 
side, or the lack of a withdrawal reflex to a toe pinch. 
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4.2.2.2. Tracheal cannulation 
The rat was transferred from the induction chamber to a mat, and 
placed in a nose-cone connected to a Y-connector and attached to the 
anaesthetic line through silicone Portex tubing. A small piece of skin 
was removed from the underside of the neck, exposing the muscle 
layers underneath, which were gently teased apart using blunt 
dissection to expose the trachea. Pointed forceps were placed under 
the trachea to support it, and two lengths of suture (Pearsalls Sutures 
Ltd., UK) were passed underneath the trachea and tied in loose knots. 
A small incision was made between two rings of cartilage approximately 
halfway along the exposed portion of the trachea, between the two 
threads. A bevelled-edged cannula, approximately 4cm in length and 
2.08mm in diameter (Portex Ltd., UK) was inserted approximately 5mm 
and secured in place using the two sutures, and connected directly to 
the Y-connector. Response to a toe-pinch stimulus was checked to 
ensure the rat was sufficiently anaesthetised. 
 
4.2.2.3. Laminectomy 
The rat was transferred to a stereotaxic frame (University of 
Nottingham, Medical Faculty Workshops) and placed into ear bars in 
order to maintain a fixed head position throughout the experiment. Core 
body temperature was monitored by insertion of a rectal temperature 
probe and was maintained at 37±0.5°C by a heating blanket. 
 
A midline incision was made through the skin and fur, from 
approximately 2cm above the base of the ribs. Two parallel incisions 
were made in the muscle on either side of the vertebral column, 
corresponding with L1-3, and the top clamp was tightly secured. A tear-
drop shaped incision, approximately 1.5-2cm in length was then made 
along the dorsal surface of the spinal column, so that the centre of the 
incision lay over the base of the ribs, which approximately corresponds 
with the location of spinal segments L4-5. Connective tissue was 
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removed, creating a reservoir to hold future applications of saline, 
ensuring that the spinal cord was kept moist throughout the experiment. 
 
Rongeurs were inserted gently into the gap between vertebrae, and 
used to expose segments L4-L5 of the spinal cord, which is innervated 
by primary afferent input from the hindpaws. The laminectomy was kept 
as small as possible to ensure stability of later electrophysiological 
recordings (Stanfa et al., 2004). The dura mater was carefully removed 
using a pair of sharp forceps, leaving the pia mater intact. A second 
clamp was positioned around the vertebral column below the 
laminectomy to ensure that the area was held secure for later 
electrophysiological recordings. The skin of the rat was pulled tight 
around the clamps and secured with a crocodile clip to minimise loss of 
fluid and prevent dehydration of the rat. The level of isoflurane was 
UHGXFHG WRDQGPDLQWDLQHGDW WKLV OHYHO for the remainder of the 
experiment. The rat was allowed a period of 30 minutes to adapt to the 
new level of anaesthesia. Hindpaw withdrawal and blink reflexes were 
regularly monitored throughout the rest of the experiment, and the 
spinal cord was kept moist by application of 50ȝORI1D&OXVLQJD
Hamilton syringe. 
 
4.2.2.4. Electrophysiological recordings 
Extracellular single-unit recordings of WDR dorsal horn neurones were 
made using glass coated tungsten electrodes (Merrill et al., and 
a Neurolog system was used for spike discrimination and audio 
monitoring (Digitimer, Hertfordshire, UK). The system was grounded 
through the stereotaxic frame. The headstage (Neurolog NL100AK in 
A-B configuration) received input from the electrode inserted into the 
spinal cord and from a second indifferent electrode which was attached 
to the skin of the rat, allowing differential recording, and therefore 
reducing interference. The voltage signal was amplified (Neurolog 
NL104 x 2K, Neurolog 106 x 80) and filtered through low and high-pass 
filters (Neurolog NL125). The filtered signal was fed into a two channel 
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digital oscilloscope (Tektronix TDS210) providing a visual 
representation of the responses of the recorded neurones. Analogue 
spike signals were converted to a digital signal by the spike trigger 
(Neurolog NL201) with variable threshold, allowing only action 
potentials of a specified amplitude to be counted. This enabled the 
separation of action potentials recorded from a single neurone from 
recordings of other closely located neurones. Evoked firing of neurones 
was in the mV range with a typical signal to noise ratio of 4:1. The 
neuronal signals were digitised using a CED micro1401 interface and 
quantified using Spike 2 data acquisition software (Cambridge 
Electronic Design, Cambridge, UK). 
 
An electrode was initially inserted level with the base of the ribs, close 
to the central vessel, and input from the hindpaw was confirmed by 
tapping the toes. The electrode was slowly withdrawn to the surface of 
the cord, and then lowered in 10ȝm steps using a SCAT-01 microdrive 
and an Epson HX210 Stepper (Digitimer) to a depth of around 500ȝm 
from the surface. It was then lowered further, whilst stimulating the toes, 
until a depth of around 1200ȝm. WDR neurones were selected if they 
displayed a sustained response to pinch stimuli, and a graded response 
to increasing stimulus intensity (Willis et al., 2004). The receptive field 
was located and marked to allow accurate stimulation of the identified 
area throughout the experiment. 
 
4.2.2.5. Characterising neurones 
WDR neurones were characterised using transcutaneous electrical 
stimulation. Two metal pins (26 gauge syringe needles), connected to 
an electrical stimulator isolator (NL800), were inserted intradermally 
either side of the receptive field (or on adjacent toes), ensuring that the 
needles did not touch. The stimulus intensity was set to 1mA and the 
toes were stimulated using a single pulse, and the intensity was 
increased in 0.1mA steps up to 3mA, until a response with a C-fibre 
HYRNHGODWHQF\ZDVVHHQ-300ms after stimulus). Once the threshold 
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for C-fibre-evoked response was determined, a train of 16 stimuli at 3 
times the C-fibre threshold current were delivered using the period 
generator (NL304) at a frequency of 0.5Hz, with a 2ms pulse width, in 
order to stimulate neuronal wind-up. Using Spike 2, the neuronal 
responses were captured and displayed in a post-stimulus time 
histogram. The number of spikes evoked by each primary afferent fibre 
type were recorded and quantified ($ȕ-fibres, 0-PV$į-fibres, 20-
ms; C-fibres, -300 ms post stimulus), along with the number of post-
discharge responses (300-800ms post-stimulus). Only neurones 
GLVSOD\LQJQHXURQDOHYHQWV IRUHDFK ILEUH W\SHwere investigated 
further.  
 
After a recovery period of at least ten minutes, the responses of the 
neurone to mechanical punctuate stimulation of the peripheral receptive 
field of the neurone on the hindpaw were characterised. The centre of 
the receptive field was mechanically stimulated with von Frey hairs of 
different bending forces (8, 10, 15, 26 and 60g) for 10 seconds in 
ascending order, with a 10s interval between each stimulation, and the 
mean firing frequency over the 10s stimulation period was recorded. 
The noxious withdrawal threshold to mechanical punctuate stimuli in 
conscious rats is 15g and so the range of von Frey hairs used included 
both innocuous and noxious stimuli (Chaplan et al.. Three sets 
of stimulations were recorded, with a 10 minute interval between each 
set. An average of 3 neurones were characterised from each rat. 
 
4.2.2.6. Production of glass coated tungsten 
microelectrodes 
A batch of 30 tungsten wires of equal length (Harvard Apparatus, Kent, 
UK) were loaded into a Perspex jig (75 x 50mm) and cleaned by gently 
brushing the length of the filament ZLWK  DFHWRQH. A piece of 
sellotape was attached to the end of the tungsten filaments, and then 
wrapped tightly around a cylindrical brass barrel, to ensure good 
contact between the barrel and the electrodes. The metal barrel was 
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attached to the arm of an electrode etcher (University of Nottingham, 
Medical Faculty Workshop) and lowered into a potassium nitrate 
(KNO2; J80 ml) electrolyte solution so that only 10 of the tungsten 
filaments were in contact with the solution at any one time. The circuit 
was completed by immersing a carbon electrode in the solution, and a 
current of 2.5mA was passed through the solution and the electrodes 
were allowed to etch until the current dropped to 2.0mA. The electrode 
barrel was then removed and the electrodes gently rinsed with distilled 
water. 
 
Using a pair of forceps, a single electrode was removed from the barrel, 
and briefly passed through a burner to remove any sellotape residue. 
The filament was then placed in a glass capillary tube (Harvard 
Apparatus), and inserted into an electrode puller (University of 
Nottingham, Medical Faculty Workshops). A current was passed 
through a coil, causing the capillary tube to melt and pull apart, coating 
the filament with glass. The capillary tube with the tungsten filament 
was then placed into the holder of a light microscope and the tapered 
end was pushed gently towards a heated borax bead attached to the 
microscope. The current supply was then turned off, causing 
contraction of the borax bead, pulling off a small glass fragment to 
expose about 1-2 mm of the tungsten wire.  
 
4.2.2.7. Choice of anaesthetic  
The choice of anaesthetic was important as it was necessary that it 
would not have any overt effects on the responses of the dorsal horn 
neurones. Previously, decerebrate animals have often been used in 
electrophysiological studies &ODUNH2JLOYLH et al. as this 
method reduces the confounding analgesic effects of anaesthesia, but 
the generation of decerebrate animals involves additional surgical 
procedures and removes the descending pain pathways which 
modulate spinal dorsal horn neuronal responses. 
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Inhalation anaesthesia was chosen as it enables tight control of the 
amount of anaesthetic being delivered, and can be rapidly increased or 
decreased as required. Halothane was not chosen due to its potential 
for hepatotoxicity, and at the dose range used in these experiments 
halothane has a greater depressant effect on neuronal responses than 
isoflurane (Mitsuyo et al., 2006). Isoflurane has been shown to have a 
minimal depressant effect on dorsal horn responses to noxious 
mechanical stimuli in rats in vivo (Antognini et al.  .LP et al., 
2007b). Isoflurane was used in combination with nitrous oxide so that a 
lower concentration of anaesthetic could be used. 
 
4.2.3. Administration of drugs 
All drug dosing was carried out blind to the treatment groups. 
Pioglitazone (10mgkg-1 RU  PHWK\OFHOOXORVH YHKLFOH ZDV RUDOO\ 
DGPLQLVWHUHG GDLO\ IURP GD\  WRGD\  RI WKH VWXG\ ZKHn the first 
cohort (n=6 for all groups) were used for electrophysiological 
experiments. A second cohort of rats (n=6 for lean/Veh, HFD/Veh and 
HFD/STZ and n=5 for HFD/STZ + pioglitazone) was assessed until day 
78, (28 days after dosing with pioglitazone had ceased), when 
electrophysiological experiments were then conducted. Pioglitazone 
was purchased from Tocris Cookson (Bristol, UK) and was dissolved in 
PHWK\OFHOOXORVHYHKLFOH 
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Figure 4.1 Timeline of the experiment 
 
 
4.2.4. Statistics 
Analysis of body weight, food intake and water intake was by an 
ANCOVA with Tukeys post-hoc test, with the average of day -7 to 0 as 
the covariate. Analysis of plasma glucose, plasma insulin, mechanical 
withdrawal thresholds, mechanically and electrically evoked neuronal 
responses and electrical thresholds and latencies was by a Kruskal-
Wallis test with Dunns post-hoc test. In all analyses, a p value of less 
than 0.05 was considered statistically significant. 
 
Rats were excluded from analysis of pain behaviour if in the two weeks 
before injection with STZ the average hindpaw mechanical withdrawal 
threshold was <10g. In this study, this represented 5 rats  1 lean/Veh, 
1 HFD/Veh, 1 HFD/STZ + vehicle and 2 HFD/STZ + pioglitazone. 
  
4.3. Results 
4.3.1. Effects of HFD/STZ on hindpaw evoked 
responses of WDR neurones in the dorsal horn 
This study examined the effects of the HFD/STZ model of diabetes on 
the activity of dorsal horn neurones in vivo DW GD\  DQG GD\  A 
total of 64 WDR dorsal horn neurones were characterized in 6 
lean/Veh, 6 HFD/Veh, 6 HFD/STZ and 6 pioglitazone-treated HFD/STZ 
rDWVDWGD\ DQGQHXURQHVSHUUHVSHFWLYHJURXS, and a 
WRWDO RI  WDR dorsal horn neurones were characterized in 6 
lean/Veh, 6 HFD/Veh, 5 HFD/STZ and 6 pioglitazone-treated HFD/STZ 
rats at day 78 DQGQHXURQHVSHUUHVSHFWLYHJURXS. The 
average depth of the dorsal horn neurones recorded from ranged 
between 756-887ȝPwhich corresponds to laminae V-VI. 
 
Prior to investigating the evoked responses of the WDR dorsal horn 
neurones, any spontaneous activity was recorded. The vast majority of 
neurones recorded exhibited negligible or no spontaneous firing 
activity. Two out of 18 neurones in both the vehicle and the pioglitazone 
treated HFD/STZ groups DWGD\KDG spontaneous firing above 1Hz 
DQG+]DQGDQG+]UHVSHFWLYHO\EXW no significant 
changes were seen between any of the groups (data not shown).  
 
Both the electrically and mechanically evoked responses of the WDR 
dorsal horn neurones were quantified. The average latency and 
threshold values, as well as total number of action potentials produced 
E\$ȕ-$į- and C-fibres during a train of 16 electrical stimuli at three 
times the C-fibre threshold, as well as post-discharge, are presented in 
Table 4.3. Although there was a trend for the Aȕ-fibre evoked response 
to be lower in the HFD/STZ rats, compared to the lean/Veh controls and 
HFD/Veh controls, this did not reach significance. An example trace of 
the response of a typical WDR neurone to the first 8 of a train of 16 
electrical stimuli can be seen in Figure 4.2. 
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Stimulation of the hindpaw receptive field of dorsal horn neurones with 
a range of von Frey hairs evoked a stimulus intensity-dependant 
increase in the firing of these neurones in the lean/Veh controls, the 
HFD/Veh controls and the HFD/STZ group. An example histogram 
showing the graded response of a single dorsal horn neurone is 
provided in Figure 4.2. There was a trend towards a decrease in the 
mechanically-evoked responses of dorsal horn neurones in the 
HFD/STZ at each different weight DWGD\, especially to the noxious 
stimuli (15-60g), although significance was not reached (Figure 4.3A), 
and an AUC analysis of the stimulus response functions for the three 
groups did not reveal a significant difference, perhaps due to the high 
variability in the data. This difference was not maintained at day 78. 
 
Table 4.3 Comparison of the C- and A-fibre evoked responses of WDR 
dorsal horn neurones in the HFD/STZ model of diabetes, compared to 
HFD/Veh and lean/Veh controls DW GD\  There were no significant 
differences in the C-fibre threshold and latency, total action potentials 
$3VIRU$ȕ-$į- and C-fibres, and also post-discharge firing, following 
a train of 16 electrical stimuli in the three groups. Pioglitazone (10mgkg-
1, p.o.) treatment from day 21-GLGQRWDOWHU WKHVHSURSHUWLHVRI WKH
dorsal horn neurones in the HFD/STZ model. All data represent mean ± 
SEM, analysis was by a Kruskal-Wallis test. 
 
Lean/Veh 
n=6 
HFD/Veh 
n=6 
HFD/STZ + 
Vehicle 
n=6 
HFD/STZ + 
Pioglitazone 
n= 6 
C-fibre Threshold (mV)  1.5 ± 0.2 1.3 ± 0.1 1.2 ± 0.1 1.4 ± 0.1 
Latency (ms) 228 ± 13    214 ± 14 
$ȕ7RWDO$3V 138 ± 12  111 ± 8 118 ±  
$į (Total APs) 161 ± 24  105 ± 21 131 ± 11 
C (Total APs)  ± 67 251 ± 37 276 ± 48 266 ± 42 
Post-discharge (Total 
APs) 
  402 ± 82 378 ± 60 
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Figure 4.2 (A) Representative trace of electrically-evoked evoked responses of a single wide dynamic range dorsal horn neurone to 
the first 8 electrical stimuli of the train of 16 stimuli. (B) Representative trace of the evoked response of a single wide dynamic range 
dorsal horn neurone following mechanical (8, 10, 15, 26 and 60g) stimulation of the hindpaw receptive field in a HFD/Veh rat. 
B 
A 
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4.3.2. Effects of pioglitazone on mechanically evoked 
responses of dorsal horn neurones 
The effects of pioglitazone (10 mgkg-1, p.o., day 21-4) treatment on the 
magnitude of the mechanically-evoked responses of the WDR dorsal 
horn neurones in HFD/STZ rats were compared to the effects of vehicle 
treatment. Immediately following 28 days of pioglitazone treatment (day 
 PHFKDQLFDOO\ HYRNHG UHVSonses of dorsal horn neurones were 
significantly larger than evoked neuronal responses in HFD/STZ rats 
treated with vehicle. As shown in Figure 4.3B, there was a significant 
increase in the evoked firing of neurones in the spinal cord of HFD/STZ 
rats treated with pioglitazone. Twenty-eight days after cessation of 
pioglitazone treatment in the HFD/STZ rats, mechanically evoked 
responses of dorsal horn neurones had returned to a similar level to 
those in the vehicle treated HFD/STZ rats (Figure 4.3B). 
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Figure 4.3 (A) Mechanically-evoked responses of WDR dorsal horn 
neurones in the HFD/STZ model of diabetes (n=6), compared to 
lean/Veh controls (n=6) and HFD/Veh controls (n=6). All data represent 
mean frequency of firing ± SEM, analysis was by a Kruskal-Wallis test. 
(B) Effects of daily pioglitazone treatment (10 mgkg-1, p.o., day 21- 
on mechanically-evoked responses of spinal neurones in HFD/STZ rats 
at day 4 (n=6 for both groups) and day 78 (n=5 for HFD/STZ, n=6 for 
HFD/STZ + pioglitazone). Data are mean neuronal firing in HFD/STZ + 
pioglitazone rats expressed DV D  RI evoked neuronal firing in 
HFD/STZ + vehicle rats. Analysis of original data, comparing HFD/STZ 
+ vehicle and HFD/STZ + pioglitazone rats, was by a Mann-Whitney 
test: * p<0.05, ** p<0.01 
B 
A 
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4.3.3. Effects of pioglitazone on metabolic parameters 
As described previously, induction of the HFD/STZ model leads to a 
threefold increase in plasma glucose levels (p<0.01; Figure 4.4A), and a 
six-fold decrease in plasma insulin levels (p<0.001; Figure 4.4B), 
compared to HFD/Veh controls. An increase in insulin levels can also 
be seen in the HFD/Veh group compared to the lean/Veh controls, as 
discussed in Chapter 3. Body weight gain was again stunted in the 
HFD/STZ rats (p<0.001), water intake was increased four-fold (p< 
0.001), and food intake was increased in all groups eating the HFD, 
although this was not significantly different between groups (data not 
VKRZQ6\VWHPLFDGPLQLVWUDWLRQRISLRJOLWD]RQH IURPGD\ WRGLG
not alter any of these parameters. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 Effects of daily pioglitazone treatment (10 mgkg-1, p.o., day 
21- versus vehicle on (A) fasting plasma glucose and (B) fasting 
plasma insulin. Day 18 is pre-pioglitazone administration, day 46 is after 
25 days of pioglitazone and day 74 is 25 days after pioglitazone 
administration had ceased. Day 18 and 46: n=12 for all, except n=11 for 
HFD/STZ + vehicle. Day 74: n=6 for all, except n=5 for HFD/STZ + 
vehicle. All data represent mean ± SEM, analysis was by a Kruskal-
Wallis test with Dunns post-hoc test: (* vs. HFD/Veh)  
* p<0.05, ** p<0.01, *** p<0.001 
 
  
 
 
B A 
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4.3.4. Effects of pioglitazone on mechanical 
withdrawal thresholds 
The mechanical withdrawal thresholds of the HFD/STZ group were 
significantly reduced compared to HFD/Veh controls from day 14 post-
STZ injection, and the mean threshold decreased further up to day 70 
)LJXUH  $W GD\  ZKHQ WKH ILUVW FRKRUW ZDV WDNHQ RXW IRU
electrophysiological experiments, the mean mechanical withdrawal 
threshold of the HFD/STZ group was 8.7±1.2g, in comparison to 
14.0±0.6g for the lean/Veh controls and 13.8±0.6g for the HFD/Veh 
controls. At day 70, just before the second set of electrophysiological 
experiments was performed, the mean mechanical withdrawal threshold 
of the HFD/STZ group was 7.0±1.2g, in comparison to 13.8±0.8g for the 
lean/Veh controls and 14.0±1.0g for the HFD/Veh controls. 
 
Rats were dosed with 10mgkg-1 SLRJOLWD]RQH RU  PHWK\OFHOOXORVH
vehicle, from day 21- Although there appears to be a separation 
between the decline in mechanical withdrawal thresholds in the 
HFD/STZ pioglitazone treated group compared to the HFD/STZ control 
group, there were no significant differences between the two groups 
over the period of treatment, and an area under the curve (AUC) 
analysis also revealed no significant difference (Figure 4.5). At the end 
RI GRVLQJ ZLWK SLRJOLWD]RQH GD\  WKH PHDQ PHFKDQLFDO ZLWKGUDZDO
threshold for this group was 10.8±1.1g compared to 8.7±1.2g in the 
HFD/STZ vehicle treated group. 
 
126 
Figure 4.5 Effects of daily pioglitazone treatment (10 mgkg-1, p.o., day 
21- versus vehicle on hindpaw mechanical withdrawal thresholds. 
8SWRGD\Q IRUOHDQ9HKDQG+)'9HKDQGQ IRU+)'67=
+ vehicle and HFD/STZ + pioglitazone. 'D\  RQZDUGV n=6 for 
lean/Veh and HFD/Veh, and n=5 for HFD/STZ + vehicle and HFD/STZ 
+ pioglitazone. All data represent mean ± SEM, analysis was by a 
Kruskal-Wallis test with Dunns post-hoc test: (* vs. HFD/Veh) 
* p<0.05, ** p<0.01, *** p<0.001 
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4.4. Discussion 
In the present study, I have demonstrated that the HFD/STZ model of 
diabetes, which is associated with mechanical hypersensitivity, is also 
associated with a trend towards a decrease in mechanically evoked 
responses of spinal neurones. This model was not associated with any 
changes in the threshold for electrical activation of C-fibres, nor any 
significant changes to electrically evoked responses. Although a trend 
towards a decrease in the electrical evoked Aȕ-fibre activity of neurones 
was evident, significance wasnt reached. There was no change in 
spontaneous firing of neurones between any groups. 
 
Pioglitazone treatment IURPGD\ WRdid not significantly alter the 
progression of mechanical hypersensitivity in the HFD/STZ rats. 
However, electrophysiological studies revealed that the pioglitazone 
treatment was associated with a significant increase in the magnitude of 
the mechanically-evoked responses of WDR dorsal horn neurones in 
the HFD/STZ rats which received pioglitazone, compared to vehicle 
treatment. This effect was significant immediately following pioglitazone 
treatment but was not maintained and evoked responses returned to 
levels similar to that in the untreated HFD/STZ group 4 weeks after 
pioglitazone treatment had ceased. 
 
4.4.1. Effects of the HFD/STZ model on 
electrophysiological parameters 
Previous studies have investigated the involvement of Aȕ-, Aį- and C-
fibres, as well as higher order neurones in diabetic neuropathy, and 
how these might contribute to the painful symptoms experienced. 
Hyper-responsiveness, a decrease in mechanical thresholds and an 
increase in spontaneous activity and wind-up in both primary afferent 
fibres, as well as higher order neurones has been shown in the STZ 
model (Ahlgren et al. $KOJUHQ et al.&KHQ et al., 2002a; 
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Chen et al., 2003; Chen et al., 2001; Fischer et al..KDQ et al., 
2002; Kimura et al., 2005; Suzuki et al., 2002). 
 
This increase in activity has been postulated to be due to sensitisation 
of the central nervous system due to the aberrant activity in afferent 
nerves (Kamiya et al., 2005a), and impairments to descending pain 
modulation (Morgado et al., 2011b). The increased levels of GABA in 
the STZ model (Malmberg et al., 2006; Morgado et al., 2008) have been 
shown to have an excitatory rather than an inhibitory effect due to a 
decrease in the expression of KCC2 (Jolivalt et al., 2008; Morgado et 
al., 2008), resulting in enhanced activity of spinal neurones, and 
therefore increased facilitation. 
 
The affect of the STZ model on neurones in the dorsal horn of the 
spinal cord has previously been examined with contrasting findings. An 
increase in spontaneous activity, enlarged receptive fields and 
increased peripherally evoked responses to brush, press, pinch and von 
Frey stimuli have been observed (Chen et al., 2002a; Ghorbani et al., 
2011; Tan et al., 2012). Pertovaara et al. (2001) also found an increase 
in spontaneous activity, but no change in noxious heat-evoked 
responses, after discharges, or receptive field size, and a decrease in 
the responses evoked by mechanical stimulation in STZ treated rats. In 
the present study, a trend towards lower firing frequencies in response 
to mechanical stimulation was observed in the HFD/STZ group. A 
decrease in the evoked neuronal response to mechanical stimulation 
has also been seen in other models; SNL (Chapman et al. , 
spinal cord injury (Hao et al., 2004) and cisplatin-induced 
chemoneuropathy (Cata et al., 2008). However, this mismatch between 
the mechanical hypersensitivity observed in the HFD/STZ model, and 
the lowered mechanically evoked responses in this electrophysiology 
study, which would normally infer sensory deficits, is difficult to explain. 
Cata et al. (2008) hypothesised that the rats might be experiencing 
paresthesias such as tingling and numbness, which are routinely 
observed in humans with diabetic neuropathy (Ziegler, 2008). It was 
  
proposed that these symptoms might result in enhanced vigilance of the 
rats to von Frey stimulation, rather than them actively becoming more 
sensitive to lower-threshold stimuli. The processing of pain in 
neuropathic conditions is very complex, and so there may be a variety 
of other mechanisms which that are responsible for the hypersensitivity 
that is observed in this model. 
 
While the observed decrease in evoked responses to mechanical 
stimulation reported herein is consistent with previous studies, the 
majority of earlier reports have found an increase in spontaneous 
activity, both in the diabetic model (Pertovaara et al., 2001; Tan et al., 
2012), and in a variety of other models of neuropathic pain (Cata et al., 
2008; Chapman et al. /DLUG et al. 3DOHFHN et al. . 
The basis for these differences is unclear, but may relate to the criteria 
used when searching for neurones. During this process, the neurone 
had to display three characteristics before it was taken further. It 
needed to; be responsive to both brush and pinch stimuli; have a 
graded response to stimulation with von Frey hairs; and display wind-up 
in response to a train of electrical stimuli. Neurones which displayed a 
large amount of spontaneous activity may have been disregarded due 
to the difficulty in making the assessment of these three characteristics. 
As the main purpose of this study was to determine whether HFD/STZ 
influenced mechanically-evoked responses, and to compare this to the 
changes seen in the behavioural experiments, this search criteria was 
necessary. Therefore it is possible that any increase in spontaneous 
firing that might have been seen in the HFD/STZ model was lost 
through the process of selecting neurones to follow, and so in a future 
study, it would be of great interest to conduct a similar experiment, but 
to be more inclusive of which neurones were followed, to allow any 
changes that might have been lost in the present study to be seen. 
 
 
130 
4.4.2. Metabolic effects of pioglitazone in the HFD/STZ 
model 
The lack of effect of pioglitazone on glucose or insulin levels is in 
agreement with previous similar studies in STZ treated rats (Majithiya et 
al., 2005; Wiggin et al., 2008; Yamagishi et al., 2008). In type 2 
diabetes, pioglitazone acts as an insulin sensitiser in peripheral tissues, 
DVZHOODVLPSURYLQJȕ-cell function (Kawasaki et al., 2005; Miyazaki et 
al., 2001)+RZHYHU LQWKLVPRGHODODUJHSURSRUWLRQRIWKHȕ-cells are 
destroyed by the STZ, and fasting plasma insulin levels are six-fold 
lower than in the HFD/Veh controls. This means that the rats are 
insulin-deficient, rather than insulin-resistant, and so improving the 
peripheral insulin sensitivity is ineffective due to the low levels of 
circulating insulin. As the insulin levels were also unchanged, this 
LQGLFDWHV WKDW WKH ȕ-cells are probably working at full capacity, and 
SLRJOLWD]RQH ZDV WKHUHIRUH XQDEOH WR VWLPXODWH PRUH ȕ-cell insulin 
secretion. Previously, Srinivasan et al. (2005) gave 10mgkg-1 of 
pioglitazone for 7 days to HFD/STZ rats, who had received either 35, 45 
or 55mgkg-1 of STZ. In the rats which received the lowest dose of STZ, 
plasma insulin levels were only reduced to a level seen in rats fed a 
normal diet, and in these rats, pioglitazone was able to produce a 
significant reduction in plasma glucose levels. In the rats that had been 
given a higher dose of STZ (45 or 55mgkg-1), there was a much greater 
reduction in insulin levels, and pioglitazone was then ineffective at 
reducing plasma glucose. This suggests that pioglitazone is most 
effective when it is able to improve whole body insulin sensitivity by 
decreasing lipolysis and enhancing insulin-mediated glucose disposal in 
skeletal muscle (Kahn et al., 2000). However, when insulin levels are 
reduced beyond a certain level, such as in the current study, 
pioglitazone is unable to affect levels of glucose or insulin. 
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4.4.3. Effects of pioglitazone on pain behaviour and 
neuronal responses in the HFD/STZ model 
In the current study, administration of 10mgkg-1 pioglitazone three 
weeks after injection with STZ had no significant effect on the 
development of mechanical hypersensitivity, compared to the vehicle 
controls. The rationale behind administering the drug at this timepoint 
was that I wanted to model the clinical situation, where the drug would 
be administered once painful symptoms had first appeared. On the 
basis of the recent publication by Morgenweck et al. (2013), a higher 
dose of pioglitazone may be required to produce an analgesic effect 
once the model is established 
 
Interestingly, despite the lack of effect on pain behaviour, in my 
electrophysiological experiments pioglitazone produced a significant 
increase in evoked neuronal responses in the HFD/STZ rats, with this 
effect not maintained 4 weeks after cessation of pioglitazone treatment. 
Pioglitazone treatment effectively restored mechanically evoked 
responses of spinal neurones in HFD/STZ rats to levels higher than 
lean/Veh controls. Given that this effect was not associated with a 
change in mechanical hypersensitivity, the biological relevance of this 
finding is unclear 
 
Pioglitazone, and other thiazolidinediones, have been shown to be 
effective at alleviating mechanical hypersensitivity in a variety of 
models: carrageenan (Cuzzocrea et al., 2004; Morgenweck et al., 2010; 
Taylor et al., 2002), post-incisional pain (Hasegawa-Moriyama et al., 
2012), spinal cord injury (Park et al., 2007), spinal nerve transection (Jia 
et al., 2013; Jia et al., 2010), partial sciatic nerve ligation (Iwai et al., 
2008; Maeda et al., 2008; Takahashi et al., 2011), tibial and sural nerve 
transection (Jain et al. , and spared nerve injury (Churi et al., 
2008; Morgenweck et al., 2013). Since the levels of glucose and insulin 
are not altered in these models, TZDs must have an analgesic effect 
that is not just due to insulin sensitisation.  
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Indeed, TZDs have marked effects on macrophage recruitment and 
activation state, and this has profound anti-inflammatory effects in 
models of inflammatory pain (Hasegawa-Moriyama et al., 2012; Taylor 
et al., 2002). 
 
TZDs analgesic effects in neuropathic pain models also seem to be 
predominantly mediated by an anti-inflammatory effect. TZDs are able 
to: decrease astrogliosis and microglial activation (Iwai et al., 2008; 
Morgenweck et al., 2013; Park et al., 2007), inhibit the activation of 
1)ț%(Costa et al., 2008; Jia et al., 2013; Jia et al., 2010), decrease the 
expression of various pro-inflammatory factorsVXFKDV71)ĮDQG,/-1ȕ 
(Costa et al., 2008; Jia et al., 2013; Jia et al., 2010; Park et al., 2007; 
Qiang et al. , increase the expression of anti-oxidant enzymes 
(Park et al., 2007), and attenuate the decrease in reduced glutathione, 
and the increase in myeloperoxidase activity (a specific marker of 
inflammation) (Jain et al.. The decrease in the production of pro-
inflammatory cytokines may be partly responsible for the suppression of 
glial activation. TZDs have also been shown to reduce oxidative stress 
in the STZ model (Majithiya et al., 2005), perhaps by activating genes 
with oxidoreductase activity (Wiggin et al., 2008). This ability of 
pioglitazone to decrease pro-inflammatory cytokines could play an 
LPSRUWDQW UROH LQ GLDEHWLF QHXURSDWK\ DV OHYHOV RI 1)ț% DQG SUR-
inflammatory cytokines are increased in both diabetic animals and 
patients (as reviewed in Wilson et al., 2012a). 
 
Therefore, from all the accumulating evidence as to the effects of 
pioglitazone in models of pain, it would seem logical that pioglitazone 
might have had an analgesic effect in the HFD/STZ model. However, 
many of these studies have shown that the TZDs are most effective 
when given at the time of injury. Indeed TZD treatment at day 26-28 
after PNL is far less effective than when given at days 1-3 (Takahashi et 
al., 2011). This group hypothesised that rosiglitazone may only be 
effective if given in the initial phase before macrophages are activated 
and recruited to the site of injury, where they exacerbate acute 
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inflammation. As pioglitazone was not seen to be effective in alleviating 
neuropathic pain in this study, experiments in the final chapter go on to 
investigate other antidiabetics, and other types of analgesics. 
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Chapter 5. 
Comparison of analgesic versus antidiabetic 
interventions on aberrant pain responses in 
the HFD/STZ model 
 
5.1. Introduction 
Having established that the HFD/STZ model leads to development of 
mechanical hypersensitivity, and having investigated some of the 
mechanisms underlying these responses, the next series of 
experiments investigated the effects of different types of interventions, 
analgesic versus antidiabetic, on aberrant pain responses in this model. 
 
5.1.1. Existing and novel analgesics for diabetic 
neuropathy 
It is generally understood that one of the most important factors in the 
treatment of diabetic neuropathy is for diabetic patients to maintain tight 
control of their blood glucose concentration. Maintaining these levels 
with intensive insulin therapy has been shown to delay, or prevent the 
development of diabetic neuropathy, especially in type 1 diabetes 
'&&7IRUUHYLHZVHH&DOODJKDQ et al., 2012; Gaede et al., 
and this effect can still be seen over 10 years later (Albers et al., 2010).  
 
Alternatively, inhibiting the pain responses directly can ameliorate the 
painful symptoms (Ziegler, 2008). Neuropathic pain, however, has 
proved difficult to treat, with little efficacy seen from conventional 
analgesics such as non-steroidal anti-inflammatory drugs and opiates, 
the latter of which has a number of side effects including nausea, 
constipation and sedation, and can also be addictive, with tolerance 
developing with prolonged usage (Benyamin et al., 2008). 
 
There are a variety of drugs that can be prescribed to offer pain relief to 
diabetic patients. NICE guidelines recommend duloxetine as the first 
line treatment, followed by either amitriptyline or pregabalin (NICE, 
2010), and the FDA has also approved tapentadol (FDA, 2004). A 
recent in-depth review of the literature recommended pregabalin as the 
first choice (Bril et al., 2011). 
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5.1.1.1. Pregabalin 
Both gabapentin and pregabalin are licensed for treatment of DPNP, 
with pregabalin being the gold-standard (Bril et al., 2011). Both drugs 
alleviate painful symptoms, as well as improving quality of life and sleep 
problems. They are, however, associated with side effects such as 
dizziness and somnolence (Freeman et al., 2008; Freynhagen et al., 
2005; Quilici et al.  6WDFH\ et al., 2008). Gabapentin and 
pregabalin are derivatives of the neurotransmitter GABA (but do not 
interact with the GABA receptor itself) (Lanneau et al., 2001). They bind 
WR WKH Įį-1 auxiliary subunits of presynaptic voltage-gated calcium 
channels (Field et al., 2006; Gee et al., with pregabalin having a 
six-fold higher binding affinity than gabapentin at the Įį-1 subunit 
(Vinik et al., 2013). 
 
The Įį subunit enhances trafficking of CavĮ1 to the plasma 
membrane, increasing the number of functional channels present, 
which results in an increase in Ca2+ currents (Davies et al., 2007). The 
gabapentinoids bind to Į2į-1, and it has been postulated that their 
mechanism of action is to displace an endogenous protein ligand that 
QRUPDOO\ DFWV DV D SRVLWLYH PRGXODWRU RI Įį-1, impairing its ability to 
traffic the calcium channel from DRG cell bodies to the plasma 
membrane of presynaptic terminals in the dorsal horn (Bauer et al., 
+HQGULFK et al., 2008). The consequence of this is less calcium 
entry into the nociceptive primary afferent fibres via this channel, which 
is located on these fibres, resulting in a reduction in transmitter release 
from the primary afferent terminals in the dorsal horn (Taylor, 2004; 
7D\ORU, and decreased activation of dorsal horn neurones in the 
spinal cord.  
 
Importantly, Įį-1 subunit expression has been shown to be up-
regulated in the DRGs (Martinez et al., 2012; Yusaf et al., 2001) and 
dorsal horn of the spinal cord in STZ diabetic rats (Luo et al., 2002). 
Electron microscopy and quantitative RT-PCR studies have provided 
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evidence that the elevation in Įį-1 in the SNL model of neuropathic 
pain occurs exclusively on the presynaptic terminals of primary sensory 
afferents (Bauer et al.. Over-expression of the Įį-1 subunit in 
mice results in the manifestation of mechanical hypersensitivity and 
thermal hyperalgesia (Li et al., 2006), illustrating a fundamental role of 
this channel in influencing nociceptive thresholds. 
 
Both gabapentin and pregabalin attenuate mechanical hypersensitivity 
in the STZ model of diabetes (Field et al.E0DUWLQH] et al., 2012; 
Wodarski et al. ; Yamamoto et al.=KDQJ et al., 2013). In 
addition, gabapentin also suppressed the flinching response during the 
formalin test in diabetic rats (Ceseña et al.. Pregabalin led to a 
decrease in the calcium channels expressing Įį-1 in the dorsal horn in 
diabetic rats (Martinez et al., 2012), and gabapentin has been shown to 
significantly reduce enhanced excitability by decreasing the rise in 
expression of Nav1.7 and p-ERK1/2 in STZ rats (Zhang et al., 2013). 
 
5.1.1.2. Cannabinoid ligands 
Another target showing promise in its ability to alleviate pain associated 
with diabetic neuropathy is the endocannabinoid system. 
Endocannabinoids exert their effects through two GPCRs; CB1 and CB2 
(cannabinoid receptors 1 and 2). CB1 receptors are located in the 
periphery, but are found most abundantly in the CNS, including the 
spinal cord, PAG and thalamus (Tsou et al.. CB2 receptors are 
primarily expressed by immune cells in the periphery with high 
concentrations in the spleen (Munro et al. , but are also 
expressed by microglia in the CNS (Romero-Sandoval et al., 2008b) 
and neurones in the brain (Gong et al., 2006; Van Sickle et al., 2005). 
These receptors can be activated by cannabinoids such as ǻ-
tetrahydrocannabinol (THC) and cannabidiol, and also by endogenous 
cannabinoids (endocannabinoids) such as anandamide (AEA) and 2-
arachidonoylglycerol (2-AG), which are synthesised and released on 
demand (Booker et al., 2012), and rapidly broken down by the enzymes 
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fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) 
respectively (for review see Muccioli, 2010). Figure 5.1 summaries the 
breakdown of these endocannabinoids, and the receptors that they are 
ligands for. 
 
The effects of cannabinoids on pain responses in models of diabetes 
have been fairly widely studied. Systemic administration of WIN55212-2 
(a mixed CB1 and CB2 receptor agonist) attenuated mechanical 
hypersensitivity in STZ mice (Dogrul et al., 2004; Toth et al., 2010), STZ 
rats (Ulugol et al., 2004; Vera et al., 2012) and ZDF rats (Vera et al., 
2012). Cannabidiol, which has a multitude of low potency targets 
including receptors CB1 and CB2, and inhibition of FAAH (Pertwee, 
2004), was effective at preventing the development of mechanical 
hypersensitivity and thermal hyperalgesia in STZ mice when 
administered at the onset of diabetes, and for a further 2 months after 
discontinuation of the drug, although it was without effect when 
administered therapeutically once mechanical hypersensitivity was 
established (Toth et al., 2010). In a more complicated behavioural 
assay, diabetic rats exhibited increased flinching behaviour compared 
to normoglycemic rats in the formalin test, and peripheral AM404 (an 
AEA reuptake inhibitor), AEA itself, and ACEA (a CB1 receptor agonist) 
all attenuated flinching behaviour during the first and second phase of 
the formalin test in the diabetic rats (Schreiber et al., 2012). Systemic 
administration of a cannabis extract decreased mechanical 
hypersensitivity, protected against oxidative stress (as evidenced by 
increased glutathione levels and decreased liver lipid peroxidation) and 
restored NGF levels in the sciatic nerve in the STZ model (Comelli et 
al. . Another study reported that the CB1 receptor antagonist 
rimonabant was also able to attenuate mechanical hypersensitivity in 
diabetic mice (Comelli et al., 2010). 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1. The key features of the endocannabinoid receptors and their breakdown. Both AEA and 2-AG can also be metabolised 
to form biologically activated metabolites. AA - arachidonic acid. Adapted from (Sagar et al..  
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5.1.1.2.1. MAGL inhibitors 
2-AG, is formed from DAG and phospholipase-C (Horváth et al., 2012), 
and activates both CB1 and CB2 receptors, but binds with highest 
affinity to the CB2 receptor (Mechoulam et al.. MAGL is one of 
the key enzymes responsible for its hydrolysis, and breaks 2-AG down 
to fatty acid and glycerol (Dinh et al., 2002). 
 
JZL184 is a selective, irreversible inhibitor of MAGL, effective at 
alleviating mechanical and cold allodynia in the neuropathic CCI mouse 
model (Schlosburg et al., 2010). This effect was not seen in CB1 
receptor knock-out mice, but was present in CB2 receptor knock-out 
mice (Kinsey et al., 2010), suggesting a CB1 receptor-selective 
mechanism of action is responsible for the inhibitory effects mediated 
by increased 2-AG. Interestingly, the ameliorative effect of FAAH 
inhibition on mechanical hypersensitivity was not present in either CB1 
or CB2 receptor knockouts, suggesting that both receptors are required 
for the action of anandamide (see 5.1.2.2 for more on FAAH inhibition). 
This hypothesis was confirmed in a later study which demonstrated that 
the analgesic effects of JZL184 in the CCI mouse model were only 
blocked by a CB1 receptor antagonist (Kinsey et al.. 
 
An issue facing the use of JZL184 is that repeated administration of a 
high dose (40 mg/kg, i.p) caused tolerance, with mice showing similar 
responses to those of vehicle-treated mice in pain assays (Schlosburg 
et al., 2010). However recent studies, using lower doses, have shown 
that repeated administration of JZL184 is effective at alleviating 
mechanical hypersensitivity in the carrageenan model, with only 
repeated high doses leading to tolerance (Ghosh et al., 2013). This was 
substantiated with the demonstration that low doses of JZL184 
increased levels of 2-AG in the brain, and decreased cold and 
mechanical hypersensitivity, with no tolerance developing with repeated 
dosing, an effect not seen with higher doses (Kinsey et al., 2013). 
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Another problem with JZL184 is that it displays a 10-fold lower potency 
in the rat (Long et al.D. However a new compound, MJN110, has 
been developed that displays high selectivity for MAGL (IC50 in rats 
<100nm, whereas the IC50 IRU)$$+!ȝ0, and has a similar potency 
in both rat and mouse (Niphakis et al., 2013), and so may be able to 
play a role in alleviating mechanical hypersensitivity in the HFD/STZ 
model. 
5.1.1.2.2. FAAH inhibitors 
FAAH is a membrane-bound serine hydrolase enzyme that breaks 
down fatty-acid ethanolamides (FAEs) such as AEA, N-
palmitoylethanolamine (PEA) and oleoylethanolamide (OEA) (Cravatt et 
al. . AEA is broken down to arachidonic acid and ethanolamine 
(Devane et al.. It binds with a four-fold higher affinity to the CB1 
receptor than the CB2 receptor (Pertwee et al. , and is also an 
agonist at TRPV1 (Tognetto et al., 2001). 
 
AEA was shown to have analgesic effects in models of inflammatory 
pain (Calignano et al.. PEA, which acts as a PPARĮOLJDQG, has 
also been shown to have both analgesic and anti-inflammatory effects 
(Calignano et al.&RQWL et al., 2002; Jaggar et al./R9HUPH 
et al., 2006), as well as having an antinociceptive effect in the CCI 
model (Costa et al., 2008). 
 
The importance of FAAH has been demonstrated in knock-out mice 
(FAAH -/-), which show a 15-fold increase in brain levels of AEA, and 
also exhibit reduced thermal and chemical pain sensation, which can be 
reversed by a CB1 receptor antagonist (Cravatt et al., 2001). Inhibitors 
RI)$$+KDYHEHHQGHYHORSHGVXFKDV85%F\FORKH[\OFDUEDPLF
acid 3-carbamoyl-biphenyl-3-yl ester), which is a rapidly binding 
irreversible FAAH inhibitor, with no activity at cannabinoid receptors or 
MAGL (IC50 in rats = 5nm for FAAH, !ȝ0IRU0$*/) (Piomelli et al., 
2006)6\VWHPLFDGPLQLVWUDWLRQRI85% OHDGV WRSURIRXQG LQKLELWLRQ
of FAAH in the brain resulting in an increased accumulation of AEA in 
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the brain and spinal cord (Fegley et al., 2005; Russo et al., 2007). 
When administered to FAAH -/- mice, the already increased levels of 
FAEs were not elevated further (Fegley et al., 2005). 
 
Repeated adPLQLVWUDWLRQ RI 85% causes a significant reduction in 
mechanical hypersensitivity and thermal hyperalgesia in the CCI model, 
and these effects were completely blocked by both CB1 and CB2 
receptor antagonists (Kinsey et al.5XVVR et al., 2007)85%
has antinociceptive efficacy in a variety of other models of pain, such 
as; the monosodium iodoacetate model of arthritis, and in Dunkin-
Hartley guinea pigs where arthritis naturally occurs (Schuelert et al., 
2011); a model of cholestasis (Hasanein et al., 2008); and the 
inflammatory carrageenan model (Okine et al., 2012), where it blocked 
the expansion of the peripheral receptive field of WDR neurones in the 
spinal cord (Sagar et al., 2008)85%KDVEHHQVKRZQWRVXSSUHVV 
the mechanically evoked responses of WDR neurones in sham-
operated rats, but had no effect on these responses in the carrageenan 
(Sagar et al., 2008) or the SNL model (Jhaveri et al., 2006). Finally, it 
was also effective in alleviating mechanical hypersensitivity and thermal 
hyperalgesia in the complete Freunds adjuvant model (Jayamanne et 
al., 2006), but conversely it had no effect in the PNL model.  
 
Other FAAH inhibitors that have also been shown to have analgesic 
effects include OL135, a selective, reversible inhibitor, which caused 
substantial reversal of mechanical hypersensitivity in the mild thermal 
injury and SNL model (Chang et al., 2006), as well as in the tail 
immersion, hot-plate and formalin tests, which were blocked by a CB1 
receptor antagonist (Lichtman et al., 2004a). 7KH HIIHFWV RI 85%
KDYH DOVR EHHQ LQYHVWLJDWHG LQ WKH 67= PRGHO 85% SURGXFHG DQ
analgesic effect: lowering nociceptive scores in both phases of the 
formalin test, as well as increasing tail-flick latencies (Hasanein et al., 
D. ST4070, another FAAH inhibitor, alleviated established 
mechanical hypersensitivity in a dose-dependent manner in the STZ 
model (Caprioli et al., 2012). 
 
143 
UR%DSHULSKHUDOO\UHVWULFWHG)$$+LQKLELWRUVLJQLILFDQWO\UHYHUVHG
mechanical and thermal hyperalgesia in the carrageenan and SNL 
model, as well as the complete Freunds adjuvant model (Sasso et al., 
2012). FinaOO\ D GXDO )$$+0$*/ LQKLELWRU -=/ ZKLFK FDXVHV D
10-fold elevation in both AEA and 2-AG in the brain, has a greater 
antinociceptive effect in the tail-flick test, than either JZL184 or PF-3845 
(a FAAH inhibitor) alone (Long et al.E. 
 
5.1.2. Antidiabetic drugs 
5.1.2.1. Metformin 
Metformin is an activator of AMPK, which can also be activated by low 
levels of cellular nutrients, or by other compounds such as AICAR or 
resveratrol. Its activation leads to the inhibition of mammalian target of 
rapamycin (mTOR) and ERK signalling (Tillu et al., 2012), which results 
in a decrease in signalling to the translational machinery (Zoncu et al., 
2011), and decreased protein synthesis. The mTOR and ERK pathways 
(Ji et al. have been linked to pathology in several animal models 
of pain. Norsted-Gregory et al. (2010) demonstrated an increase in 
downstream targets of mTOR in the ipsilateral dorsal horn in the 
carrageenan model of inflammatory pain, suggesting an increase in 
mTOR related signalling. 
 
Metformin is effective in alleviating mechanical hypersensitivity, 
inhibiting translation regulation pathways and decreasing sensory 
neuronal excitability (Melemedjian et al., 2011). In addition, resveratrol 
has been shown to reduce mechanical hypersensitivity in a model of 
post-surgery induced pain (Tillu et al., 2012), as well as the formalin 
model (Torres-Lopez et al., 2002), and the carrageenan model of 
inflammation (Gentilli et al., 2001). Another method of inhibiting one of 
the mTOR complexes, mTORC1 (mammalian target of rapamycin 
complex 1), is through use of rapamycin itself, which alleviated 
mechanical hypersensitivity when applied locally in both an 
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inflammatory model (Geranton et al. and a model of neuropathic 
pain (Jiménez-Díaz et al., 2008), emphasising the important role the 
mTOR pathway plays in nociceptor sensitivity. Intrathecal administration 
of rapamycin was also effective at alleviating tactile and thermal 
hyperalgesia in the carrageenan model (Norsted Gregory et al., 2010), 
and pain behaviour in the SNI (Geranton et al.  and formalin 
model (Asante et al., 2010; Price et al., 2007). 
 
Obara et al. (2011), used temsirolimus (CCI- D UDSDP\FLQ
derivative, and Torin1, an inhibitor of both mTORC1 and mTORC2, and 
found that they were both effective in alleviating mechanical and cold 
hypersensitivity in the neuropathic SNI model, and mechanical 
hypersensitivity in the carrageenan model. As mTOR is mainly 
expressed in myelinated A-fibres in the peripheral nerve and dorsal 
roots, they postulated that this effect was mediated through A-fibres, 
leading to a decreased input to the dorsal horn. This hypothesis is 
supported by the observation that the carrageenan-induced thermal 
hypersensitivity, which is associated with peripheral sensitisation of C-
fibres, was not altered by CCI- 
 
Collectively there is strong evidence that metformin, through its 
activation of AMPK, may be able to play a role in alleviating the painful 
systems of diabetic neuropathy. One of the aims of the present study 
was to evaluate the potential analgesic effects of metformin in the 
HFD/STZ model. 
 
5.1.2.2. Linagliptin 
Preliminary evidence so far suggests that DPP-4 inhibitors, such as 
linagliptin, may also be able to play a role in alleviating painful 
symptoms. Two studies have investigated the effect of DDP-4 inhibitors 
on thermal/mechanical thresholds in the STZ model; PKF275-055 
reversed thermal hypoalgesia and mechanical hypersensitivity (Bianchi 
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et al., 2012), and alogliptin improved thermal nociception (Davidson et 
al., 2011a).  
 
5.1.3. Aim of the Study 
The aim of the first study was to investigate the ability of a new, more 
potent MAGL inhibitor, MJN110, to alter the already established 
mechanical hypersensitivity associated with the HFD/STZ model, as it 
has not yet been investigated in a neuropathic pain model. The 
inhibitory effects of this compound were compared to a well-studied 
FAAH inhibitor, U5% DV ZHOO DV SUHJDEDOLQ WKH JROG VWDQGDUG
treatment for DPNP, in the HFD/STZ model of diabetes. 
The aim of the second study was to determine whether two currently 
prescribed oral antidiabetics (metformin and linagliptin) are able to alter 
the manifestation of mechanical hypersensitivity in the HFD/STZ model. 
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5.2. Methods 
For detailed methods of induction of diabetes, blood sampling and von 
Frey testing see Chapter 2. 
 
5.2.1. Animals 
All experiments were carried out in accordance with the UK Home Office 
Animals 6FLHQWLILF3URFHGXUHV$FW78 male Sprague-Dawley rats 
(200-250g), obtained from Charles River (Kent, UK), were individually 
housed on a normal light cycle (lights on: 07:00 -  ZLWK IUHH
access to a high fat dieW  IDW E\ FDORULF FRQWHQW D GLHW; 
Research Diets, New Jersey, USA) and water at all times. Food and 
water intake, and body weight were monitored twice weekly. After three 
weeks consumption of the HFD, rats received either an i.p. injection of 
STZ (45mgkg-1), or citric acid buffer. 
 
As specified in Chapter 2, any HFD/STZ rat with a plasma glucose 
concentration of <15mM was to be excluded from the study, and two 
rats met this criteria in the present study and were excluded.  
 
5.2.2. Administration of drugs 
0-185%DQG3UHJDEDOLQ 
The rats were divided into five stratified groups on the basis of body 
weight, blood glucose concentration and mechanical withdrawal 
thresholds. To DVVHVV WKH HIIHFW RI V\VWHPLF 0-1 85% DQG
pregabalin on established pain behaviour, baseline von Frey testing 
was carried out 30 minutes before administration of the drug, and 
further testing was carried out at 1 hour and 3 hours after 
administration. MJN110 (5mgkg-1 DQG 85% PJNJ-1) were 
administered via i.p. injection, whereas pregabalin (10mgkg-1) was 
DGPLQLVWHUHG RUDOO\ DOO DW D YROXPH RI PONJ 0-1 DQG 85%
were dissolved in a vehicle of ethanol, Emulphor-620, and saline in a 
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ratio of 1:1:18, and pregabalin was dissolved in saline. Drug 
administration was carried out by two assistants to ensure that 
subsequent behaviour was assessed blind to treatment. 
 
85% ZDV JLYHQ E\ LS LQMHFWLRQ LQ DFFRUGDQFH ZLWK SUHYLRXV
literature where it tends to be given via this route (or through local 
administration) (Hasanein et al.E-D\DPDQQH et al., 2006; Kinsey 
et al.2NLQH et al., 2012), and MJN110 was therefore given via 
the same route, as has been shown to be effective in mice (Niphakis et 
al., 2013). There are numerous literature reports on the delivery of 
pregabalin, and in the majority it is given orally, and so the oral route 
was used in this study (Field et al.E+DKP et al., 2012; Miyazaki 
et al., 2012; Wodarski et al.<DPDPRWR et al.. 
 
Metformin and Linagliptin 
HFD/STZ rats were divided into three stratified groups on the basis of 
body weight, blood glucose concentration and mechanical withdrawal 
thresholds. To assess the effect of systemic linagliptin (3mgkg-1) and 
metformin (200mgkg-1) on development of pain behaviour, animals were 
orally dosed daily with the drug, or saline vehicle, from day 4 until the 
conclusion of the study at day 40. All dosing was carried out blind to the 
treatment groups.  
 
Both linagliptin and metformin were given orally in accordance with 
previous studies (Cheng et al., 2006; Kern et al., 2012; Kim et al., 
2012a; Klein et al., 2012; Reed et al., 2000; Vickers et al., 2012). The 
dose of 3mgkg-1 of linagliptin was used as this dose is reported to 
improve glucose control when given once daily in animal models of 
diabetes (Hocher et al., 2012), and it has been shown to significantly 
increase plasma GLP-1 in diet-induced obese rats and mice (Kern et 
al., 2012; Vickers et al., 2012), and to cause 67-'33-4 inhibition 
(Kern et al., 2012). 
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5.2.3. Quantification of endocannabinoids in spinal 
cord using liquid chromatography/tandem mass 
spectrometry (LC-MS/MS) 
LC-MS/MS analysis was carried out to look at the changes induced in 
endocannabinoid OHYHOV LQ WKH VSLQDO FRUG E\ 85% DQG 0-1
compared to the 1:1:18 vehicle. Analysis was carried out by Dr Sarir 
Samad. Spinal cords were removed and stored at -80°C before 
analysis, and the extraction was performed on ice. Samples were 
weighed and transferred to homogenisation tubes. Internal standards 
(100µl of 2-AG-d8 (10µM) and 15 µl of AEA-d8 (28 µM); Cambridge 
Biosciences, Cambridge, UK) were added to each sample, blank 
sample, and endocannabinoid standard (Cambridge Biosciences). 5ml 
of ethyl acetate:KH[DQH  Yol./vol.) was added to each sample and 
homogenised thoroughly, then 3ml of deionised distilled water was 
added and the samples were homogenised further. Samples were then 
centrifuged (13000rpm, 10mins, 4 qC). The supernatants were 
transferred to glass tubes, and the procedure was repeated two more 
times and the supernatants pooled and then evaporated in a centrifugal 
evaporator. Prior to analysis, each sample extract was reconstituted in 
200µl of acetonitrile. The injection volume was 5µl. Reproducibility was 
checked by repeated injections (n=6) of a mixed standard (1µM). 
 
The HPLC system used was an Agilent 1100 series (Agilent 
Technologies, Germany). The HPLC Column used was a BDS Hypersil 
C8 column with BDS Hypersil C8 precolumn (100 x 2.1mm, 3Pm) with 
guard column. Mobile phase A was water + 1g/L ammonium acetate 
 IRUPLFDFLG  $&1DQGPRELOHSKDVH % ZDV DFHWRQLWULOH 
J/DPPRQLXPDFHWDWHIRUPLFDFLG+20. The starting flow 
rate was 300µL/min. The MS system used was a Micromass Quattro 
Ultima triple quadrupole mass spectrometer (Waters, Manchester, 
UK) equipped with an electro spray ionisation interface.  
 
  
Quantification of the endocannabinoids was done using fully extracted 
calibration standards for each of the analytes. Quantification was 
performed using QuanLynx v4.1. Identification of each compound in 
plasma was confirmed by LC retention times of each standard and 
precursor and product ion m/z ratios. The peak area of each analyte 
was compared to a known amount of standard to determine the amount 
of target compound present. Measured concentrations of AEA, OEA, 
PEA and 2-AG in each sample were corrected for sample weight. 
 
The standards used were: 
Arachidonyl ethanolamide (N-(2-hydroxyethyl)-5Z,8Z,11Z,14Z-
eicosatetraenamide, anandamide, AEA) 
2-arachidonyl glycerol (2-AG, (5Z,8Z,11Z,14Z)-5,8,11,14-
eicosatetraenoic acid, 2-hydroxy-1-(hydroxymethyl)ethyl ester) 
Palmitoyl ethanolamide (PEA, N-(2-hydroxyethyl)-hexadecanamide) 
Oleoyl ethanolamide (OEA, N-(2-hydroxyethyl)-=-octadecenamide) 
Arachidonyl ethanolamide-d8 (N-(2-Hydroxyethyl)-5Z,8Z,11Z,14Z-
eicosatetraenamide-d8, AEA-d8) 
2-arachidonyl glycerol-d8 (2-AG-d8, (5Z,8Z,11Z,14Z)-5,8,11,14-
Eicosatetraenoic acid-d8, 2-hydroxy-1-(hydroxymethyl)ethyl ester-d8)  
 
5.2.4. Drugs 
85% was purchased from Sigma Aldrich (Poole, UK), pregabalin 
was kindly provided by Pfizer (Cambridge, UK), and MJN110 was a 
kind gift from Micah Niphakis and Ben Cravatt (Scripps Research 
Institute, San Diego).  
 
Metformin hydrochloride was purchased from Sigma Aldrich (Poole, 
UK), and linagliptin was a kind gift from Boehringer Ingelheim 
Pharmaceuticals (Ingelheim, Germany).  
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5.2.5. Statistics 
0-185%DQG3UHJDEDOLQ 
Analysis of plasma glucose was by a Repeated Measures ANOVA with 
Dunnetts post-hoc test. Analysis of changes in mechanical withdrawal 
thresholds, and plasma insulin was by Friedman test with Dunns post-
hoc test. Effects of drugs on mechanical withdrawal thresholds were 
analysed with a Kruskal-Wallis test with Dunns post-hoc test. 
 
Two rats were excluded from this study as the STZ injection did not 
cause an increase in plasma glucose concentration and so they could 
not be considered diabetic. 
 
Metformin and Linagliptin 
Analysis of plasma glucose and insulin, and mechanical withdrawal 
thresholds was by a Kruskal-Wallis test with Dunns post-hoc test. 
Analysis of body weight, food intake and water intake was by an 
ANCOVA with Tukeys post-hoc test, with the average of day -7 to 0 as 
the covariate. In all analyses, a p value of less than 0.05 was 
considered statistically significant. 
 
Two rats were excluded from this study as the STZ injection did not 
cause an increase in plasma glucose concentration and so they could 
not be considered diabetic. Additional rats were excluded from analysis 
of pain behaviour if in the week before injection with STZ the average 
hindpaw mechanical withdrawal threshold was < 10g. In this study, this 
represented 10 rats  1 HFD/Veh, 3 HFD/STZ + vehicle, 3 HFD/STZ + 
metformin and 3 HFD/STZ + linagliptin.  
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5.3. Results 
5.3.1. Acute effects of MJN110, URB597 and 
Pregabalin on established mechanical 
hypersensitivity 
As described previously, induction of the HFD/STZ model leads to a 
significant increase (p<0.001) in plasma glucose (Figure 5.2A), which is 
maintained throughout the study, and a significant decrease (p<0.001) 
in plasma insulin at day 3, which decreased further by day 31 (Figure 
5.2B). In addition, rats had a lower body weight following the induction 
of diabetes compared to basal body weight, and significantly increased 
water consumption (p<0.001, data not shown).  
 
By day 15 of the model, HFD/STZ rats exhibited lowered mechanical 
withdrawal thresholds to stimulation of the hindpaw (Figure 5.3A). At 
day 37 following model induction, the mechanical withdrawal threshold 
of the hindpaws was reduced to 6.7±0.6g, compared to basal vales of 
13.5±0.4g (p<0.001). Systemic administration of MJN110 (5mgkg-1, i.p.), 
85%PJNJ-1, i.p.) and pregabalin (10mgkg-1, p.o.) reversed this 
decrease in mechanical withdrawal thresholds compared to the effects 
of vehicle treatment (Figure 5.3B). The effects of MJN110 and UR%
followed a similar pattern: an increase in the mechanical withdrawal 
thresholds was seen at 1 hour after administration of the drug, and this 
effect was further increased at 3 hours, although only the effects of 
MJN110 were significant. Pregabalin, however, had a maximal 
inhibitory effect at 1 hour post-administration, which was maintained, 
but not further increased at 3 hours post-administration. 
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Figure 5.2 Fasting plasma (A) glucose and (B) insulin in HFD/STZ rats 
(n=36). All data represent mean ± SEM, analysis of glucose was by a 
Repeated Measures ANOVA with Dunnetts Multiple Comparison post-
hoc test, and analysis of plasma insulin was by a Friedman test with 
Dunns post-hoc test:  
*** p<0.001, compared to baseline (day -5). 
B 
A 
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Figure 5.3 (A) Mechanical withdrawal thresholds of the hindpaw in 
HFD/STZ rats (n=36). All data represent mean ± SEM, analysis was by 
a Friedman test with Dunns post-hoc test: ** p<0.01, *** p<0.001, 
compared to baseline (day -2). (B) Effects of MJN110 (5mgkg-1, i.p., 
n=8) 85% PJNJ-1, i.p., n=8) and pregabalin (10mgkg-1, p.o., 
Q RQPHFKDQLFDOZLWKGUDZal thresholds in HFD/STZ rats (at day 37 
post model induction) at 1 and 3 hours following drug administration. All 
data represent mechanical withdrawal thresholds expressed as a 
percentage of baseline values ± SEM, analysis was by a Kruskal-Wallis 
test with Dunns post-hoc test: * p<0.05, ** p<0.01 
B 
A 
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5.3.2. Acute effects of MNJ110 and URB597 on 
endocannabinoid levels in spinal cord and brain 
85% FDXVHG D VLJQLILFDQW LQFUHDVH LQ 3($ DQG 2($ OHYHOV LQ WKH
spinal cord in comparison with the 1:1:18 vehicle (p<0.05), and there 
was also a trend towards an increase in the level of AEA (Figure 5.4A- 
C). The same pattern is seen in the mid-brain where it caused a 
significant increase in all three FAEs (Figure 5.5A-C; p<0.01). This 
LQGLFDWHV WKDW 85% ZDV DEOH WR EORFN )$$+ WKH HQ]\PH
responsible for degrading PEA, OEA and AEA, resulting in an increase 
in the levels of these endocannabinoids in both the brain and the spinal 
cord. MJN110, however, did not cause a significant increase in 2-AG in 
the spinal cord (Figure 5.4D), but a significant increase was seen in the 
mid-brain (Figure 5.5D; p<0.05). This suggests that MJN110 was able 
to block MAGL, the enzyme responsible for breaking down 2-AG, 
resulting in an increase in the level of this endocannabinoid in the mid-
brain. 
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Figure 5.4 Effects of MJN110 (5mgkg-1, i.p., n=8)85%PJNJ-1, i.p., n=8) and 1:1:18 vehicle (n=5) on levels of (A) AEA (B) 
PEA (C) OEA and (D) 2-AG in the spinal cord of HFD/STZ rats (at day 37 post model induction), approximately 4 hours after drug 
administration. All data represent mean ± SEM, analysis was by a 1-way ANOVA with Tukeys post-hoc test: * p<0.05 
B 
D C 
A 
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Figure 5.5 Effects of MJN110 (5mgkg-1, i.p., n=8)85%PJNJ-1, i.p., n=8) and 1:1:18 vehicle (n=5) on levels of (A) AEA (B) 
PEA (C) OEA and (D) 2-AG in the mid-brain of HFD/STZ rats (at day 37 post model induction), approximately 4 hours after drug 
administration. All data represent mean ± SEM, analysis was by a 1-way ANOVA with Tukeys post-hoc test:  
* p<0.05, ** p<0.01, *** p<0.001 
B 
D C 
A 
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5.3.3. Effects of Metformin and Linagliptin on 
metabolic parameters 
As previously described there was a threefold increase in plasma 
glucose in all three HFD/STZ groups, in comparison to the HFD/Veh 
group (Figure 5.6A). Neither linagliptin (3mgkg-1) nor metformin 
(200mgkg-1) altered plasma glucose in HFD/STZ rats. The threefold 
decrease in plasma insulin in all the HFD/STZ rats, compared with the 
HFD/Veh group, was also not attenuated by linagliptin or metformin 
treatment (Figure 5.6B). 
 
The growth rate of the HFD/STZ rats was severely stunted in 
comparison to the HFD/Veh animals (Figure 5.7A), with no effect of 
intervention with linagliptin or metformin.  There was no significant 
change in food intake in the HFD/STZ rats compared to HFD/Veh 
controls, and this was also not altered by either antidiabetic drug 
(Figure 5.7B). Finally, the water intake in the HFD/STZ rats was 
significantly increased compared to the HFD/Veh rats (Figure 5.7C), 
with no effect of treatment except for around day 31 when the water 
intake was significantly higher in the linagliptin group, in comparison to 
the metformin group (p<0.05). 
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Figure 5.6 Effects of linagliptin (3mgkg-1, p.o.; n=10) and metformin 
(200mgkg-1SRQ , given daily from day 4 onwards, on (A) fasting 
plasma glucose and (B) fasting plasma insulin, in comparison with 
vehicle trHDWHG +)'9HK Q  DQG +)'67= Q  rats. All data 
represent mean ± SEM, analysis was by a Kruskal-Wallis test with 
Dunns post-hoc test: * p<0.05, ** p<0.01, *** p<0.001 
 
 
 
 
 
 
B 
A 
  
Figure 5.7 Effect of linagliptin (3mgkg-1, p.o.; n=10) and metformin 
(200mgkg-1 SR Q  RQ (A) body weight, (B) water intake, and (C) 
food intake, in comparison with vehicle treDWHG +)'9HK Q  DQG
HFD/STZ (n=11) rats. All data represent mean ± SEM, analysis was by 
an ANCOVA (with the average of day -7 to 0 as a covariate) with 
Tukeys post-hoc test: # p<0.05.  
In comparison to HFD/Veh controls, body weight and water intake,  
p<0.001 from day 3 for all HFD/STZ rats. 
A 
B 
C 
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5.3.4. Effects of Metformin and Linagliptin on the 
development of mechanical hypersensitivity 
Consistent with my earlier studies, HFD/STZ caused a decrease in 
mechanical withdrawal thresholds compared to HFD/Veh rats, which 
became significant at day 21 (Figure 5.8). Both linagliptin and metformin 
(treatment from day 4) prevented the decrease in mechanical 
withdrawal thresholds in HFD/STZ rats. The withdrawal thresholds of 
these rats were not significantly different from the HFD/Veh rats at any 
timepoint, but were significantly different from the vehicle treated 
HFD/STZ rats from day 24, with this significance increasing as the 
study progressed. 
 
 
Figure 5.8 Effects of linagliptin (3mgkg-1, p.o.; n=7) and metformin 
(200mgkg-1, p.o.; n=6) on mechanical withdrawal thresholds of the 
hindpaws, in comparison with vehicle treated HFD/Veh (n=8) and 
HFD/STZ (n=8) rats. All data represent mean ± SEM, analysis was by a 
Kruskal-Wallis test with Dunns post-hoc test: 
* p<0.05, ** p<0.01, in comparison with HFD/Veh + Vehicle 
# p<0.05, ## p<0.01, in comparison with HFD/STZ + Vehicle 
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5.4. Discussion 
One of the problems facing patients with diabetic neuropathy today is 
the lack of medication that is effective at alleviating the neuropathic pain 
that can accompany this disease. One of the key objectives is therefore 
to develop new drugs, or to find alternative uses of current drugs, that 
are able to provide symptomatic relief of pain. In the present study it 
was demonstrated that MJN110, a novel MAGL inhibitor, was as 
effective as pregabalin at alleviating established mechanical 
hypersensitivity in the HFD/STZ model, highlighting a possible role of 
endocannabinoids in providing pain relief in diabetes. It was also 
demonstrated that two antidiabetic drugs, metformin and linagliptin, 
showed promise in preventing the development of mechanical 
hypersensitivity in this model when administered early on. It is worth 
investigating these findings further as both of these drugs are already 
licensed and have undergone all necessary safety testing, and so they 
could rapidly be put to use if effective. 
 
5.4.1. Cannabinoids in the HFD/STZ model 
The first study investigated the effects of two modulators of the 
endocannabinoids: MJN110  DQRYHO0$*/LQKLELWRUDQG85% a 
FAAH inhibitor, in the HFD/STZ model of diabetes, and compared their 
effects to those of pregabalin, one of the first-line treatments for pain in 
diabetic neuropathy.  
 
Mechanical hypersensitivity was well established by day 37, when a 
single acute administration of MJN110 produced a significant inhibition 
of mechanical hypersensitivity. Indeed, hindpaw withdrawal thresholds 
were returned close to control values in the presence of MJN110, 
demonstrating that it can block established hypersensitivity in this 
model of diabetic neuropathy. The inhibitory effects of MJN110 were 
comparable to those produced by the gold standard treatment, 
pregabalin, and even became more significant at the 3 hour timepoint. 
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85%ZDVDOVRHIIHFWLYHDQGVKRZHGWKHVDPHUHVSRQVHSDWWHUQDV
the other two drugs, but its effects did not reach significance at either 
timepoint, suggesting that significance could likely be reached with a 
slightly higher dose. LC-0606 DQDO\VLV VKRZHG WKDW 85%
significantly increased levels of the three FAEs in the spinal cord and 
mid-brain, and that MJN110 significantly increased levels of 2-AG in the 
mid-brain. These results indicate that endocannabinoid modulation may 
have a promising future in the treatment of diabetic neuropathy. 
 
The analgesic effects of a variety of cannabinoids have previously been 
investigated in the STZ model (as discussed in the introduction), 
including WIN55212-2 (Dogrul et al., 2004; Toth et al., 2010; Ulugol et 
al., 2004; Vera et al., 2012), cannabidiol (Toth et al., 2010) and 
cannabis extract (Comelli et al.. However the usefulness of these 
cannabinoid agonists is often limited clinically by the occurrence of 
unwanted psychotropic side effects. 
 
My findings are consistent with previous reports that FAAH inhibitors 
possess analgesic activity in a wide variety of rodent models of 
nociception (Cravatt et al., 2001) 85% KDV VKRZQ DQDOJHVLF
properties in two models of hyperalgesia in STZ rats (Hasanein et al., 
D, and ST4070, another FAAH inhibitor, increased mechanical 
thresholds in STZ rats (Caprioli et al., 2012). In the same study, they 
VKRZHG67WREHPRUHHIIHFWLYHWKDQ85%or pregabalin in the 
CCI model. 
 
One of the limitations of my study was that only a single acute dose of 
each drug was studied, which does not accurately reflect the situation in 
the clinic where the correct dose is titrated up, and long-term exposure 
may be required to see the full clinical efficacy (Berge, 2011). A single 
high dose may produce a different drug distribution and lead to 
unexpected effects, such as recruitment of antinociceptive mechanisms 
that would not be activated by a repeated dosing regime with a lower 
dose, and this could explain why drugs that seem efficacious in animal 
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models often fail in the clinic (Berge, 2011). It is therefore important to 
investigate the effect of repeated administration, to see whether the 
same effects would be seen, and if these could be maintained, or 
whether any tolerance would develop. Furthermore, if given from an 
earlier timepoint, it could be investigated whether either of these 
inhibitors would be able to prevent the development of neuropathic 
pain. 
 
The effects of repeated administration of a FAAH inhibitor has been 
examined in several models with mixed results. In the CCI model, 
DGPLQLVWUDWLRQ RI 85% PJNJ-1 p.o.) for four days was more 
effective at alleviating hypersensitivity than a single administration 
(Russo et al., 2007)DQGWKHVDPHJURXSIRXQGWKDW85%PJNJ-1 
i.p.) given daily for 7 days was indistinguishable from single drug dosing 
(Clapper et al., 2010). In agreement with this, PF3845, another FAAH 
inhibitor, maintained its anti-allodynic effect in the CCI model when 
given for 6 days (Schlosburg et al., 2010), but, in the carrageenan 
PRGHO  GD\V RI 85% PJNJ-1 i.p.) was unable to reduce 
inflammatory hyperalgesia compared to a single acute dose (Okine et 
al., 2012). Additionally, FAAH -/- mice exhibit reduced pain behaviour in 
the tail immersion, hot-plate and formalin tests (Cravatt et al., 2001), 
and the carrageenan model, but not in the CCI model, which Lichtman 
et al., (2004b) postulated may be due to adaptive changes caused by 
nerve injury itself. From these results, it would appear that FAAH 
inhibitors are able to maintain their efficacy following repeated dosing in 
neuropathic models of pain, but studies with longer duration would be 
needed to see what the effects of long-time use might be. 
 
Conversely, repeated dosing of the MAGL inhibitor JZL184 for six days, 
seems to lead to tolerance when given at high doses (40mgkg-1). It 
loses its analgesic effects in both the CCI model (Kinsey et al., 2013; 
Schlosburg et al., 2010) and the carrageenan model (Ghosh et al., 
2013), but when given at a lower dose (4mgkg-1) it is able to maintain its 
effectiveness in both models (Ghosh et al., 2013; Kinsey et al., 2013). 
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Furthermore, Mgll-/- mice , although displaying a 10-fold increase in 2-
AG levels in the brain, display similar tail-withdrawal latencies to wild-
type mice. These studies help to reinforce the importance of selecting 
an appropriate dose when planning any future studies with repeated 
dosing to avoid the possibility of tolerance developing. 
 
Modulation of the endocannabinoid system is also showing promise in 
other areas of diabetes such as diabetic nephropathy, retinopathy and 
also cardiovascular complications (as reviewed by Horváth et al., 2012). 
Additionally, with obesity becoming a growing problem, blockade of CB1 
receptors has shown promise, but its use so far has been limited due to 
its effect of increasing anxiety in patients. Several trials have found that 
in obese patients, rimonabant (a CB1 receptor antagonist) is not only 
able to promote weight loss, but also decreases weight circumference 
and produces significant improvements in HDL-cholesterol, triglycerides 
and fasting insulin (Despres et al., 2005; Pi-Sunyer et al., 2006; 
Rosenstock et al., 2008; Scheen et al., 2006; Van Gaal et al., 2005). 
However, a more recent trial had to be stopped prematurely as 
rimonabant was found to have serious neuropsychiatric side-effects, 
causing an increased risk of suicide (Topol et al., 2010). This study 
highlights the importance of evaluating the risk of side-effects, and 
emphasises that perhaps modulation of levels of endocannabinoids 
may be a better way of tackling the problems associated with diabetes. 
 
5.4.2. Antidiabetics in the HFD/STZ model 
In the previous study in Chapter 4, the antidiabetic pioglitazone was 
administered 21 days after injection with STZ, and no significant 
alleviation of mechanical hypersensitivity was seen. As this drug was 
administered once pain behaviour was established, it was decided to 
administer the antidiabetic drugs in this study from day 4 after injection 
with STZ to see whether they could slow or prevent the development of 
mechanical hypersensitivity.  
 
 
165 
The two currently prescribed antidiabetics drugs investigated in this 
study were metformin and linagliptin, both of which significantly 
prevented the development of mechanical hypersensitivity. These 
findings are consistent with the report of analgesic effects of metformin 
in the SNI and SNL models (Melemedjian et al., 2011; Melemedjian et 
al., 2013). Resveratrol, another AMPK activator, has also been shown 
to be effective in acute, inflammatory, and chronic rodent pain models 
(Gentilli et al., 2001; Tillu et al., 2012; Torres-Lopez et al., 2002). 
 
Metformin is currently prescribed in diabetes for its ability to improve 
glycemic control and decrease blood sugar levels through multiple 
mechanisms, and in this study it was shown to also be effective at 
attenuating the development of mechanical allodynia. As metformin and 
other AMPK activators are effective in models of pain which do not have 
metabolic syndrome associated with them, I would hypothesise that it 
has a direct analgesic effect through activation of AMPK, and the 
inhibition of mTOR and ERK signalling pathways (Melemedjian et al., 
2011; Melemedjian et al., 2013; Soares et al., 2013). Inhibition of mTOR 
leads to inhibition of local protein synthesis (Jiménez-Díaz et al., 2008), 
and blockade of ERK signalling has a multitude of effects, including 
decreased phosphorylation of Nav1.7, (which prevents the changes in 
channel gating properties toward a hyperexcitable state (Stamboulian et 
al., 2010)) resulting in a decrease in sensory neuronal excitability. 
 
Further evidence of the effectiveness of inhibiting mTOR as a way to 
alleviate pain comes from the use of rapamycin, which inhibits 
mTORC1, and has been shown to alleviate mechanical hypersensitivity 
in preclinical models of inflammation (Geranton et al.  and 
neuropathic pain (Jiménez-Díaz et al., 2008) when applied locally. CCI-
 DQG 7RULQ (a rapamycin derivative, and an inhibitor of both 
mTORC1 and mTORC2 respectively) both reduced mechanical 
hypersensitivity in a mouse model of neuropathic pain when given 
systemically (Obara et al., 2011). They hypothesised that the effects of 
mTORC1 inhibitors are mediated through A-fibres, where mTOR and its 
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active form (P-mTOR) are localised (Jiménez-Díaz et al., 2008; Obara 
et al., 2011). 
 
Although metformin crosses the blood-brain-barrier, it appears that this 
drug and other AMPK activators, as well as direct mTORC1 inhibitors, 
have their effects on mechanical hypersensitivity through a peripheral 
mechanism of action. Both local (intraplantar) and systemic injections of 
CCI-SURGXFHGFRPSDUDEOHUHGXFWLRQVLQQHXURSDWKLFVHQVLWLYLW\DQG
systemic Torin1, which has limited access to the CNS, reduced 
mechanical and cold hypersensitivity (Obara et al., 2011). Metformin 
caused a reversal of PNI-induced enhanced nascent protein synthesis, 
implying a direct action on the injured peripheral nervous system 
(Melemedjian et al., 2011). 
 
The findings of current studies suggest that AMPK activators may be a 
novel solution for the current problem of neuropathic pain, including that 
of painful diabetic neuropathy, and they warrant further investigation for 
the role they may be able to play clinically. Attention should also be paid 
to the development of more efficacious AMPK activators. 
 
An unexpected outcome of this study was the inability of metformin to 
reduce blood glucose levels after prolonged administration. Other 
studies have found that dosing with metformin for four weeks causes a 
significant decrease in glucose levels in diabetic animals (Alhaider et 
al., 2011; Erejuwa et al., 2011). However only the higher dose of 
500mgkg-1 is effective after 4 weeks of administration, and 100mgkg-1 
does not have a significant effect until after 8 weeks (Alhaider et al., 
2011). Further studies have shown that long-term daily dosing with 300-
350mgkg-1 metformin did not cause a change in blood glucose (Hauton, 
2011; Kim et al., 2012a), and finally, in other studies where metformin 
causes a decrease in glucose, blood samples were only taken shortly 
after an acute dose of metformin (Cheng et al., 2006; Reed et al., 2000; 
Wilson et al., 2012b). It is possible that an acute effect of metformin on 
blood glucose levels was missed because dosing of metformin was 
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always carried out before blood samples were taken, or that a higher 
dose of metformin was needed in these rats to have a significant effect 
on blood glucose. Metformins effect on AMPK, and the activation of the 
downstream signalling pathways, would still account for its analgesic 
properties.  
 
To date, the effects of DPP4-inhibitors on pain behaviour have not been 
widely studied, with only two groups showing their ability to improve 
thermal nociception and reverse mechanical hypersensitivity (Bianchi et 
al., 2012; Davidson et al., 2011a). The findings in this chapter build on 
these previous studies, highlighting the ability of linagliptin to prevent 
the development of mechanical hypersensitivity in the HFD/STZ model. 
 
The mechanism of action through which linagliptin is able to alleviate 
mechanical hypersensitivity has not yet been fully elucidated. Treatment 
with a DPP-4 inhibitor for 32 weeks was able to improve sensory 
thresholds to pressure, vibration, pain and temperature in the current 
perception threshold test in the STZ model, as well as decreasing the 
IENF loss (Jin et al.. This suggests that the GLP-1 pathway may 
play a role in attenuating nerve damage, as well as its metabolic effects 
on lowering glucose levels.  
 
GLP-1 receptors are present in sciatic nerve and DRGs (Himeno et al., 
2011; Jolivalt et al., 2011; Kan et al., 2012; Liu et al., 2011), and these 
receptors have been shown to have a neuroprotective effect (During et 
al., 2003). Exendin-4, which functions as a GLP-1R agonist is able to 
attenuate cutaneous nerve fibre damage, alleviate hypoesthesia as 
implied by the current perception threshold, protect Schwann cells and 
reduce the loss of IENFs in the STZ model without lowering glucose 
levels, suggesting that it a mechanism independent of glycemic control 
is responsible for these effects (Liu et al., 2011). Other studies using 
exendin-4 showed it was able to ameliorate impaired neurite outgrowth 
of DRGs under high-glucose conditions in vitro (Himeno et al., 2011; 
Perry et al., 2002b), as well as improving: reduced sensory perception, 
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slowed NCV, and decreased IENF density in the plantar skin in vivo 
(Himeno et al., 2011; Jolivalt et al., 2011). Exendin-4 also significantly 
improved slowing of sensory NCV in type 1 diabetic STZ mice and 
motor NCV in type 2 diabetic db/db mice, and was also able to improve 
thermal withdrawal latencies and restore mechanical sensitivity in the 
STZ mice (Kan et al., 2012). However, in the db/db mice, exendin-4 
caused a lowering of the thermal withdrawal latency, and had no effect 
on the loss of mechanical sensation (Kan et al., 2012). Finally, GLP-1 
and exendin-4 were also able to improve indices of pyridoxine-induced 
sensory peripheral neuropathy in rats (Perry et al., 2007). It has been 
hypothesised that the neuroprotective effects of GLP-1 may be 
mediated by a cascade involving cAMP, and work through increasing 
trophic support (Kan et al., 2012; Perry et al., 2002a; Perry et al., 
2002b), or by coupling to anti-apoptotic signalling pathways (Li et al., 
2003). 
 
In this study, linagliptin did not change either fasting glucose or insulin 
levels, which is consistent with other studies of DPP-4 inhibitors 
(Poucher et al., 2012). Inhibition of DPP-4, and changes in GLP-1 were 
not measured in this study, but previous studies have reported 
decreased DPP-4 activity (Davidson et al., 2011a), and an increase in 
GLP-1 (Jin et al..OHLQ et al., 2012; Pipatpiboon et al., 2013). 
 
My data suggest that the increase in GLP-1 by DPP-4 inhibition may 
contribute to the prevention of the development of mechanical 
hypersensitivity, but other substrates of DPP-4, such as stromal cell-
derived factor-1a have also been shown to modulate neuropathic pain 
behaviour (Oh et al., 2001). Further consolidation of evidence showing 
how DPP-4 inhibitors and GLP-1 agonists modulate altered fibre 
function and pain responses is needed to identify whether this treatment 
has any promise for diabetic neuropathic pain. 
 
In conclusion, the results of the present study demonstrated that 
modulation of levels of endocannabinoids through use of a MAGL 
  
inhibitor was as effective at alleviating the pain behaviour in the 
HFD/STZ model as the commonly prescribed first-line treatment 
pregabalin. These data provide an interesting first look at how these 
compounds might have a future in the treatment of painful diabetic 
neuropathy, but the long term effects of dosing with these compounds 
has yet to be investigated. Furthermore, metformin and linagliptin, two 
antidiabetic treatments, also showed promise in preventing the 
development of mechanical hypersensitivity in the HFD/STZ model, and 
this, combined with results from other recent studies, suggests they 
may be able to play a bigger role in diabetes than just their current role 
in glucose control. 
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Chapter 6. 
General Discussion  
 
The aim of this thesis was to assess the validity of the HFD/STZ model 
as one of type 2 diabetes, and also of diabetic neuropathy. The 
phenotype of the HFD/STZ model is summarised in Table 6.1. The 
model was found to produce some symptoms similar to the STZ-alone 
model: a rapid rise in plasma glucose and a rapid fall in plasma insulin, 
coupled with a huge increase in water intake and urine excretion. 
HFD/STZ was also found to produce a robust decrease in mechanical 
withdrawal thresholds, a behavioural correlate of mechanical 
hypersensitivity, compared to both lean/Veh and HFD/Veh controls. As 
the HFD/STZ combination resulted in a reproducible model of diabetic 
neuropathy, various aspects were examined further. There was no 
evidence for neuronal degeneration in DRGs or the spinal cord up to 50 
days after model induction, but there was a decrease in GFAP 
expression, and in activated microglia in the spinal cord at this 
timepoint. Furthermore, there was a trend towards a decrease in the 
mechanically evoked responses of dorsal horn WDR neurones, but no 
changes in spontaneous firing or electrically evoked responses of these 
neurones. The pain behaviour associated with the HFD/STZ model of 
diabetic neuropathy was responsive to the gold standard analgesic 
gabapentin, antidiabetic treatments and two novel analgesic 
approaches. 
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Table 6.1 Summary of major findings 
MWT  Mechanical withdrawal threshold 
ļ no change   ĹRUĻWUHQGWRZDUGVDQLQFUHDVHGHFUHDVH 
ĹĹRUĻĻ significant increase/decrease 
 
 
6.1. HFD/STZ: a model of type 2 diabetes? 
The HFD/STZ model has emerged as an interesting alternative to the 
STZ-alone model, which has been widely characterised and produces a 
robust model of type 1 diabetes (for review see King, 2012). As the vast 
majority of diabetic patients suffer from type 2 diabetes (Cheng, 2005), 
and as there have been some reports that diabetic neuropathy can vary 
between type 1 and type 2 diabetes (Arnold et al., 2013; Loseth et al., 
 Lean HFD HFD/STZ 
Body weight Ĺ ĹĹ ĻĻ 
Water intake ļ ļ ĹĹ 
Food intake ļ Ĺ ĹĹ 
Glucose ļ Ĺ ĹĹ 
Insulin ļ Ĺ ĻĻ 
MWT ļ ļ ĻĻ 
Immunohistochemistry: 
Microglia ļ ļ ĻĻ 
GFAP ļ ļ ĻĻ 
CGRP ļ ļ ļ 
Fluoro-Jade B ļ ļ ļ 
Electrophysiology: 
Mechanically evoked ļ ļ Ļ 
Electrically evoked ļ ļ ļ 
Spontaneous firing ļ ļ ļ 
C-fibre threshold ļ ļ ļ 
C-fibre latency ļ ļ ļ 
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2010; Sima et al., 2006), it is important that we use animal models that 
are relevant to the clinical situation.  
 
The HFD/STZ model is often referred to as a model of type 2 diabetes, 
but I think the model used in this thesis could be further refined to more 
closely reflect the clinical situation. The current model is based on 
feeding a high fat diet for a three week period before injection with STZ, 
but in reality this does not mimic the duration of the pre-diabetic stage in 
humans, which has been shown to last years before full-blown diabetes 
develops (Meigs et al., 2003). ȕ-cell dysfunction also develops slowly as 
the body becomes less able to compensate for insulin resistance 
(Rydén et al., 2007), and during this period plasma insulin levels are 
fairly comparable to those seen in non-diabetic individuals (Reaven et 
al.. To further improve the model, a lower dose of STZ could also 
be used so that only a proportion of the ȕ-cells are destroyed, allowing 
the rat to maintain a relatively normal level of insulin. 
 
However, there has only been one previous report of pain assessment 
in the HFD/STZ model, and in this study, which used a lower dose of 
STZ (35mgkg-1), there was no change in mechanical withdrawal 
thresholds (Ferhatovic et al., 2013). This may not be surprising since 
the diabetic symptoms were much milder, with lower blood glucose 
concentrations, and greater gains in body mass (Ferhatovic et al., 
2013). Since the aim of this thesis was to investigate the signs of 
mechanical hypersensitivity that are associated with diabetic 
neuropathy and to explore the effects of a variety of therapeutic 
interventions on mechanical hypersensitivity, I selected the 45mgkg-1 
dose of STZ. However, it is feasible that with a longer period of 
exposure to HFD prior to STZ treatment, a lower dose of STZ would 
then produce significant changes in pain behaviour. 
 
Although the HFD/STZ model does not exactly reproduce diabetic 
neuropathy as it develops in humans, it aids in the understanding of 
some of the complex mechanisms underlying the development of 
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chronic pain associated with the disease, and it is important to 
remember that diabetic patients are themselves a heterogeneous 
population. It also highlights the importance of choosing an appropriate 
animal model for the endpoint you are interested in. If the goal of 
research is to specifically model the progression of type 2 diabetes, this 
would best be achieved with genetic models. However, if the aim is to 
investigate the mechanisms of chronic pain associated with type 2 
diabetes, then the HFD/STZ (45mgkg-1) model which mimics aspects of 
type 2 diabetes and exhibits robust pain behaviour is appropriate. 
 
6.2. Assessment of mechanical hypersensitivity in 
the HFD/STZ model 
Assessment of the development of mechanical hypersensitivity in this 
model used calibrated von Frey hairs. It has been suggested that these 
tests are not a direct measure of pain itself, but that they are a reflection 
of the hypersensitivity that develops alongside pain (Le Bars et al., 
2001; Mogil, 200. Whilst allodynia and hyperalgesia are both 
associated with diabetic neuropathy, spontaneous pain is also an 
important symptom. There are a variety of proposed methods to assess 
spontaneous pain in animal models, but their use in the diabetic model 
is limited. 
 
A video-tape can be used to monitor spontaneous, unprovoked pain 
behaviour, looking at factors such as immobility, locomotion, grooming, 
rearing and elevation of the paw, which can be scored by a blinded 
observer. While this method minimises handling, which may influence 
the behavioural response itself, it is very time consuming, and large 
numbers of rats are needed due to the high variability in behaviour 
(Olmarker et al., 2002). It is also an indirect measure of pain, as while 
immobility, elevation of the paw and rearing can be interpreted as signs 
of spontaneous pain, they could also be altered by a variety of other 
factors. This method may prove useful in surgical models where 
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development of pain is rapid and very pronounced; but its application to 
the slower development of pain in the diabetic model is more 
questionable. Rats are prey animals and so any behaviour indicating 
pain which could be interpreted as weakness must be hidden, even 
though the underlying pain state may persist. The Rat Grimace Scale 
has recently been proposed as a method of quantifying pain through 
facial expressions such as orbital tightening, nose/cheek flattening, ear 
changes, and whisker changes (Sotocinal et al., 2011). However it has 
only been shown to be effective up to 48 hours after the induction of 
inflammatory pain (Sotocinal et al., 2011), and the SNI model in mice, 
which is of longer duration, is not associated with a pain face (Langford 
et al., 2010). Therefore the limited duration of facial grimacing is not 
applicable for models of neuropathic pain, such as diabetic neuropathy. 
These methods could therefore provide utility in other animal models, 
but in this thesis the effect of HFD/STZ was only assessed on evoked 
responses, as it was considered impractical to use any of the current 
methods that may be able to assess spontaneous pain in other shorter-
term models.  
 
In future studies, it would be interesting to quantify dynamic mechanical 
hypersensitivity in the HFD/STZ model, as this symptom is more often 
observed clinically, such as when clothing brushes against the skin. 
Static mechanical hypersensitivity is measured by the change in 
withdrawal threshold induced by von Frey hairs, whereas dynamic 
mechanical hypersensitivity is studied by light stroking with a cotton bud 
and measuring the withdrawal latency (Field et al.D. Field et al. 
E reported static mechanical hypersensitivity in the majority of 
diabetic rats within 10 days after injection with STZ, whereas the 
development of dynamic mechanical hypersensitivity had a slower 
onset, with fewer rats displaying sensitivity to stimulation with the cotton 
bud. They postulated that static mechanical hypersensitivity could be 
FDXVHG E\ WKH DFWLYDWLRQ RI $į- and C-fibres, whereas dynamic 
mechanical hypersensitivity may be due to inappropriate activation of 
$ȕ-fibres, and may be the result of more severe nerve damage. This 
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has been confirmed by studies in humans which have also shown that 
dynamic mechanical hypersensitivity is signalled by large myelinated 
$ȕ-fibres, whereas the static component of mechanical hypersensitivity 
is signalled by unmyelinated fibres (Koltzenburg et al. . In the 
future, it would be valuable to determine whether the same pattern is 
observed in the HFD/STZ model, and whether any drug intervention is 
effective against both of these parameters, to ensure any results are 
more likely to show relevance in the clinical situation. 
 
6.3. Mechanisms underlying the development of 
mechanical hypersensitivity 
It is important to consider how the temporal development of the model 
is related to the progression of pain behaviour. Figure 6.1 shows a 
timeline of the progression of the HFD/STZ model, which brings about 
the question: what causes the switch to the development of mechanical 
hypersensitivity?
 
177 
Figure 6.1 Temporal development of the HFD/STZ model of diabetes 
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As can be seen in Figure 6.1, it is not the rapid rise in plasma glucose, 
or the rapid decrease in plasma insulin that is directly responsible for 
the development of mechanical hypersensitivity, but it must be longer-
term changes that underlie the later development of diabetic 
neuropathy. This would suggest that pain is not a direct consequence of 
hyperglycaemia, but it is the result of a variety of slower and longer-
term molecular changes that are brought into play by elevated blood 
glucose and/or decreased insulin. Mechanisms, such as an increase in 
oxidative stress, may eventually lead to damage to neurones and 
altered function. On the basis of the findings of previous studies, it is 
likely that damage to these neurones induces a whole raft of changes, 
such as an increase in sodium channels and ectopic discharges, and 
neurochemical changes at the spinal cord level, which both lead to, and 
are influenced by, activation of glia. All of these slower changes are 
known to contribute to the manifestation of hypersensitivity in models of 
neuropathy, as well as other aberrant pain responses that are 
experienced in humans with diabetic neuropathy. Therefore it makes 
sense that the painful symptoms in this model take a few weeks to 
develop. A number of possible underlying mechanisms were 
investigated in this thesis. 
 
The potential contribution of changes in spinal excitability to the 
manifestation of mechanical hypersensitivity was determined using 
electrophysiology. There was a trend towards a decrease in evoked 
responses of WDR dorsal horn neurones to mechanical stimulation, 
which has been observed previously in both the diabetic (Pertovaara et 
al., 2001), SNL (Chapman et al., spinal cord injury (Hao et al., 
2004) and cisplatin-induced chemoneuropathy (Cata et al., 2008) 
models of neuropathic pain. Fluoro-Jade B staining was examined in 
both the DRGs and spinal cord to assess whether neuronal death might 
be responsible for this decrease in evoked responses, but very little 
positive staining was observed in any of the groups, with no increase in 
Fluoro-Jade B staining in the HFD/STZ group. However, it is possible 
that the neurones are already in an early damaged state, but have not 
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yet started to degenerate and produce the molecule that is detected by 
Fluoro-Jade B. It is feasible that in this state they are unable to function 
properly, resulting in the trend towards a decrease in evoked neuronal 
responses. If the model was taken out to a much later stage, I would 
expect an increase in the number of Fluoro-Jade B positive cells in the 
DRGs, consistent with previous studies of later stage apoptosis in the 
STZ animal model (Russell et al.  6FKPHLFKHO et al., 2003; 
Zochodne et al., 2001). 
 
The importance of the role of astrocytes and microglia in the 
development and maintenance of neuropathic pain has been widely 
studied, and the results from the HFD/STZ model complement what has 
been reported so far. While an increase in astrocytes has been 
observed in many neuropathic pain models (Garrison et al. 
Obata et al., 2006; Raghavendra et al., 2004; Sweitzer et al. 
Wang et al. , in diabetic models a decrease in the amount of 
GFAP staining in the spinal cord is generally reported (Afsari et al., 
2008; Wodarski et al.. In my hands, a significant decrease in the 
mean grey intensity of GFAP staining was observed in both the dorsal 
and the ventral horn, as well as the central region, with greater changes 
seen in the dorsal and ventral horn at day 50 compared to the other 
timepoints. It has been hypothesised that this decrease is due to the 
reduction in the levels of circulating plasma insulin, as insulin has been 
shown to be important in the development of astrocytes (Aizenman et 
al. , and so a decrease may contribute to the reduction in the 
amount of GFAP staining in diabetic models. A decrease in glutamate 
transporters is observed in activated astrocytes in various pain models 
(Sung et al., 2003; Wang et al., 2006; Xin et al. . It would be 
interesting to investigate whether the decrease in the amount of GFAP 
staining is associated with a decrease in the expression of glutamate 
transporters, as increased levels of glutamate could lead to 
excitotoxicity (Nakagawa et al., 2010), which could be one of the factors 
responsible for the pain experienced in diabetic neuropathy. As well as 
effects on the development of astrocytes, prolonged low levels of 
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insulin, as well as hyperglycaemia, have been proposed to contribute to 
the development of painful diabetic neuropathy. Insulin treatment has 
been shown to prevent or reverse mechanical hypersensitivity (Calcutt 
et al.  +R\EHUJV et al., 2007; Otto et al., 2011), and levels of 
insulin have been shown to be correlated with mechanical 
hypersensitivity (Romanovsky et al., 2006). The impact of insulin 
deficiency on the function of sensory afferent fibres warrants further 
investigation. 
 
Whilst the decrease in GFAP staining was as expected, the decrease in 
the number of activated microglia in the spinal cord was not. My data 
emphasise the importance of not just relying on phenotypic changes in 
microglia to assess whether they are activated, but to measure the 
change in markers, such as iNOS and CD16/32 for classically activated 
M1 microglia, and arginase-1 and CD206 for alternatively activated M2 
microglia (Hirai et al., 2013; Mantovani et al., 2004). Another option 
would be to stain with p-erbB2, the receptor for the growth factor NRG1, 
which has been shown to be upregulated within activated microglia in 
the SNL model, correlating with the development of microgliosis (Calvo 
et al., 2010), and also activates the ERK pathway (Calvo et al., 2011). It 
would therefore be beneficial to double-label cells with markers for 
phospho-ERK (Morgado et al., 2011a; Sweitzer et al., 2004; Tsuda et 
al., 2008) and phospho-p38 (Morgado et al., 2011a; Sweitzer et al., 
2004), to see whether these pathways, which are switched on by 
microglia, are also activated in the HFD/STZ model. Further 
investigations would help to tease apart whether the numbers of 
classically activated, pro-inflammatory microglia are increased, 
regardless of whether they would be assessed as activated through 
morphology alone, helping to explain why an initial decrease was 
observed in this model. 
 
If further studies were to be carried out in this model, it would be 
beneficial to examine the changes in sensory neurone morphology, in 
order to be able to make more conclusive statements about what is 
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happening at the level of the nerve, as in this thesis the main focus was 
the spinal cord. 
 
6.4. Possible treatments for diabetic neuropathy 
The current treatments for diabetic neuropathic pain are limited, and are 
often ineffective. It is therefore of major clinical importance to 
investigate the analgesic potential of current treatments as well as 
investigating the effects of novel compounds on diabetic neuropathic 
pain responses. This thesis was able to investigate both of these 
possibilities. 
 
Pioglitazone, linagliptin and metformin, or drugs that bind to/activate the 
same target, have all recently shown promise at alleviating painful 
symptoms in animal models of neuropathic pain, through a variety of 
different mechanisms (Bianchi et al., 2012; Churi et al., 2008; Iwai et al., 
2008; Jain et al.-LD et al., 2013; Jia et al., 2010; Maeda et al., 
2008; Melemedjian et al., 2011; Morgenweck et al., 2010; Morgenweck 
et al., 2013; Takahashi et al., 2011; Tillu et al., 2012).  
 
Both linagliptin and metformin, two currently prescribed antidiabetics, 
prevented the development of mechanical hypersensitivity in the 
HFD/STZ model when given 4 days after injection with STZ, without 
altering glucose or insulin levels. Whether these interventions can 
influence established pain behaviour requires future investigation. 
Given the large number of people currently being treated with these 
types of drugs, an epidemiological investigation of the prevalence of 
neuropathic pain in diabetic patients being treated with these different 
classes of compounds may help to provide much needed clinical 
evidence for whether these antidiabetic drugs alter the manifestation of 
chronic neuropathic pain. As both of these drugs were able to prevent 
the development of mechanical hypersensitivity without altering the 
changes in plasma glucose and insulin, this suggests that their effects 
must arise through their influence on mechanisms independent of 
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glycemic control. This lends further support to the hypothesis that it is 
not just the altered plasma glucose and insulin levels themselves which 
are directly responsible for the development of mechanical 
hypersensitivity, but other slower, molecular changes. 
 
As discussed in Chapter 5, the analgesic properties of metformin have 
been demonstrated in other rodent models of neuropathic pain, 
suggesting that in the HFD/STZ model these effects may also be due to 
activation of AMPK. AMPK activation results in the inhibition of mTOR 
and ERK signalling pathways and insulin receptor substrate (IRS)-
mediated feedback signalling, causing multiple effects such as inhibition 
of local protein synthesis and decreased phosphorylation of the Nav1.7 
channel, and it is thought that these effects are due to a peripheral 
mechanism of action. DPP-4 inhibitors such as linagliptin are also 
thought to have a peripheral action, as they improve sensory 
thresholds, and decrease nerve fibre loss (Jin et al., suggesting 
an attenuation of nerve damage through the GLP-1 pathway. This is 
strengthened by the fact that GLP-1R agonists are able to attenuate 
nerve damage without lowering glucose levels, suggesting a 
mechanism independent of glycemic control (Himeno et al., 2011; 
Jolivalt et al., 2011; Liu et al., 2011).  
 
Further studies should be carried out to confirm whether these are the 
mechanisms by which these drugs are effective. For example, the 
effects of GLP-1R agonists could be investigated in this model, as well 
as quantifying changes in IENF density in the HFD/STZ model, and the 
effects of DPP-4 inhibitors and GLP-1R agonists on this parameter. 
Experiments to determine the localisation of GLP-1 receptors in 
peripheral nerve would also be advisable. To further consolidate the 
evidence, it would be important to quantify changes in: the activity of 
mTOR and ERK; phosphorylation of their downstream targets; and the 
levels of proteins involved in RNA processing and transport in the 
sciatic nerve of HFD/STZ rats; as well as the level of eIF4F complex 
formation and nascent protein synthesis. From here it would be possible 
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to investigate whether administration of metformin, or other AMPK 
activators sucK DV UHVYHUDWURO RU $ LV able to change these 
levels, helping to identify whether it is the activation of AMPK, and the 
inhibition of mTOR and ERK, that is responsible for the changes in pain 
behaviour. If these changes in the activity of mTOR and nascent protein 
synthesis are partly responsible for the development of pain behaviour 
in this model, it would help to explain why the slower changes in the 
development of mechanical hypersensitivity do not happen in parallel 
with the rapid changes in glucose and insulin. 
 
Previous studies have reported that early intervention with pioglitazone 
can also alter neuropathic pain symptoms in rodent models of 
peripheral nerve injury or spinal nerve transection (Iwai et al., 2008; Jia 
et al., 2013; Jia et al., 2010; Maeda et al., 2008; Morgenweck et al., 
2013). Treatment with the PPARȖ ligand pioglitazone once pain 
behaviour was established (3 weeks after STZ injection) was unable to 
reverse decreases in mechanical withdrawal thresholds. This raises the 
important issue that while identifying drugs that are able to prevent the 
development of mechanical hypersensitivity in an animal model may be 
a promising first step, whether they will show any efficacy when given to 
a diabetic patient who may have had the condition for many years 
before it was diagnosed, is unknown. This was the rationale behind 
giving pioglitazone at a relatively late timepoint, as it seemed that it 
would give a better indication of whether it would produce a clinically 
relevant result. It does highlight that whilst the results obtained from the 
antidiabetic drugs may show some promise, rigorous testing must be 
undertaken to see if they can be effective in patients when not 
administered under ideal conditions. 
 
In the last study, an acute dose of pregabalin was shown to alleviate the 
well-established mechanical hypersensitivity at day 37 in the model. 
Pregabalin is one of the gold standard drugs prescribed for the 
treatment of neuropathic pain (Bril et al., 2011). It has been shown to be 
effective at attenuating mechanical hypersensitivity in the STZ model of 
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diabetes (Field et al. E 0DUWLQH] et al., 2012; Yamamoto et al., 
 Zhang et al., 2013), as well as alleviating painful symptoms in 
diabetic patients, where it has been shown to be beneficial even in 
those patients who have had an unsatisfactory response to other 
treatments (Freeman et al., 2008; Freynhagen et al., 2005; Quilici et al., 
6WDFH\ et al., 2008). My observation that gabapentin can alleviate 
established pain behaviour in the HFD/STZ model provides important 
new evidence of the translational value of this model for diabetic 
neuropathic pain. This is promising for the results that were obtained 
with the novel MAGL inhibitor, MJN110, and hopefully forward 
translation of this work might result in another effective treatment being 
made available to patients. MJN110 was found to be as effective as 
pregabalin at attenuating mechanical hypersensitivity in this study, and 
at 3 hours after administration it caused a greater attenuation of 
mechanical withdrawal thresholds than pregabalin itself. The FAAH 
inhibitor, 85%, also showed a trend towards increasing withdrawal 
thresholds, but this did not reach significance. 
 
6.5. Conclusions 
In conclusion, this thesis has highlighted the role that the HFD/STZ 
model can play in investigating underlying mechanisms of diabetic 
peripheral neuropathic pain, and its use in exploring potential new 
therapeutic options for alleviating this pain. There is a potential role of 
endocannabinoid modulators such as MJN110, and currently prescribed 
drugs such as linagliptin and metformin in the future treatment of the 
pain associated with this disease, as a diverse range and a combination 
of treatments will prove to be important in the future management of 
DPNP. 
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